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Abstract 
Human immunodeficiency virus/Acquired immunodeficiency syndrome, HIV/AIDS is a 
significant medical problem worldwide with nearly 60 million infected people. Therefore, an 
effective and safe vaccine remains a high priority. To date, most HIV vaccine candidates have 
failed to elicit effective humoral and cellular immune responses that are necessary to control 
HIV infection. A promising phase III trial was conducted in Thailand in 2009 using a 
recombinant canary pox vector vaccine (ALVAC) expressing HIV Gag protein in combination 
with recombinant HIV Env glycoprotein gp120 (AIDSVAX), and was the first trial to show 
significant (31.2%) efficacy in humans. 
 
This project aimed to use influenza viruses as a mucosal live vaccine vector to stimulate an 
effective CD8+ T cell immunity. Reverse genetics technology was used to generate 
recombinant influenza A viruses H3N2 (HK-X31) and H1N1 (A/PR8/8/34) expressing a 
defined mouse HIV-CD8+ T cell epitope (H-2Kd Gag197) in the neuraminidase (NA) stalk (X31-
NA-Gag197 and PR8-NA-Gag197). This epitope was cloned into a pHW2000 reverse genetics 
plasmid encoding the appropriate influenza virus NA segment using recombinant PCR. 
Following co-transfection with the other seven influenza gene segments in a co-culture of 293T 
and MDCK cells, facilitated the generation of live influenza-HIV vaccine vectors. 
 
Live recombinant influenza viruses were successfully used as HIV vaccine vectors, utilising 
various mucosal prime-boost vaccination routes in a mouse model, as evidenced by the 
induction of robust CD8+ T cell responses. This was shown through intracellular cytokine and 
tetramer staining, which detected HIV and influenza-specific CD8+ T cell immunity. Mucosal 
CD8+ T cells were also characterized through expression of specific mucosal homing integrins. 
These HIV-specific CD8+ T cells migrated to mucosal regions following intranasal or 
intravaginal prime boost administration of the recombinant vaccine.  
 
Following intranasal prime-boost vaccination, tetramer and intracellular cytokine staining 
showed comparable HIV and endogenous influenza-specific CD8+ T cell responses in the 
spleen, and broncho-alveolar lavage, the mediastinal and inguinal lymph nodes. These mucosal 
HIV-specific CD8+ T cells expressed the integrins α4β7, CD103 and CCR9. The mucosal 
α4β7+CD8+ T cells expressed higher levels of the cytokine IL-15 cytokine and the IL-15Rα 
receptor compared to α4β7- controls. 
IX 
 
Finally, challenge with a rVac-Gag virus revealed that Gag197+α4β7+CD8+ T cells contributed 
to protection following vaccination. This research highlights the importance of mucosal CD8+ 
T cells in viral immunity and emphasizes the need for additional studies to provide key insights 
to underpin future vaccine development. 
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1. Chapter 1: Literature review 
1.1. General introduction 
Since its identification in 1983, Human immunodeficiency virus/Acquired immunodeficiency 
syndrome (HIV/AIDS) has become a serious threat to humanity. More than 60 million 
individuals have been infected in this epidemic, with 34 million of those currently living with 
HIV/AIDS. Moreover, more than 2.6 million new cases of infection are reported every year 
(UNAIDS 2013; UNAIDS 2012). Most cases of infection have occurred in the developing 
world, with nearly half of those infected succumbing to the disease (Duerr, Wasserheit and 
Corey, 2006; Mathers and Loncar, 2006; UNAIDS 2010). 
 
The first cases of HIV/AIDS were identified among homosexual men with complicated 
respiratory distress from unusual pneumonia in mid-1981 in the United States of America 
(USA). It was later discovered that the disease had been transmitted from central Africa to Haiti 
and then onto the USA. Several different modes of transmission were identified, and included 
blood transfusions, mother to-child and sexual transmission (Piot, 1989; Quinn et al., 1986). 
Many approaches have been used to reduce the risk of HIV transmission from infected persons 
to healthy individuals. For example, testing of blood and blood products of donors before 
transfusion, use of condoms during sexual intercourse and immediate use of antiretroviral 
therapy as a prophylactic treatment in neonates or in adults after exposure. However, none of 
these interventions have completely prevented the spread of HIV infection (Carvalho et al., 
2011; Haile-Selassie, Townsend and Tookey, 2011; Shevkani et al., 2011). 
 
The generation of a safe and effective HIV vaccine remains the most likely approach to 
eliminate infection (Johnston and Fauci, 2008). Several clinical trials have been conducted to 
test new HIV vaccine candidates in the last 25 years. Many of these vaccine candidates are still 
under study. Since 1987, more 200 Phase I/II trials have been used for testing 60 HIV-1 
candidate vaccines. These include DNA vaccines and recombinant vector and subunit vaccines. 
However, only a few candidate vaccines have been tested for efficacy in humans at the phase 
III level (Esparza and Van Regenmortel, 2014; Esparaza, 2013; Richert et al., 2014). These 
vaccine candidates were designed to induce HIV-specific T cells alone or both T cell and 
antibody responses (Chanzu and Ondondo, 2014). All have resulted in poor efficacy with the 
exception of one vaccine (RV144: phase III trial performed in Thailand 2009) using a 
heterologous prime-boost vaccine strategy that elicited a moderate level of protection against 
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HIV (31%) (Nath, 2010; Vaccari, Poonam and Franchini, 2010; Rerks-Ngarm et al., 2009). 
The need for an alternative, more robust vaccine is the motivating factor for this body of work. 
The following literature review firstly introduces the Retroviridae family, while the second part 
discusses influenza virus and its use as a vector in HIV vaccine research. 
1.2. Retroviridae 
Retroviral diseases have been known for more than two centuries, with the first reported cases 
being ovine pulmonary adenocarcinoma and bovine leucosis identified in 1825 and 1870, 
respectively. In the decades following, the causative agent of these two diseases was reported 
as a retrovirus (Johnson and Kannene, 1992; Voisset, Weiss and Griffiths, 2008). Retroviruses 
were first isolated from mice and birds between 1908-1910 in the form of oncogenic viruses 
(cancer-causing viruses), such as the mouse mammary tumor virus (MMTV) and the avian 
leukosis virus (ALV) (Mathews, 1982). However, other retroviruses were subsequently 
identified that led to non-malignant diseases characterized by immunological and neurological 
symptoms, such as HIV-1 and HIV-2 (Burmeister et al., 2007; Voisset, Weiss and Griffiths, 
2008). 
 
All Retroviridae family viruses have the ability to invade host cells and incorporate into their 
genome. Indeed, about 5-10% of the human genome is composed of sequences resulting from 
reverse transcription of viral-derived genes called retro-sequences (Lander et al., 2001; Levy, 
1993). The current classification of retroviruses depends on the genetic variation of the reverse 
transcriptase protein to differentiate between seven major genera within this family (Coffin, 
Hughes and Varmus, 1997) (Figure 1.1).  
 
These seven major genera of the retroviridae family included the following: 
1) Alpha-retroviruses: simple retroviruses characterized by C-type morphology. These 
viruses are widespread in avian species, such as an avian leukemia virus (ALV) (Coffin, 
Hughes and Varmus, 1997). 
2) Beta-retroviruses: simple retroviruses characterized by a round eccentric core and B- 
type morphology. These viruses infect primates, sheep and mice causing tumor 
diseases, such as the mouse mammary tumor virus (MMTV) (Hardy, 2009). 
3) Gamma-retroviruses: simple retroviruses characterized by C-type morphology that 
cause leukemia in different animals, such as the feline leukemia virus (FLV) (Cohen 
and Fauci, 2001). 
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4) Delta-retroviruses: complex retroviruses characterized by C-type morphology. These 
infect humans and other animals causing leukemia, for example human T-lymphotropic 
virus (HTLV) (Burmeister, Schwartz  and Thiel, 2001). 
5) Epsilon-retroviruses: simple retroviruses characterized by C-type morphology. These 
are found in fish and reptiles, for example, Walleye dermal sarcoma virus (WDSV) 
(Hardy, 2009). 
6) Spumaviruses: complex retroviruses characterized by unique virion morphology with 
an uncondensed core and foamy pathogenic changes in infected cells, for example 
human foamy virus (HFV). These viruses originated in chimpanzees and were 
subsequently transmitted to humans (Buchschacher, 2001; Delelis, Saïb and Sonigo, 
2003). 
7) Lentiviruses: complex retroviruses distinguished from other retroviruses by unique 
virion morphology with cylindrical cores. These viruses infect humans, cattle, horses, 
sheep, primates and rabbits causing malignancies as well as lymphatic and neurological 
disorders, such as HIV/AIDS (Baig et al., 2008; Gilbert et al., 2009; Katzourakis et al., 
2007). 
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Figure 1.1. Phylogeny of Reteroviruses. Phylogenetic tree showing the seven genera of 
endogenous retroviruses, including simple and complex genome viruses, with HIV-1 grouped 
with the Lentiviruses (Weiss, 2006). 
ALV: Avian Leukemia Virus; RSV: Rous Sarcoma Virus; JRSV: Jaagsiekte Sheep Retrovirus; MMTV: Mouse 
Mammary Tumor Virus; SRV: Squirrel Retrovirus; HERV-K: Human Endogenous Retrovirus-K; HERV-W: 
Human Endogenous Retrovirus-W; PERV: Porcine Endogenous Retrovirus; GALV: Gibbon Ape Leukemia 
Virus; MLV: Murine Leukemia Virus; FeLV: Feline Leukemia Virus; HTLV: Human T-Lymphotropic Virus; 
BLV: Bovine Leukemia Virus; WDSV: Walleye Dermal Sarcoma Virus; SnRV: Snakehead Retro-Virus; FFV: 
Feline Foamy Virus; BFV: Bovine Foamy Virus; SFVagm: Simian Foamy Virus (African green monkey); 
SFVcpz: Simian Foamy Virus (in Chimpanzees); EIAV: Equine Infectious Anemia Virus; FIV: Feline 
Immunodeficiency Virus; MVV: Maedi-Visna Virus; SIVmac: Simian Immunodeficiency Virus (in Macaques); 
HIV: Human Immunodeficiency Virus. 
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1.2.1. Lentiviruses 
Lentiviruses are a genus of viruses that represent one of the largest subgroups of the 
Retroviridae family (Şenocak et al., 2009). The name of the virus originates from the Latin 
words, lent, lenta, lento and lenti, to indicate the slow nature of disease progression. They are 
found endemically worldwide (Ross and Craigo, 2010). These viruses are characterized by 
continuous genome evolution in the host cell due to high mutation rates (Hirsch et al., 1995). 
Lentiviruses include large and ubiquitous viruses that cause highly infectious diseases in 
humans, such as HIV-1 and HIV-2, as well as other primate lentiviruses, such as simian 
immunodeficiency virus (SIV), which shares genetic similarity with HIV-1 and 2 (Peeters, 
Courgnaud and Abela, 2001).  In addition to the major structural genes that are represented in 
all retroviruses (pol, gag and env), lentiviruses encode accessory genes, such as rev and tat, 
(Buchschacher, 2001; Kerbs, Goldstein and Kilpatrick, 2010; Liu et al., 2009) (Figure 1.2). 
HIV is a member of the lentivirinae subfamily within the lentivirus genus that causes 
significant disease in humans (Chiu et al., 1985). 
 
 
Figure 1.2. Phylogenic relationships among lentiviruses. Classification of the lentiviruses on 
the basis of accessory genes, such as nef, vif, vpr and vpu, with HIV-1 showing similarity to 
other lentiviruses within the primate group (Gifford et al., 2008). 
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Figure 1.3. Structure of the HIV-1 virion. The genome of HIV-1 is composed of 2 copies of 
single stranded RNA covered by a double lipid envelope in which two surface glycoproteins 
(Envgp120 and gp41) are embedded (Roberts, 2009).  
 
1.2.2. Discovery of HIV 
Between 1970 and 1980, several cases of unknown infection with symptoms of immunologic 
dysfunction were recognized as an unusual syndrome among homosexual men in the USA and 
Europe (Cohen and Fauci, 2001). This syndrome was characterized by several distinctive 
symptoms, such as generalized lymphadenopathy cytomegalovirus-associated retinitis, and 
cryptococcal meningitis (Cohen and Fauci, 2001; Mayer and Bell, 2007). 
 
By June 1981, HIV was proposed as the causative agent of AIDS reported mainly in 
homosexual males, intravenous drug users and hemophiliacs. This designation was officially 
confirmed in 1983 (Barré-Sinoussi et al., 1983; Luft, Seme and Poljak, 2004). Indeed, 
HIV/AIDS has now become one of the largest causes of death around the world, particularly 
in Sub-Saharan Africa and within the African American population in the USA (Carter  and 
Saunders, 2009; Crampin et al., 2002). 
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1.2.3. HIV-1 genes 
The genome of HIV-1 is 9749 nucleotides in size, consisting of nine genes, which are flanked 
by two long terminal repeats (Gallo et al., 1988; Varmus, 1988) (Figure 1.4). These genes are 
classified into three types: i) structural genes, such as gag, pol, and env; ii) regulatory genes 
including tat and rev; and iii) accessory genes, such as vpu, vpr, vif and nef  (Berger et al., 
1991). Various HIV genes have been expressed in delivery vectors for induction of HIV-
specific immune responses (Yusim et al., 2002).  
1.2.3.1. Envelope glycoprotein (Env) 
Env is an envelope glycoprotein (Env gp160) trimer that forms the viral envelope and 
surrounds HIV particles with 72 little spikes. It mediates virus entry into host cells using the 
trimeric envelope glycoprotein spike in order to attach to the cellular receptors and then fuses 
to the viral and target cell membrane. It also represents a direct target for antiviral antibodies. 
The Env glycoprotein trimer is encoded by a 2.5 kilo-base (Kb) gene and contains 850 amino 
acids in total (Sattentau, 2013; Mao et al., 2013). It is made up of two glycoproteins subunits: 
(i) surface gp120 (SU), located on the outside of the HIV-1 virus, which plays an important 
role in initiating attachment to target cells by binding to the CD4 receptor; and (ii) 
transmembrane gp41 (TM), a hydrophobic protein normally embedded within the viral 
envelope but exposed after conjugation of gp 120 with the CD4 receptor molecule, which leads 
to activation of gp 41 for enhancement of viral-cell membrane fusion (Capon and Ward, 2003). 
Some regions of the Env protein are conserved between different strains of HIV-1, but this 
protein is generally characterized by alternative glycosylation and divergent sequences. Each 
conserved region of the Env protein (C1-C5) is separated by highly variable regions (V1-V5), 
leading to altered immunogenicity of Env glycoproteins that play an important role in the 
evasion of the immune response. This is because of the high diversity of the HIV-1 Env amino 
acid sequence among the nine clades of the HIV-1 virus, A, B, C, D, F, G, H, J and K, and also 
because there is more than 35 circulating recombinant forms that can be mutated to 20% within 
a clade and to 35% between different clades (Walker and Korber, 2001; Gaschen et al., 2002). 
Accordingly, the HIV-1 clades are distinguishable on the basis of their Env glycoprotein 
sequences (Dorn et al., 2000; Go et al., 2009; Ho et al., 2008; Huang et al., 1997). Despite this, 
Env has also been considered as a potential candidate for HIV-1 vaccines (Ahmad et al., 1994; 
Betts, Yusim and  Koup, 2002).  
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As a consequence of high variable regions of Env gene sequences of the same HIV-1 virus 
strain or between different clades that contributes to inducing a less protective CD8+ T cell 
response (Go et al., 2009; Ho et al., 2008), it is highly recommended that multiple Env peptides 
or the highly conserved positions of other HIV-1 peptides like Gag and Tat be used in HIV 
vaccine candidates. 
1.2.3.2. Group specific or associated antigen (Gag) 
The gag, or group-associated antigen, encodes capsid proteins that influences the physical 
structure of the virus. Gag is directly associated with the membrane of the host cell and 
enhances the assembly of new immature virions (Bryant and Ratner, 1990). After virus 
maturation, gag is cleaved into 4 major specific proteins. The first of these is the matrix protein 
(MA or P17) that is embedded into the envelope of the virus where it initiates binding of the 
precursor polyprotein (Pr55 gag) to the host cellular envelope. This is an important step in 
regulating and controlling assembly and maturation of the virion (Hayakawa et al., 1992). The 
capsid protein (CA or P24) forms the main shell structure surrounding the viral genome, located 
in the central core of the viral ribonucleoprotein (Göttlinger, Sodroski and Haseltine, 1989). 
The nucleocapsid protein (NC or P7) is localized in the virion and has an important role in 
assembly of RNA proteins into the HIV-1 virion. A fragment of NC (P6) also has an important 
function in facilitating the release of complete viruses from infected cell membranes (Clavel 
and Mammano, 2010; Patil, Gautam and Bhattacharya, 2010). Most previous HIV vaccine 
candidates failed to control HIV infection because a high diversity of the HIV-1 protein 
sequences between different clades of virus enabled the virus to escape the immune response 
as the majority of induced CD8+ T cell responses were directed against variable HIV epitopes 
(Kunwar et al., 2013; Yoshimura et al., 1996). Therefore, the main aim in the development of 
an effective vaccine against HIV is to induce a strong immune response targeting conserved 
regions of the HIV-1 virus. This would elicit a breadth of CD8+ T cell responses that recognize 
the most conserved positions of HIV epitopes that have an important role in controlling HIV 
viremia (Kunwar et al., 2013; Kulkarni et al., 2013). There is a high degree of functional 
conservation in the sequence of the whole Gag protein among the 8 major clades of HIV-1, 
especially in the capsid subunit. This was evident by a low diversity of amino acid sequences 
throughout the full length of the Gag protein subunit, with 17% between different clades of the 
HIV-1 virus, and only 9% within the same virus clade (Li et al., 2013). Also, Gag is commonly 
targeted by CD8+ T cell responses across various HIV-1 clades as a result of a high cross 
reactivity of Gag peptide sequences among these clades. Gag-specific CD8+ T cells obtained 
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from HIV-1 clade C infected individuals were able to recognize at least one Gag peptide from 
different HIV-1 clades. For instance, these CD8+ T cells recognized the Gag peptide of 92% 
from African clade CDu422, 90% for the Chinese clade CCH, 77% for clade A, 69% for clade B, 
and 87% for clade D (Zembe et al., 2011). This was demonstrated by a higher magnitude of 
functional HIV-1 CD8+ T cells detected in HIV-1 infected case with 96% against the Gag pool 
compared to 86% for Pol and Nef. Moreover, the level of Gag-specific CD8+ T cells were 
inversely correlated with the HIV-1 virus load in those infected individuals (Edwards et al., 
2002). Indeed, highly conserved regions of the HIV-1 Gag protein encode the main HIV-1 
cytotoxic CD8+ T cell epitopes that are used as vaccine targets and induced CD8+ T lymphocyte 
responses (Goonetilleke et al., 2009; Nchinda et al., 2010; Tritel et al., 2003). As a result of the 
highly conserved regions of the HIV-1 Gag, this protein is regarded as one of the best 
candidates for use in HIV vaccines (Addo et al., 2001; Currier et al., 2006; Yusim et al., 2002). 
Therefore, the HIV-1 Gag antigen is widely considered as one of the most conserved viral 
proteins used in CD8+ T cell based vaccines, and has also induced a breadth of Gag specific 
CD8+ T cell responses. For instance, there was a significant level of IFN-γ+CD8+ T cell 
response detected in BALB/c mice vaccinated subcutaneously with multiple doses of the HIV-
1 Gag protein alone or when combined with the Tat protein. Broad CD8+ T cell responses were 
directed to the limited nine amino acids of 197 to 205 of the Gag compared to the other Gag 
peptides (Cellini et al., 2008). 
1.2.3.3. Transcriptional transactivator (Tat) 
The HIV-1 Tat gene encodes two specific proteins; the 72 residue “Tat-1  protein”  and the 86 
residue “Tat-2 protein” (Howoroft et al., 1993; Ma and Nath, 1997). These proteins serve to 
regulate transcription and translation of polymerase (pol) and transcription of double stranded 
DNA after incorporation into the host genome. They do so by binding to specific 
transactivation elements called the Tat activating region (TAR), which stimulate the activity of 
RNA polymerase II and enhance transcription of viral RNA (Braddock et al., 1993; Jones and 
Peterlin, 1994; Liang and Wainberg, 2002; Raha et al., 2005). Tat proteins are also released by 
cells infected by HIV-1 and transmitted to non-infected cells which interfere with normal 
immune responses. This is achieved through the inhibition of MHC-1 presentation of HIV-1 
antigens by dendritic cells and other antigen presenting cells (APCs) (Gavioli et al., 2004; 
Petersen, Morris and Solheim, 2003; Raha et al., 2005). Tat is also considered one of the main 
regulatory proteins that is frequently targeted by cytotoxic CD8+ T cells and is induced 
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following natural HIV-1 infection; therefore it may be considered an important target for CD8+ 
T cell based vaccines to control HIV (Addo et al., 2001). 
 
 
Figure 1.4. Organization of the HIV-1 genome. Specific gene architecture distinguishing HIV-
1, including structural genes (gag, pol and env), and each of the regulatory (tat and rev) and 
accessory genes (vpu, vpr, vif  and nef), arranged between the two long terminal repeats (LTR) 
(Frankel and Young, 1998). 
 
1.2.4. HIV-1 pathogenesis 
HIV-1 enters the human body through mucosal surfaces and is dependent on the high affinity 
binding of surface envelope glycoprotein (Env gp120) with the host cell CD4+ receptor. HIV-
1 also needs to bind to specific major co-receptors such as the chemokine receptors CCR5 and 
CXCR4, which are located on the surface of target cells (Kramer, 2007; Lee and Montaner, 
1999; Nguyen and Taub, 2002), in order to facilitate the effective entry of the HIV virus into 
CD4+ cells. Indeed, the mechanism of interaction between HIV-1 and these co-receptors is a 
critical step in the HIV-1 life cycle that influencesthe progression of the disease (Gorry and 
Ancuta, 2011). Acute HIV-1 infection generates a high level of viremia, leading to accelerated 
depletion of CD4+ cells accompanied by severe acute symptoms. This is followed by a partial 
recovery of CD4+ T cell numbers with management of the virus infection, followed by clinical 
latency that lasts for 3-10 years (Weiss, 2001; Mayer and Bell, 2007) (Figure 1.5). HIV-1 
emerges from latency through alteration of the host’s immune responses through ongoing 
exhaustion of immune cells, high depletion of CD4+ T cells (<200 cells/μl) and decreased 
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cytokine activity (Banda et al.,  1999; Berger et al., 1998; Gorry and Ancuta 2011). Most cases 
of HIV-1 infected individuals are known as chronic progressors, characterized with a high level 
of virus replication which leads to extreme decline of CD4+ T cells (Blankson, 2010). As a 
result, opportunistic diseases occur that ultimately lead to death 10-15 years following initial 
infection (Lü and  Jacobson, 2007; Mayer and Bell, 2007; Rodrı´guez et al., 2006; Weiss, 2001) 
(Figure 1.5).  
 
 
Figure 1.5. Stages of HIV infection. Delineation of the different stages of HIV-1 infection 
with respect to CD4+ T cell count and number of HIV RNA copies. The primary infection, 
which extends from the initial infection for several months, is accompanied with acute 
symptoms followed by a long clinical latency period and complete destruction of host 
immunity (Coffin, Hughes and Varmus, 1997). 
1.3. HIV immunity 
The immune system defends the human body against a wide range of different pathogenic 
agents. The recognition of these microorganisms by the immune system is a necessary step in 
initiating the battle against pathogens. The host immune system includes two major arms: 
innate and adaptive immunity (Levy, Scott and Mackewicz, 2003; Mogensen et al., 2010; Sui 
et al., 2010).  
1.3.1. Innate immunity 
The innate immune response is the first line of immune defense following acute HIV-1 
infection. The immune response starts with recognition of the HIV-1 antigen and includes 
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various parts, such as the epithelial barrier, phagocytic and antigen presenting cells (Mogensen 
et al., 2010). The innate immune response is characterized by a fast onset and a short period of 
response (Guatelli, 2010; Lehner et al., 2008). The main aim of the innate immune response 
against HIV infection is to reduce virus replication by inducing the cascade of inflammatory 
cytokines like interferons (IFNs) and natural killer (NK) cells, which play a critical role in 
controlling of infection. The natural killer cells contain specific receptors and killer 
immunoglobulin-like receptors (KIRs) that recognized the HIV-1 infected cells and then 
destroy these infected cells (Carrington and Alter, 2012). Activation of innate immunity that is 
induced directly following early HIV-1 infection includes a contribution by recruited cells, 
such as granulocytes, macrophages and lymphocytes. Both lymphocytes and macrophages 
target the HIV-1 virus (Mogensen et al., 2010). There are other antigen-specific immune cells 
that contain surface Toll-like receptors that recognize molecules from the HIV-1 virus (Bafica 
et al., 2004; Datta and Raz, 2005; Klotman and Chang, 2006). The dendritic cell (DC) also acts 
as an early innate immune effecter cell that responds rapidly following HIV infection and arms 
the immune system by recognizing of the HIV-1 antigen and stimulating naïve T lymphocytes 
(Howie, Ramage and  Hewson, 2000). There are two main types of dendritic cells: myeloid 
dendritic cells (MDCs), which secrete IL-2 to stimulate a proliferation of T lymphocytes, and 
plasmacytoid dendritic cells (PDCs), which produce interferons (mostly IFN-α) (Colonna, 
Trinchieri and Liu, 2004; Fitzgerald-Bocarsly and Jacobs, 2010; Hardy et al., 2007). Innate 
immune response to HIV-1 infection includes trigerring specific Toll-like receptors, such as 
TLR7 and TLR8, and activating the protective role of dendritic cells (DCs) (Meier et al., 2009). 
As a result, PDCs are able to directly inhibit replication of HIV in the infected cells, particularly 
in the spleen and lymph nodes, by releasing both type 1 IFNs and tumor necrosis factor α (TNF-
α) (McKenna, Beignon and Bhardwaj, 2005; Nascimbeni et al., 2009). Furthermore, dendritic 
cells in women induce a higher level of IFN-α compared tothe same age group of men, which 
is influenced by their response to the HIV RNA triggering of TLR7/8. This would lead to a 
lower level of virus replication, thus enhancing control of a HIV-1 infection, compared to HIV-
1 infected individuals (Meier et al., 2009).  
 
Another important component of the innate immune response are neutrophils, which secrete 
cytokines such as IL-12 into the circulation to stimulate mucosal immune responses, 
particularly in the genital mucosa (Fahey et al., 2005; Gaudreault and Gosselin, 2009). 
Additionally, neutrophils release specific proteinase inhibitors such as human neutrophil 
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elastase inhibitor (HNE). HNE is one of the serine proteinase released into the mucosa that 
targets invading microorganisms. HNE also plays an important role in the migration of 
neutrophils through infected tissues and up-regulates the expression of several types of 
cytokines, such as IL-6, IL-8 and transforming growth factors (TGF-β). This further stimulates 
the innate immune response (Fitch et al., 2006; Wiedow and Meyer-Hoffert,  2005). 
 
Innate immunity functions also include serum specific proteins called mannose-binding lectin 
(MBL), which have the ability to attach to HIV and evoke a host cell response to destroy the 
invading virus (Alfano and Poli, 2005; Bouwman, Roep and Roos, 2006; Ezekowitz et al.,  
1989). Depletion of MBL enables a high titer of the virus, leading to a rapid progression of 
HIV infection  (Martin et al., 2003; Rantala et al., 2008; Spear, 1993).  
1.3.2. Adaptive Immunity 
The adaptive immune response involves contributions from different immune components, and 
are referred to as the humoral and cellular immune responses (Vieillard et al., 2006; Yamamoto 
and Matano, 2008). The humoral immune response includes B lymphocytes, responsible for 
the production of antibodies, while the cellular immune response involves T lymphocytes, 
including cytotoxic CD8+ T lymphocytes and CD4+ T lymphocytes. Both the humoral and cell 
mediated immune responses play critical roles in the defense against HIV-1 (Clerici et al., 
1993; Weber et al., 2001; Zhu et al., 2001). 
1.3.2.1. CD4+ T lymphocytes and HIV immunity 
CD4+ T lymphocytes are characterized by a specific receptor located on their surface, CD4. 
This molecule is the primary target of the HIV-1 envelope glycoprotein, Env (gp120/41) and 
the HIV-1 infection (Bourgeois et al.,  2006; Selig et al., 2001). As such, the CD4+ T cells are 
specifically targeted by HIV-1 during acute infection, leading to an abrupt depletion of CD4+ 
cells (Bentwich, 2005; López-Balderas et al., 2007; McKinnon et al., 2010). This is highly 
significant as CD4+ T lymphocytes play a critical role in the control of HIV/AIDS. Activating 
B lymphocytes to produce antibodies assists helper T cells to secrete cytokines necessary for 
the  regulation of a productive immune response (Ostrowski et al., 2000). Two types of helper 
T cells perform this function. The first T helper 1 (TH1) cells, which release the cytokines 
interferon-γ (IFN-γ) and interleukin-2 (IL-2) necessary for activation of macrophages and 
cytotoxic CD8+ T lymphocytes (Bandera et al., 2010; Fortna et al., 2004). The second type of 
helper T (TH2) cells, which produce other interleukins, such as IL-4, IL-5, IL-6 and IL-10, 
Chapter 1:                                                                                                        Literature Review 
14 
 
which are involved in antibody production. These cells collectively act to reduce the spread of 
HIV by stimulating antibodies and enhancing the immune response, through the recruitment of 
neutrophils, eosinophils and lymphocytes (Bandera et al.,  2010; Fortna  et al.,  2004; Plana et 
al.,  2004). 
1.3.2.2. Cytotoxic CD8+ T lymphocytes immune response 
Cytotoxic CD8+ T cells also play a key role in controlling HIV infection (Gómez, Smaill and 
Rosenthal, 1994; Landay et al., 1993; Liu et al., 1998). The protective role of HIV-1 specific 
CD8+ T cells can be identified by a rise in the initial HIV-1-specific CD8+ T cell responses 
during the first weeks of infection, which are directed against a limited number of HIV-1 
epitopes, like Env, Pol and Gag (Streeck and Nixon, 2010). The level of these initial CD8+ T 
cells is positively related to the slow progression of the virus and alow viremia rate and there 
is a direct link between the rapid progression of HIV infection and the reduction of HIV-1 
specific CD8+ T cells (Betts et al., 2001; Streeck et al., 2009). CD8+ T cells are normally 
stimulated during primary viral infections in humans to support the host immune response and 
inhibit HIV-1 virus replication (Callan et al., 1998; Reddehase and Koszinowski, 1984; Reusser 
et al., 1999; Rickinson and Moss, 2003). During acute HIV-1 infection, CD8+ T cells are 
involved in the reduction of the viral load through the destruction of HIV-1 infected cells by 
secreting a high amount of HIV-1 specific-IFN-γ (Cao et al., 2003; Borrow et al., 1994).  
Despite the low number of CD8+ T cells induced following acute HIV infection, they do inhibit 
the virus titer after an early period of HIV-1 viremia. These CD8+ T cells induced for chronic 
HIV infection are also less effective in inhibiting virus replication. In addition, following 
persistent viremia caused by the rapid progression of the HIV-1 infection, the level and 
functional activity of specific CD8+ T cells is impaired and exhausted as a result of certain 
death factors expressed on HIV tetramer+CD8+ T cells, such as inhibitory receptor programmed 
death 1 (PD-1 or PDCD1), which down-regulates the activated CD8+ T cells (Day et al., 2006; 
Miguele et al., 2002). This evident in the observation that first CD8+ T cells stimulated in an 
acute infection has a highly functional role in the suppression of virus replication compared to 
the impaired suppressive role of equivalent cells that are induced later. This suggests that early 
CD8+ T cells directly targeta limited number of HIV-1 epitopes (Streeck and Nixon, 2010). For 
example, there was a high detection level of Env-specific CD8+ T cells responses in acute HIV-
1 infected individuals showing a rapid reduction of viremia compared to a high viremic stage 
of infection characterized by a low level of CD8+ T cell response (Borrow et al., 1994). Also, 
CD8+ T cell responses directed for HIV-1 antigens like Gag, Pol and Env, detected in most 
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primary infected individuals showlow levels of virus replication. These cells were detected 
within a period of a few weeks to a few months while no neutralizing antibodies were detected 
during the same period of infection. This can be regarded as evidence there is a critical role of 
CD8+ T cell response to the primary HIV-1 infection (Koup et al., 1994). 
Furthermore, highly active CD8+ T cells are also involved in the immune response against HIV 
infection. These poly-functional CD8+ T cells are characterized by high proliferative capacity 
and the ability to secrete a range of cytokines, including IFNγ, IL-2 and TNF-α, thus resulting 
in a high level of cytotoxicity (Betts et al., 2006; Harari et al.,  2007; Kiepiela et al., 2004). 
HIV-specific CD8+ T cells are highly stimulated by specific HIV antigens, such as Gag, Pol 
and Env. These cells were detected in HIV-1 infected individuals after 3-6 months following 
presentation of the HIV-1 virus antigen (Koup et al., 1994; Duvall et al., 2008; Holmgren and 
Czerwinski, 2005). Human leukocyte antigen-restricted CTLs (HLA-class 1) were also 
detected, which induced highly protective immune responsesthat controlled HIV infection 
through the reduction of viremia (Koup et al., 1994). These cytotoxic CD8+ T cells have the 
ability to eliminate HIV-1 infected cells by secreting soluble factors, such as β-chemokines and 
specific CD8+ T cell antiviral factor (CAF), to combat HIV-1 infection by suppressingthe 
binding and transcription of the virus (Gulzar and Copeland, 2004). For example, HIV-1 
specific CD8+ T cells have been shown to play an effective role in preventing replication of the 
virus at mucosal surfaces, such as the genital mucosa, thus resulting in control of HIV infection. 
Also, sero-negative, highly exposed but resistant Kenyan sex workers have been shown to 
possess a high level of mucosal cytotoxic CD8+ T cells when compared to HIV-1 seropositive 
sex workers (Kaul et al., 2000). The protective role of HIV-1 specific CD8+ T cells includes 
their ability to clear the low level of infection and prevent HIV-1 virus dissemination (Card, 
Ball and Fowke 2013). In general, 5-10% of commercial female sex workers in the Pumwani 
district in Kenya were identified as HIV-exposed seronegative (HESN). These individuals were 
resistant to HIV infection, characterized by a higher level of HIV-CD8+ T cells detected in the 
genital mucosa compared to the HIV sero-positive female sex workers (Fowke et al., 1996). 
Furthermore, less than 1% of HIV-1 infected individuals, known as Elite controllers or 
suppressors (ES), have shown a clinically undetectable infection in addition to a low level of 
virus replication (<50 RNA copies/ml) without using antiretroviral treatment (ART). These 
individuals contain a higher significant level of polyfunctional CD8+ T cells which enhance 
suppression of HIV-1 replication compared to chronic progressive HIV-1 infected individuals 
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(Blankson, 2011; Buckheit et al., 2012). All of these studies indicate the critical role of highly 
functional subsets of CD8+ T cells in control of HIV-1 infection in non-progressive HIV-1 
chronic cases (Betts et al., 2006). 
A high response of polyfunctional CD8+ T cells was also detected in uninfected volunteers in 
the United Kingdom. These were administered subcutaneously with a prime-boost vectored 
vaccine expressing highly conserved amino acid positions of Gag, Pol, Vif and Env proteins 
obtained from the most conserved regions of the HIV-1 clades. This induced CD8+ T cells to 
target both Gag and Pol conserved epitopes which led to inhibited virus replication (Borthwick 
et al., 2014). Moreover, HIV-1 resistant individuals were similarly characterized by high levels 
of granzyme and perforin compared to progressive HIV-1 infected cases. This led to high 
cytolytic activity of cytotoxic CD8+ T cells. Although both non-progressive and progressive 
HIV-1 infected individuals were included in HIV-specific CD8+ T cells, only non-progressor 
individuals characterised with a higher significant proliferation were up-regulated by the 
highest perforin expression compared to HIV progressors (Migueles et al., 2002). This was 
also evident by measuring the level of granzymes and perforin expressed on human CD8+ T 
cells obtained from four groups of chronic-HIV-infected individuals in relation to their stage 
of progression and viremia. According to the results, the highest level of granzymes and 
perforin was detected in the elite controllers compared to viremic controllers, chronic 
progressive and viremic non-progressive individuals. Also, a negative correlation was detected 
between the HIV-1 RNA copy number and the level of granzymes and perforin expressed by 
CD8+ T cells. This was due to the highly proliferative capacity of induced CD8+ T cells up-
regulated by the highest level of expressed perforin and also because of the higher lytic function 
of granzyme B granules destroying the HIV-1infected cells (Migueles et al., 2008; Hersperger 
et al., 2010).  
Furthermore, the protective role of SIV-CD8+ T cells was detected in macaques (macaca 
mulatta) injected subcutaneously with the recombinant RhCMV/SIV virus expressing multiple 
SIV proteins, like Gag, Rev, Tat, Nef and Env. Polyfunctional CD8+ T cells were induced that 
enabled control of the intrarectal challenge of the SIVmac239 virus (Hansen et al., 2009).  
This protective role was also confirmed in SIVmac-infected macaques (Macaca mulatta) which 
were administered intravenously for three days with anti-CD8+ T cell monoclonal antibodies 
(OKT8F). The effectiveness of these anti-CD8+ T cell monoclonal antibodies was firstly 
apparent with the early depletion of CD8+ T cells following the first hour of first dose, with 
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99.9% depletion CD8+ T cells, thus leading to an increase in SIV virus replication. Following 
a complete reduction of these monoclonal antibodies, a reduced SIV virus titer had been 
detected (Jin et al., 1999). Similar results have also been identified in African green monkeys 
injected intravenously with anti-CD8+ T cell antibodies (cM-T807) following infection with 
the SIVagm virus (Gaufin et al., 2010). 
1.3.2.3. HIV-1 specific binding neutralizing antibodies 
HIV-1 specific neutralizing antibodies are directed mainly against the HIV-1 Env proteins and 
control the primary HIV infection by preventing the viral envelope from binding to CD4+ 
receptor molecules (Mascola and Montefiori, 2010). In general, the effectiveness of 
neutralizing antibodies is mainly restricted to halting the progression of chronic HIV infection 
(Morris, 2002). Their effectiveness has been shown in macaque trials where animals have been 
vaccinated with recombinant HIV Env proteins and have acquired a high level of anti-Env 
neutralizing antibodies that protected them against a homologous highly virulent simian- 
human immunodeficiency virus (SHIV) (Someya et al., 2005).  
Moreover, heterologous multi-clade HIV-1 epitopes of HIV Env gp140, were identified from 
six patients with HIV infection. The antibodies were neutralizing and poly-reactive when tested 
against HIV-1 virus in vitro (Mouquet et al., 2010). High levels of neutralizing antibodies, such 
as HIV specific mucosal IgA, have been detected in the genital tract and the plasma of resistant 
groups of female sex workers (Broliden et al., 2001; Devito et al., 2002; Kaul et al., 1999). 
However, one limitation of HIV specific antibodies induced for HIV-1 Env (gp120) is the lack 
of cross clade protection. This is due to the high diversity of HIV envelope glycoprotein 
sequences between HIV-1 clades (Letvin, 2009; Letvin, 2009a), which results in the escape of 
virus recognition of the antibody (Anzinger, Olinger and Spear, 2008; McGrath et al.,  2001; 
Montpetit, 1995; Morris, 2002). However, this has been changed in recent years after the 2009 
isolation of broadly neutralizing antibodies (Nabs) from chronic HIV-1 infected patients that 
can bind to different regions of HIV-Env gp120 i.eV1/V2 loop and V3 glycan region to control 
HIV-1 virus titers in long-term non-progressors (Benjelloun, et al., 2012; Mascola and Haynes, 
2013).  
1.3.3. Mucosal immunity 
The first line of defense for the human body against the external environment involves skin 
and the mucosal system (Jakasa et al., 2010; Proksch et al., 2008). The mucosal system includes 
nasal, oral, gastrointestinal, respiratory, conjunctival and urogenital mucosal surfaces, and 
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these are important for mucosal transmitted pathogens, such as influenza virus, Herpes simplex 
virus and HIV (Kaetzel and Bruno, 2007; MacDonald, 2003). Mucosal defense is characterized 
by physical barriers (such as epithelial cells) to protect against the invasion of pathogens and 
immune cells, such as dendritic cells and macrophages stimulated as a result of a bacterial or 
viral infection. This mode of defense also leads to the induction of both mucosal IgA and 
cytotoxic T lymphocytes (Kunisawa and Kiyono, 2005). Mucosal CD8+ T lymphocytes are 
important for providing long term protection against mucosal transmitted viruses, such as HIV-
1 (Belyakov and Berzofsky, 2004; Belyakov etal., 2004; Gallichan and Rosenthal, 1996; Suvas 
et al., 2007). For instance, HIV-resistant female sex workers in Kenya are characterized by 
persistent mucosal CD8+ T cells in the cervix compared to those at risk of HIV infection (Kaul 
et al., 2000). Additionally, the humoral immune response also plays an important role in 
mucosal immunity by stimulation of specific mucosal antibodies, such as IgA, blocking the 
main portal of HIV virus entry through mucosal surfaces like urogenital mucosa (Mascola  et 
al., 2000). 
 
The main aim of developing HIV vaccines is to induce a strong and stable level of mucosal 
immune response in addition to systemic immunity. This may be achieved by using the mucosal 
route for the delivery of HIV vaccines rather than the systematic route. This is not to say that 
systemic vaccination cannot induce mucosal immunity. For example, Gag-specific CD8+ T 
cells were shown to migrate to different effector mucosal sites after a prime boost intramuscular 
vaccination with recombinant adenovirus vectors expressing Gag protein in mice and macaques 
(Kaufman et al., 2008). It should be noted there is also an important role for HIV-specific 
neutralizing antibodies in immunity against human immunodeficiency virus type 1 (HIV-1) 
infection. This antibody immune response may include a local induction of IgA but this role is 
very limited when compared to more potent role of IgG for controlling HIV-1 at different 
mucosal sites. This role was highlighted in maccaque studies where administered IgG induced 
protection following vaginal challenge using SHIV virus compared to control macaques (Klein 
et al., 2013).  Mucosal immune responses induced by mucosal HIV vaccines aim to decrease 
virus transmission and progression (Gardner and Luciw, 2008; Gherardi and Esteban, 2005; 
Im and Hanke, 2004), by stimulating mucosal IgA and IgG responses, in addition to a cytotoxic 
CD8+ T cell responses (Bretscher, 1999; Caley et al., 1997). There are several routes of mucosal 
immunization; however, HIV mucosal vaccines are the most effective when administrated 
intrarectally or intragastriclly (Belyakov et al., 1998; Duerr, 2010). Vaccines administered 
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intranasally, leading to high mucosal and systemic CD8+ T cell immune responses that have 
protected BALB/c mice against the challenge virus, and the recombinant vaccinia virus 
expressing HIV- 1IIIB gp160 when compared to the subcutaneous route of vaccination 
(Belyakov et al., 1998). Also, in macaques there was no significant difference between various 
mucosal route of vaccination, such as intrarectal, intragastric, oral and intranasal vaccination, 
that induced robust CD8+ T cells in different mucosal regions following vaccination (Duerr, 
2010). 
1.3.3.1.Mucosal CD8+ T cells and homingintegrin receptors 
Integrins are a large family of heterodimeric glycoprotein receptors first identified over 25 
years ago (Tamkun et al., 1986). In addition to their direct role in cell adhesion, integrins play 
also important role in cell migration which is essential in many vital activities, such as 
embryonic development, tissues repair and regeneration, and immune responses (Ridley et al., 
2003). Lymphocytes are continually migrating between the peripheral blood circulation and 
different tissues. These cells are trafficked from circulation to various organs via lymph nodes 
and pass through venues high endothelial venules (HEV) (Girard and Nerem, 1995). 
 
In order to detect mucosal CD8+ T cell responses, research groups have been studying various 
homing receptors, such as LPAM-1, CD103 and CCR9 expressed on antigen-specific CD8+ T 
cells migrating to different lymphoid organs.These homing CD8+ T cell integrins include α4β7 
(LPAM-1), αEβ7 (CD103) and CCR9 (CD199) integrins that are mainly expressed following 
HIV-1 infection or vaccination to prevent dissemination of the HIV-1 virus (Hogg et al., 2003). 
Mucosal homing integrins are heterodimeric transmembrane protein receptors that work as 
bridges for cell-cell and cell-extracellular matrix (ECM) interactions. They participate in many 
important biological functions, such as migration, differentiation and apoptosis (Gupta et al., 
2005; Tang and Rosenthal, 2010). These homing integrins up-regulated trafficking of antigen-
specific CD8+ T cells to mucosal compartments. For instance, polyfunctional HIVGag-specific 
CD8+ T cells obtained from prime boost intramuscular vaccination of BALB/c mice using the 
recombinant rAd26-Gag and Ad5HVR48-Gag virus, transferred intravenously into naïve mice, 
led to the migration of these cells to the gastro-intestinal tract with higher expression of homing 
integrins, such as β7 integrin, CCR9, and CD103 compared to non-transferred mice (Kaufman 
et al., 2008). Furthermore, transfer of mucosal CD8+ T cells expressing these homing integrin 
receptors has been shown to be critical for protection against the intranasal A/PR/8/34 influenza 
infection in BALB/c mice. This included an intravenous adoptive transfer of 107 effector CD8+ 
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T cells after one hour of intranasal influenza infection.The influenza virus titer was reduced by 
the fourth day following infection compared to the negative control (Cerwenka et al., 1999). 
These mucosal CD8+ T cells were functionally important in the clearance of the rotavirus from 
intraperitoneal infected mice following the intravenous adoptive transfer of α4β7+ expressed 
CD8+ T cells (Rose et al., 1998). 
1.3.3.2.Basic structure of integrins 
Homing T cell integrins include α (alpha) and β (beta) subunits that form the main chain 
subunits of the homing integrin. Both subunits differ in their nature of expression by 
lymphocytes and endothelial cells. There are 8β subunits (β1-β8) and 18α chain subunits. Both 
α and β subunits combine for 24 different integrins with distinct αβ integrin subunit pairs (Hogg 
et al., 2003). The main structure of integrins consists of two parts. The first part is the 
extracellular part, which is elongated from stalk and ends with a globular head region. This part 
includes approximately 700 amino acids in the length of α subunit and 1000 amino acids in the 
length of the β subunit. The second part is the cytoplasmic tail of less than 75 amino acid in 
length (Xiong et al., 2001) (Figure 1.6). 
 
Figure 1.6. The basic structure of mucosal homing CD8+ T cell receptors. These integrins are 
transmembrane receptors consisting of a heterodimer of alpha and beta subunits. They are 
expressed on mucosal homing T cells and mediate the attachment specific to endothelial cells 
(Eslami, 2005).  
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These integrins also mediate cell adhesion through attachment of their globular head region 
(ligand binding extracellular part) with the extracellular matrix glycoproteins, such as laminins 
and collagens located on the cellular plasma membrane. The β subunit is shared between 
different integrin molecules located in different animals. For example, the β1 subunit works as 
the main active subunit of integrins in chickens, the human fibronectin receptor, the human 
laminin receptor and VLA proteins (Stroeken, 2002). T cells mainly express the two β7 subunit 
integrins, α4β7 and αEβ7, that are highly involved in the migration of effector T cells to 
peripheral lymph nodes (Hogg et al., 2003). About 12 of these integrins are expressed by T 
cells and are highly involved in T cell mediated immunity. The ability of T cells to express 
these integrin heterodimers depends on their specific subsets and maturation (Pribila et al., 
2004). For example, low levels of these integrins, such as αLβ2 (leukocyte function associated 
antigen-1: LFA-1), α4β1 (very late antigen-4: VLA-4) and α4β7 (lymphocyte Peyer's patch 
adhesion molecule integrin: LPAM) are expressed by naïve CD8+T cells compared to effector 
or memory CD8+ T cells. In order to enhance migration of T cells to lymphoid effector sites, 
these integrins are binding specific ligands like intracellular adhesion molecule-1 (ICAM-1), 
vascular cellular adhesion molecule-1 (VCAM-1), and mucosal addressin cell adhesion 
molecule-1 (MAdCAM-1) (Egger et al., 2002; Pribila et al., 2004). This facilitates the adhesion 
of CD8+ T cells to the endothelial layer and their migration into different lymphoid organs like 
the peripheral lymph nodes (DeNucci, Mitchell and Shimizu, 2009; Hogg et al., 2003; 
Stroeken, 2002) (Figure 1.7). 
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Figure 1.7. The multi-steps model of CD8+ T cell migration to mucosal surfaces. Migration 
of specific CD8+ T cells from the effector sites of infection to mucosal regions includes 
expression of specific mucosal integrins, such as α4β7 (LPAM-1), αEβ7 (CD103) and CCR9 
(CD199) on epithelial cells transmit through perivascular membranes on their way to mucosal 
surfaces of different lymphoid tissue (Hogg et al., 2003). 
In addition, a migration strategy includes a contribution of these integrins with specific secreted 
chemokines, such as CD44, CD62L and CCR9, which combine with these expressed integrins 
to facilitate the migration of antigen-specific T cells to the effector sites of infection (Fousteri 
et al., 2009; Wermers et al., 2011). In general, high expression of beta 1 or 7 integrin subunits 
facilitates the attachment of high endothelial venules of Peyer’s patches and T cells with 
adhesion molecules, such as LPAM-2 (α4β1) which only binds the very late antigen 4 (VLA-
4). While the beta 7 integrin subunit molecule has a high affinity of adhesion property by 
binding to specific legand molecules, such as (MAdCAM-1) for LPAM-1(α4β7) and vascular 
adhesion molecules (VCAM-1) for CD103 (αEβ7) (Strauch et al., 1994; Yang et al., 1998).  
1.3.3.2.1. LPAM-1 (α4/β7) integrin 
The lymphocytepeyer's patch adhesion molecule (LPAM-1 or α4β7 integrin heterodimer) is 
one of the homing integrin receptors expressed on T cells characterized by adhesive properties 
responsible for the recognition of migrated lymphocytes into lymphoid compartments, such as 
the gut-associated lymphoid tissues (Rosé et al., 1998). LPAM-1 is binding to its ligand called 
the mucosal addressin cell adhesion molecule (MAdCAM), which is located mainly on high 
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endothelial venules (HEVs) of mucosal lymphoid organs (Gorfu, Rivera-Nieves and Ley 2009; 
Petrovic et al., 2004). This enables the antigen-specific T cells to migrate from the main 
circulatory system to mucosal areas, particularly the endothelium of the gut or other related 
lymphoid tissues (such as Peyer’s patches and other lymph nodes except the peripheral lymph 
nodes) (Gorfu, Rivera-Nieves and Ley, 2009). Indeed, the homing integrins are differentially 
expressed on migrated T cells depending on the status of these cells (Petrovic et al., 2004). For 
instance, the low level of α4β7 integrin is expressed on naïve T and B cells while it increases 
following inflammation or infection. The α4β7 integrin is also expressed on different types of 
cells, such as natural killer (NK) cells, and stimulated monocytes, macrophages and eosinophils 
(Erle et al., 1994). However, the α4 subunit has the main role to mediate migration of activated 
CD8+ T cells to the intestinal mucosa. Therefore, α4β7 has been considered the more dependent 
T cell homing marker which has been highly expressed in the intestinal mucosa following the 
intravenous injection of C57BL/6J mice using the recombinant vesicular stomatitis virus 
expressing ovalbumin (VSV-ova) peptide, SIINFEKL. Mucosal CD8+ T cells expressing α4β7 
were transferred intravenously into naïve mice. These mice were infected intravenously with a 
wild type of vesicular stomatitis virus which led to high trafficking of the transferred cells to 
effector mucosal regions to control virus infection (Lefrançois et al., 1999). Some pathogenic 
microorganisms that invade mucosal regions, such as rotavirus, herpes simplex virus type-2, 
HIV and Chlamydia, generate a mucosal CD8+ T cell response that provides protection against 
the invading pathogens. The overall response is affected by the migration of CD8+ T cells to 
infected mucosal tissues and is mediated by the α4β7 integrin homing receptor which facilitates 
attachment to specific lymph nodes in the intestine, respiratory and vaginal mucosal surfaces 
(Gupta et al., 2005; Tang and Rosenthal, 2010). 
There are some differences in the structure and affinity of binding between LPAM-1 and 
LAPAM-2. For instance, LPAM-2 (α4β1) integrin contains an α subunit which is recognize 
the specific analogous to α chain of the human specific integrins heterodimer (VLA-4) while 
LPAM-1 works analogous to other T cell homing heterodimer integrin molecules in humans 
(Holzmann, McIntyre and Weissman, 1989). Therefore, LPAM-1 also binds other ligands, such 
as VCAM-1 or the CS-1 subdomain of human fibronectin, but with lower affinity compared to 
MAdCAM (Rott et al., 1996). The LPAM-1 integrin and other groups of integrins work as the 
CD8+ T cell homing receptors detect mucosal CD8+ T cell immune responses. These can also 
be used to distinguish memory and effector T cells in response to a rotavirus infection in mice. 
For example, functional CD8+ T cells obtained from rotavirus infected mice induced a high 
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percentage of the α4/β7+ subset of CD8+ T cells compared to naïve T cells that included a 
subset α4/β7-CD8+ T cell. Therefore, LPAM-1 is mainly expressed on antigen-specific CD8+ 
T cells and is used for detecting mucosal CD8+ T cell immune responses that are induced 
following an intraperitoneal (i.p) rotavirus infection in mice.These mucosal cells are highly 
effective in clearing infection compared to other mucosal homing CD8+ T cell integrin 
receptors (Rosé et al., 1998). 
1.3.3.2.2. CD103 (αEβ7) integrin 
CD103 or αEβ7 is a mucosal integrin receptor and is composed of a heterodimer of two 
subunits, αE and β7. This integrin works mainly as a homing receptor in various cell types, 
such as epithelial cells that are localized in various mucosal compartments including the gastro-
intestinal and female reproductive tract, and the important entry sites of mucosal infections, 
such as herpes simplex and HIV (Gebhardt et al., 2009; Tang and Rosenthal, 2010; Kiravu et 
al., 2011). It is characterized as one of the T cell homing receptors that have an important role 
in trafficking of the activated CD8+ T cells from the blood to the genital and gastrointestinal 
tract mucosa (Kiravu et al., 2011). Also, CD103 mediates an interaction or adhesion of mucosal 
T cells and it surrounds the epithelial layers through its binding to a specific ligand called E-
cadherin or L-CAM, which has a combined function for determining the shape and motility of 
lymphocyte cells (Kiravu et al., 2011; Schlickum et al., 2008). A high percentage of mucosal 
HSV-2 specific CD8+ T cells found in genital tract mucosa have been shown to stain positive 
for the homing integrins CD103 (αEβ7 integrin) and CD49a (α1β7 integrin or VLA-1) one 
week after HSV-2 infection in a mouse model (Tang and Rosenthal, 2010), thus suggesting an 
important role for these integrin expressing cells in anti-viral immunity and in the control of 
these viruses. 
The ability of these integrins to be expressed on migrating effector T cells depends not only on 
the integrin but also on the area of localization. For instance, CD103 (αEβ7) was expressed on 
90% of gut intraepithelial lymphocytes (IEL) localized on Peyer’s patches and other villi to 
mediate their attachment to epithelial cells (Koseki et al., 2001). This was not available for 
other integrins like L-Selectin. Indeed, it has been confirmed that CD103 is directly involved 
in trafficking HIV-specific CD8+ T cells to the cervical mucosa, which are mainly included in 
specific Gag+CD8+ T cells (Kiravu et al., 2011). The highly effective role of the αEβ7 integrin 
heterodimer is represented by the induction of CD8+ Tcells in both peripheral and intestinal 
epithelium as a response to an infection or tumor. For instance, there is a highly effective role 
for CD103 chemokine receptors in regulatory functions to stimulate the migration of effector 
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T cells to the infected foci, such as mesenteric lymph nodes and Peyer’s patches, which are 
represented by a CD103+CD8+ subset of T cells (Wermers et al., 2011; Apostolaki et al., 2008). 
1.3.3.2.3. CD199 (CCR9) integrin 
CCR9 or CD199 is a mucosal homing integrin mainly expressed on lymphoid cells following 
its binding to the specific legand (CCL25) that is presented on epithelial cells in the gut with 
enhanced migration of T cells from the periphery and secondary lymphoid organs to the gut 
mucosa (Johansson-Lindbom and Agace, 2007). Indeed, the CCR9 integrin heterodimer has an 
important regulatory role in the migration of T cells to the infected regions during a specific 
inflammatory status, particularly in the intestine, which was represented by an increase in the 
subset of CCR9+CD8+T cells found in the spleen, MLN, the lamina propria and the mesenteric 
lymph nodes in infected mice. This regulatory role of CCR9 has also been been confirmed by 
intraperitoneal administration of the anti-mouse CCR9 monoclonal antibody which led to an 
increase in the severity of ileitis in B6 mice (Wermers et al., 2011). 
 
It has also been confirmed that mucosal CD8+ T cells are differentiated by expressing CCR9, 
which mediates the fast recovery of BALB/c mice from acute colitis. This was achieved by the 
migration of effector CD8+ T cells from blood circulation to Peyer’s patches and the small 
intestine, compared to a low level of expressed CCR9 in the large intestine (Wurbel et al., 
2011). As a result of induced mucosal CD8+ T cells expressing CCR9, wild mice were shown 
with normal weight after 17 days of infection compared to CCR9 deficient mice who suffered  
severe lose weight and a high mortality rate (Wurbel et al., 2011). Furthermore, CCR9 was also 
highly required to control ileitis in mice through its expression on lymphocytes at the last stage 
of infection that were localised in intestinal lamina propria and mesenteric lymph nodes 
(Wermer et al., 2011). In addition, a high level of SIV-specific CD8+ T cells expressing both 
CCR9 and αEβ7 were detected especially in mesentric lymph nodes of intranasally infected 
monkeys using recombinant modified vaccinia virus expressing SIV-Gag, Pol and Env proteins 
(rMVTTSIVgpe). The monkeys were then boosted with an intramuscular infection with 
recombinant adenovIrus expressing SIV-Gag, Pol and Env proteins (rAd5SIVgpe). This 
mucosal T cell response was able to protect mokeys against mucosal infection from the 
SIVmac239 challenge virus (Tang et al., 2012). 
 
Indeed, there are many factors regulating expression of mucosal homing integrins and 
stimulating the migration of CD8+ T cells to various mucosal compartments. For instance, 
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retinoic acid is up-regulating both α4β7 and CCR9 expressed on CD8+ T cells. Also, retinoic 
acid works through enhancing the signaling receptors of retinoic acid in CD8+ T cells in the 
spleen and mesenteric lymph nodes by expressing CD103+CCR9+ subset of CD8+ T cells 
(Svensson et al., 2008). Furthermore, 90% of T cells in the intestinal mucosa express α4β7 and 
CCR9 as they are trafficked from the peripheral to the gut and this would be impaired in α4β7- 
and CCR9- deficient mice (Berlin et al., 1993; Wurbel et al., 2001). There are several other 
factors affecting the migration of effector CD8+T cells to mucosal surfaces. 
1.3.3.2.4. Interleukin 15 (IL-15) 
IL-15 was first discovered in 1994 and identified as one of the T cell growth factors. 
Interleukin-15 (IL-15) is a glycoprotein and is a member of the 4 α-helix bundle cytokine 
family of approximately 15-kDa (Waldmann and Tagaya, 1999). There is a high similarity of 
IL-15 sequences among different species. For instance, there is about a 97% of identical 
residues between human and simian IL-15, and 82% identical residues between human and 
porcine IL-15 (Canals et al., 1997; Anderson et al., 1995). IL-15 is mainly produced by 
dendritic cells (Kuniyoshi et al., 1999), monocytes, macrophages (Sandau et al., 2004) and T 
cells (Grabstein et al., 1994; Bamford et al., 1996). 
IL-15 is a pleiotropic cytokines highly involved in an innate and adaptive immune response 
and is mainly active on natural killer (NK) cells (Ma, Koka, and Burkett, 2006). IL-15 utilizes 
the same common receptors chains as IL-2, β (CD122) and γ (CD132) chain of their trimeric 
receptors. Both cytokines also share similar biological properties and particular function 
enhancements of T cell proliferation, generation of cytotoxic T cells and survival of NK cells 
(Bodnar et al., 2008; DiSanto et al., 1997). However, IL-15 has little sequence homology with 
IL-2. Indeed, IL-15 has an important role in the development and function of NK/NKT cells 
and also in the maintenance of naive and memory CD8+ T cells (Gill and Ashkar, 2009). 
Furthermore, IL-15 is highly required for the differentiation and persistence of both effector 
and memory CD8+ T cells (Munger et al., 1995). Also, the regulatory role of cytokine IL-15 
for the development and maintenance of different types of immune cells is confirmed by a high 
decrease of CD8+ T cells, natural killer cells, NKT cells and intraepithelial T cells detected in 
defective cytokine IL-15 mice (Yajima et al., 2006). IL-15 also stimulates the immunological 
function of CD8+ T cells by enhancing their cytolytic activity and inducing long lived memory 
T cells that controlling malaria re-infection in mammalian host as IL-15 gives rise the level of 
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IFN-γ producing CD8+ T cells in addition to its role in increasing CD44hiCD62Llo CD8+T cell 
subset necessary to control malaria re-infection (Krzych et al., 2012). 
The main role of cytokine IL-15 is to maintain, survive, proliferate and turnover CD8+ T cells 
detected with high availablibility during periods of inflammation in mice. This is necessary to 
improve the immune response in the infected mice (Rubinstein et al., 2008), with less antigen-
specific CD8+ T cells maintained in IL-15-deficient mice. Also, the cytokine IL-15 is 
considered one of the key cytokines generated in response to mucosal infection. IL-15 enhances 
the proliferation and migration of effector CD8+ T cells to the infected areas such as the lung 
following intranasal influenza infection (Verbist et al., 2011), the gut in mice after infection 
with the lymphocytic choriomeningitis virus (LCMV) (Masopust et al., 2006) and the skin 
following epicutaneous infection using the vaccinia virus (Jiang et al., 2012). For example, 
high levels of IL-15 have been identified in the lung airways at day 6 of intranasal influenza 
infection in mice. This promotes specific CD8+ T cells to migrate throughout the mucosal area 
of the lung (Rubinstein et al., 2008).  
 
IL-15 also works as an adjuvant used to increase the ability of the antigen to be stimulated for 
a longer time in order to induce higher immune response and enhance the migration of specific 
natural killers or CD8+ T cells to effector sites following intranasal influenza infection of mice 
(Verbist et al., 2011; Verbist et al., 2012). Moreover, the removal of specific dendritic cells 
that produce cytokine IL-15, or the administration of a specific IL-15 antagonist, inhibits the 
proportion of influenza specific CD8+T cells in the lungs and increases the virus load (McGill, 
Van Rooijen and Legge 2010; McInnes et. al., 1996). 
 
It is also recognized that cytokine IL-15 has a responsibility to stimulate effector influenza 
specific CD8+ T cells to migrate to the site of infection (lungs airways) in the intranasal infected 
IL-15-deficient B6 mice using either A/HK-X31 (X31, H3N2) or A/Puerto Rico 8 (PR8, H1N1) 
influenza viruses and intranasally administered with IL-15 plus IL-15Rα soluble complex 
(Verbist et al., 2011). Furthermore, IL-15 is necessary to stimulate a protective CD8+ T cell 
response in HIV infected chimpanzees as a result of the regulatory role of interleukin IL-15 to 
maintain the level of interferon-gamma (IFN-γ). For instance, a highly significant reduction of 
both IL-15 and tumor necrosis factor alpha (TNF-α) interferon-gamma (IFN-γ) were detected 
in progressive HIV-infected chimpanzees compared to a robust maintained level of IL-15 and 
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interferon-gamma (IFN-γ) in those resistant to infection (Rodriguez et al., 2007). The role of 
IL-15 is directly controlled by the specific receptor, IL-15Rα, which is mainly expressed 
mainly on various types of cells, such as dendritic cells, monocytes and macrophages (Steel, 
Waldmann and Morris 2012; Anderson et al., 1995) and T cells (Rowley et al., 2009). The IL-
15Rα receptor ischaracterized by a high affinity binding to soluble IL-15, and IL-15 acts 
through its binding to IL-15Rα receptors on CD8+ T cells to enhance the survival and 
proliferation of CD8+ T cells (Mortier et al., 2006; Mortier et al., 2008). For example, higher 
levels of expressed IL-15 mRNA on CD8+ T cells were detected in BAL, mediastinal draining 
lymph nodes and the spleen of intranasally infected BL/6 mice with A/Hong Kong-
X31influenza virus. There was a four fold increase in its expression at day 3 of infection 
compared to naïve mice, and expression of  IL-15 mRNA continued to increase in the lung 
airways until the day 7 of infection (Verist et al., 2011). Furthermore, IL-15 had an important 
role for the expansion of primary antigen-specific CD8+ T cells detected indifferent organs, 
such as the spleen, peripheral lymph nodes, mesenteric lymph nodes, lung, liver, and small 
intestinal lamina propria (LP) of the intravenous infected C57BL/6J mice with vesicular 
stomatitis virus (VSV). However, VSV specific CD8+ T cells were reduced significantly (less 
than 50%) in IL-15−/− and IL-15Rα−/− mice. Also, the level of IL-15Rα expression was 
correlated to the status of a CD8+ T cell as it was fairly low on naive CD8+ T cells while up-
regulated on Ag-specific effector cells.  As a result, IL-15 is necessary for the generation and 
maintenance of specific antiviral CD8+ T cells (Kimberly et al., 2002). Therefore, both IL-15 
cytokine and IL-15Rα receptor expression by specific immune cells, such as dendritic and 
CD8+ T cells are considered as an indicator of highly migrated T cells to mucosal regions to 
control various mucosal infections, such as an influenza infection and or other inflammatory 
diseases like rheumatoid arthritis (McGill, Van Rooijen and Legge 2010; McInnes et. al., 
1996). In addition, other cytokines have a role in the migration of T cells to mucosal effector 
sites following mucosal or parenteral vaccination. One of these cytokines is IL-12, which was 
highly expressed in draining lymphoid tissues, such as mesenteric lymph nodes and Peyer’s 
patches following oral or intraperitoneal reovirus infection in BALB/c mice (Mathers and Cuff, 
2004). 
 
On the other hand, high expression of IL-4 and IL-13 down-regulates HIV-1 specific CD8+ T 
cells. This was identified in IL-14-/- and IL-13-/- mice primed intranasally with recombinant 
Fowl Pox Virus expressing the HIV-Gag, Pol and Env proteins.The mice were then inoculated 
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with an intramuscular dose of recombinant vaccinia virus expressing the Gag and Pol protein. 
As a result, polyfunctional CD8+ T cells specific for H-2Kd Gag197-205 were only detected in the 
IL-14-/- and IL-13-/- compared to the wild type of infected mice. Accordingly, it is recognized 
that higher protective HIV-specific CD8+ T cells induced following mucosal vaccination can 
be enhanced perfectly by down-regulating expression of IL-4 and IL-13 at mucosal lymphoid 
regions (Wijesundara et al., 2013). Furthermore, other cytokines were generally suppressed 
following vaccination. For example, IL-10 is one of the inhibited cytokines and suppressed in 
lymphoid tissues like Peyer's patches and mesenteric lymph nodes. Also, IL-4 is highly 
inhibited and suppressed in the mesenteric lymph nodesin oral or intraperitoneal vaccinated 
miceusing reovirus compared to unvaccinated mice (Mathers and Cuff, 2004; Jackson et al., 
2014 
1.3.3.2.5. CD62L and CD44 molecules 
CD62L or L-Selectin is a cell adhesion molecule or homing receptor expressed on lymphocytes 
as a member of the Selectin family of protein. It enhances lymphocytes moving to secondary 
lymphoid tissues and regulates migrationof T cells to the peripheral lymph nodes via their 
rolling through the endothelium of blood vessels (Robbins et al., 1998). CD62L, in addition to 
IFN-γ and TNF-α, was highly produced by both CD8+ and CD4+ T cells induced in lymph 
nodes isolated from vaccinia virus naturally infected individuals after a zoonotic outbreak that 
occurred in Brazil in 2005 (Medeiros-Silva et al., 2013). It was also detected in 40% of CD4+ 
and 50% of CD8+ T cells located in cervical draining lymph nodes, or spleen and distal lymph 
nodes after intranasal immunization of C57BL/6 mice using ovalbumin (OVA) plus CpG oligo-
deoxynucleotide adjuvant (Ciabattini et al., 2011). CD62L also differentiates effecter T cells 
from naïve T cells. For instance, T cells can be recognized by subsets of CD62Lhi CD8+ T 
lymphocytes in naïve mice comparedto CD62Llo specific subset of CD8+ T cells in influenza 
infected mice, and C57BL/6J using recombinant influenza virus (HKx31-OVA) expressing the 
ovalbumin (SIINFEKL) (Kedzierska et al., 2007). 
 
CD44 is a polymorphic group of proteins controlled by highly conserved gene, the CD44 gene 
and binds to various legands, such as osteopontin, collagens, and matrix metalloproteinases 
(MMP) (Spring et al., 1988). The CD44 is within the size range of 80–200 KDa, which was 
firstly identified as an antigen recognized by a monoclonal antibody raised against human 
leukocytes (Screaton et al., 1992). The CD44 is a transmembrane cell surface glycoprotein 
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molecule working as a homing cell adhesion molecule, which regulates certain changes like 
differential glycosylation in extracellular matrix composition. This leads tothe control of 
different cellular functions, such as growth, survival and differentiation (Ponta, Sherman and 
Herrlich, 2003). The CD44 is also involved in several cellular functions, such as cell–cell 
interactions, and the migration of lymphocytes to effector sites (Screaton et al., 1992). 
Furthermore, CD44 is the most dominant subset of CD8+ T cells as lymph nodes homing 
receptors recognize the specific CD8+ T cell induced during primary intranasal influenza 
infection in mice (Kedzierska et al., 2007). 
1.4. HIV-1 Vaccines 
Vaccines are still regarded as the most effective way to control the majority of infectious 
diseases, particularly those diseases that are caused by highly pathogenic viruses (Johnston and 
Fauci 2008). Since the first identification of HIV/AIDS, more than 50 vaccine candidates have 
been tested to control HIV infection (Barouch, 2008; Girard, 2006).  
All of these trials have failed due to the following key challenges: 
(i) Highly variable antigensof HIV-1; 
(ii) The high mutation rate of HIV-1 permitting the virus to escape host immunity; 
(iii) The lack of efficient immune responses against latently infected cells; 
(iv) The absence of synergistic activity between humoral and cellular immunity to control HIV; 
and 
(v) The limitations of standard laboratory animal models used for HIV vaccine trials (Barouch,  
2008; Girard, 2006). 
 
The most important function of any HIV-1 vaccine is to produce an immune response that will 
prevent transmission and replication of the virus at the entry portal, such as the vaginal, rectal, 
urethral and oral mucosa (Haase, 2010; Haynes and Shattock, 2008; Veazey, 2005). To achieve 
this, HIV vaccines must be safe, immuno-efficient, highly prophylactic and capable of reducing 
viral loads to less than 1500 RNA copies per ml in the HIV infected persons, at which point 
HIV progression can be controlled (Newman et al., 2010; Quinn et al., 2000). 
1.4.1. Traditional vaccines strategies 
Traditional strategies for HIV vaccines include live-attenuated virus vaccines, whole killed 
virus vaccines and subunit vaccines (Barouch  2008). 
Chapter 1:                                                                                                        Literature Review 
31 
 
1.4.1.1.Live attenuated vaccines 
Live attenuated vaccines have been used to control highly infectious diseases such as small 
pox, poliomyelitis and herpes viruses, and are still regarded as potentially the most protective 
vaccines (Chakrabarti et al., 1996; Plotkin, 1994; Riedel, 2005). Use of live attenuated SIV 
vaccines in monkeys provided significant protection to macaques against a virulent 
homologous SIV (Koff et al., 2006; Wyand et al., 1996). Also, there is an inverse correlation 
between the level of virus attenuation and the level of protective immune response in macaque 
studies (Wodarz, 2008). The use of attenuated viruses with deleted or truncated genes, such as 
nef or deletion of both nef and vpr resulted in a strong level of protective immune responses in 
vaccinated macaques (Johnson and Desrosiers, 1998). Moreover, intravenous vaccination of 
rhesus monkeys using attenuated SIV with deleted nef and vpr sequences (SIVmac239), or the 
deleted nef and vpx sequences, or deleted nef, vpr, vpx sequences, then intravenously or 
intravaginally infected with the SIVmac251 challenge virus. The less attenuated SIV vaccine 
induced robust SIV specific T cell responses leading to higher protection in the intravaginal 
challenged group than protection against those intravenously challenged (Johnson et al., 1999). 
 
Furthermore, other trials with macaques used attenuated simian immunodeficiency virus 
(SIVmac239) constructed with the six deleted accessory genes, nef, vpr, vpx, vif, tat, and rev 
genes. These were the given within multiple doses of intravenously to macaques and then 
challenged intrarectally using pathogenic type of homologous SIV challenge virus, produced 
protection in 75% of vaccinated macaques with decreasing viral load to less than 1,000 
copies/ml for 6 months, and with a stable count of CD4+ T cell for 2 years following challenge 
(Guan et al., 2001). However, there was no complete protection for the rhesus monkeys who 
were vaccinated intravenously with SIVmac316-D-nef (deleted nef), or with SIVmac239-D3 
(deleted nef and vpr), and then challenged intravenously using the wild type of SIV 
(SIVmac251). The result was the most vaccinated monkeys were infected after 18 to 44 weeks 
of challenge (Wyand et al., 1996). Also, there was a concern with the safety of the SIV 
attenuated vaccine represented by a persistent rise of viremia in vaccinated neonate macaques 
because of inability of immune response induced for nef or vpr to decrease the pathogenicity 
of SIV in neonate macaques (Baba  et al., 1999). In another study in macaques vaccinated with 
highly attenuated SIVmac239-Delta 3 which included large deletions of nef and vpr, and then 
challenged with a wild type of the SIV virus, saw the level of immune response decline, 
accompanied with serious adverse reactions. These reactions included recurrent viremia, 
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thrombocytopenia, wasting, and opportunistic infections aftera few years of vaccination in 
vaccinated macaques compared to non-vaccinated macaques (Baba et al., 1999). Accordingly, 
a live attenuated vaccine is unlikely to be used in humans, this is because of the risk of reversion 
to the virulence of virus and the attenuated virus strain could cause HIV infection as a result of 
a virus mutation which can lead to immune dysregulation in the vaccinated individuals (Baba 
et al., 1999; Baba et al., 1995; Foster and Garcia, 2008; Gorry et al., 2007). 
1.4.1.2.Whole killed and subunit vaccines 
Whole killed and subunit vaccines have also been used for immunization against HIV/SIV 
infection. Preclinical trials of formalin-killed potentiated with respective adjuvants or subunit 
SIV vaccines have resulted in protection against experimental homologous infection 
ofpathogenic SIV virus in rhesus macaques (Macaca mulatta) (Mascola and Montefiori, 2010; 
Patterson, Robey and Robert-Guroff, 2000). However, whole killed viruses and protein 
subunits are recommended in vaccination programs because of their inability to induce broad 
antibody or CD8+ T cell responses multiple doses potentiated adjuvants (Murphey-Corb et al., 
1989; Flynn et al., 2005). The mucosal adjuvants used included combinations of cytokines, 
such as IL-1α, IL-12, and IL-18 to potentiate an antibody immune response in BALB/c mice 
intranasally vaccinated with the polyvalent C4/V3 HIV-1 Env peptide as the HIV vaccine 
candidate (T1SP10 MN) (Bradney et al., 2002). When used to deliver the HIV-1 Env peptide 
with multiple doses, it resulted in a high level of antibodies involving serum IgG1 and secretory 
IgA in different sites of mucosal surfaces, such as  saliva, and the vaginal lavage in vaccinated 
mice (Bradney et al., 2002; Staats and Ennism, 1999; Staats et al., 2001). One of the first 
generations of subunit vaccines represented by the Phase I HIV vaccine trial was conducted in 
50 healthy adult participants who were at risk of HIV infection but were sero-negative for HIV-
1.  This group was given the vaccine composed of recombinant HIV-1 Env proteins (gp 120 or 
gp160) conjugated with alum adjuvant, which led to the induction of a specific HIV-1 Env 
antibody response in sera. There were samples of sera obtained from 16 HIV-1 infected persons 
used to evaluate neutralizing antibody activity against the 5 primary viruses (US 1-US5) that 
were isolated from the HIV-1 infected volunteers in addition to the heterologous laboratory-
adapted HIV strains or  (MN, IlIB, and SF2) (Frey, 1999; Mascola et. al., 1996; VanCott et al., 
1997). However, there was no long term protection against virus infection due to the lack of 
long active HIV neutralizing antibodies (nAbs) (Goebel et al., 1999; Mascola et. al., 1996). 
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1.4.2. Novel vaccine strategies 
Traditional HIV vaccine strategies have failed to provide significant protection (Foster and 
Garcia, 2008; Das, Jeeninga and Berkhout, 2010). Accordingly, there is currently no 
commercially available vaccine to prevent HIV infection (Koup and Douek, 2011; Wahren et 
al., 2010). Due to safety concerns and the ineffectiveness of traditional HIV candidate vaccines, 
alternative strategies involving various genetic approaches are being used to develop novel 
vaccines (Excler, 2007; Letvin, 2004; Voronin, Manrique and Bernstein, 2010). These novel 
HIV vaccine strategies include DNA vaccines and live recombinant vectors (Dubensky, Liu 
and Ulmer, 2000; Letvin, 2005). 
1.4.2.1. DNA vaccines 
DNA vaccines utilize plasmids that encode specific viral proteins as immunogens for the 
induction of strong immune responses (Casimiro et al., 2003; Graham et al., 2006; Vasan et 
al., 2010). In general, most DNA candidate vaccines for HIV-1 have been shown to be safe 
when injected in mice or macaques, although they have failed to induce a protective immune 
response (Johnston  and  Flores 2001). The immunogenicity of plasmid DNA vaccines has been 
improved with adjuvants (Barouch  et al., 2000a; Chong et al.,  2007; Kutzler et al.,  2009; Xu 
et al.,  2008). For example, DNA vaccines have been conjugated with conventional adjuvants, 
such as aluminum salts, which increase antibody responses 100-fold in mice and 10-fold in 
macaques compared to non-conjugated DNA vaccines. They also enhance cellular immunity 
as represented by Th1 and Th2 cytokine responses (Petrovsky and Aguilar, 2004; Ulmer et al., 
1999). Recent preclinical trials of DNA plasmid vaccine candidates have expressed genes 
within the highly conserved regions, such as gag, pol and nef. These have been isolated from 
multiple HIV-1 clades, and then followed by a recombinant adenovirus vector expressing 
SIVmac Gag, Pol and Nef proteins alone or combined with the Gag protein. Following these 
trials, all vaccinated Indian-origin rhesus monkeys were challenged using the simian-human 
immunodeficiency virus (SHIV-89.6P) with no protection against the virus. These monkeys 
expriences a rapid loss of CD4 T cells, despite of robust IFN-γ ELISPOT responses to the 
Gag/Pol/Nef and Env plus the high-titer antibodies, especially in the Env vaccinated group 
(Letvin et al., 2004). The same strategy was also conducted in Russia was used in BALB/c 
mice who were vaccinated intramuscularly with recombinant plasmids expressing the HIV-1 
genes, env, gag, pol and nef,  the induced robust cytotoxic T cell and IFN-γ+CD8+ T cell 
responses for HIV-1 peptides mainly for Env (Murashev et al., 2007). Another trial of a DNA 
vaccine, expressing recombinant SIV-Gag and HIV-1 Env was used in macaques induced with 
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a low level of cytotoxic T lymphocytes and CD8+ T cell responses that resulted in high viremia 
and rapid loss of CD4+ T cells following an intravenous challenge infection using the 
pathogenic SHIV-89.6P virus (Barouch  et al., 2000). 
1.4.2.2. Recombinant viral vaccine vectors 
Recombinant live vaccine vectors express HIV antigens or epitopes from a recombinant virus. 
The most common viral vectors used as HIV vaccine candidates are the adenoviruses, modified 
vaccinia viruses, canarypox and rabies viruses. It is important that there is a difference in the 
ability of various HIV genes to induce immune responses (Liu, 2010). For example, gag, vif 
and nef expressed in Hela-CD4 cells leads to the stimulation of an immune response sufficient 
to reduce the viral titers, while the use of other HIV genes, such as tat, rev and vpu increased 
the rate of infection compared to no inhibitory effect of HIV env, vpr and pol expressed genes 
to control the homologous T-cell-line-adapted HIV-1 strain (D'Aloja et al., 1998). Indeed, viral 
vector vaccines were considered the most likely used vaccine candidates to induce both a 
humoral and T cell immune response against infectious diseases in humans and animals 
(Draper and Heeney, 2010). Recently, viral vector vaccines have been regarded as the most 
likely vaccines to be used to stimulate both a humoral and cellular immune response (Draper 
and Heeney, 2010). 
1.4.2.2.1. Adenovirus vectors 
The adenovirus serotype 5 (Ad5) has been used as a vector in many preclinical and clinical 
trials of recombinant HIV vaccines. For example, one clinical trial of a randomized, doubleǦ
blind phase 1 trial conducted by the Vaccine Research Center (VRC), utilized 4 rAd5 vectors 
to express the recombinant HIV-1 GagǦPol fusion protein (subtype B) and also the Env protein 
(subtypes A, B, and C) to evaluate safety. The immunogenicity of this recombinant vaccine 
was administered intramuscularly to 30 healthy non-infected volunteers, with induced T cell 
responses included in 93.3% of vaccine recipients, IFN-γ+CD8+ T cells in 60% of vaccine 
recipients, and EnvǦspecific antibody responsesin only 50% with moderate adverse reactions, 
such as headache, malaise, myalgia, chills or mild fever persisting for 1 day after vaccination 
(Catanzaro et al., 2006). A trivalent MRK Adenovirus type 5 has also been used in a Merck 
trial for the expression of HIV-1 antigens, such as Gag, Pol and Nef (MRKAd5-Gag MRKAd5-
Pol, and MRKAd5-Nef of clade B), in 259 intramuscular vaccinated recipients. This trivalent 
vaccine induced cell mediated T cell included CD8+ T cells immune responses without serious 
adverse reactions, however this trial was discontinued due to lack of efficacy (Priddy et al., 
2008). 
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 Recombinant adenovirus serotype 5 vectors were also used to express whole SIV Gag/Pol and 
Env proteins in a prime-boost vaccine given to rhesus macaques primed with a plasmid DNA 
vaccine, including SIVmac239 gag-pol-nef genes, that stimulated both cytotoxic CD8+ T cells 
and antibodies (Santra et al., 2005). Another preclinical trial of the SIV vaccination used 
replication-deficient Ad5 expressing HIV-1 Tat, Env (gp140), recombinant Env (SHIV-89.6P 
gp140) and a combination of SIV Gag and Env (gp140) as one of the SHIV challenge studies 
administered intramuscularly in macaques (Macaca mulatta), and then challenged 
intravenously using SHIV-89.6P. Each of the vaccines induced significant protective cytotoxic 
CD8+ T cells targeting Env gp140, and Gag compared to lower induced immune response to 
Tat (Liang et al., 2005). However, rAd5 vectors used in the phase 2 STEP study to express 
HIV-1 Gag, Pol, and Nef antigens, induced insufficient T cell immune responses and no env-
specific antibody responses which failed to protect vaccinated individuals against HIV-1 
infection (Barouch, 2010). However, serious adverse reactions after vaccination including 
viremia were shown in participants. This was due in part to a high mutation of the virus 
escaping  from the host immune response (Flynn et al., 2005; Patterson and Robert-Gouroff,  
2008). Furthermore, the recombinant adenovirus 5 expressing HIV-1 Gag protein (rAd5-gag) 
was used in BALB/c mice as an intramuscular or intravaginal prime dose of prime boost 
vaccine following the recombinant Listeria monocytogenes expressing HIV-Gag protein (rLm-
Gag). This was administered via different mucosal routes, such as orally, intrarectally or 
intravaginally, and resulted in a robust Gag-specific CD8+ T cell response in the spleen and the 
vaginal secretion and lamina propria. The best CD8+ T cell response detected in the vagina was 
induced after the intravaginal route of vaccination, particularly in intravaginal-intravaginal 
prime boost vaccinated mice that produced higher protection against intravaginal challenge 
using vaccinia virus expressing the whole HIV-Gag protein compared to other routes of 
vaccination (Li et al., 2008).  
1.4.2.2.2. Modified vaccinia virus vectors 
Most HIV vaccine studies in humans or animals have utilized modified vaccinia virus as a safe 
and effective vector for expressing viral proteins and for delivering them to mucosal surfaces 
to induce a mucosal protective mucosal immune response against respiratory pathogens, such 
as the influenza virus, respiratory syncytial virus and mycobacterium tuberculosis (Artenstein, 
2008; Gherardi and Esteban, 2005; McCurdy et al., 2004). In addition, the recombinant 
modified vaccinia virus vector (rMVA) has been used to deliver HIV or SIV antigens, induced 
HIV specific immune responses not only in genital and rectal mucosa in mice or macaques but 
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also controlled HIV or SIV progression and dissemination of the virus (Gherardi and Esteban, 
2005). For example, a modified vaccinia virus vector expressing the HIV-1 Env IIIB protein 
(MVA-Env) conjugated to cholera toxin was given to BALB/c mice intranasally and 
intravaginally, which induced mucosal CD8+ T cells with both IgA and IgG1 specific 
antibodies (Gherardi et al., 2004). Another trial in the UK, using recombinant modified 
vaccinia viruses expressing HIV-Gag proteins (p24 and p17) from HIV-1 clade A administered 
intradermally in healthy males and females between 18-60 years of age after an intramuscular 
priming dose of HIV DNA plasmid (expressing Gag protein of HIV-1 clade A). This vaccine 
induced specific CD4+ and CD8+ T cell immune responses in 89% of volunteers (Mwau et al., 
2004). In a similar clinical trial, DNA containing HIV-Env gp160 (subtypes A, B, and C), Rev 
(subtype B) and the p17/p24 Gag (subtype A) was injected intradermally or intramuscularly 
into 40 healthy volunteers as a priming, followed by a recombinant HIV Env, Gag and Pol-
vaccinia virus boost. This vaccine trial induced IFN-γ+ from CD8+ and CD4+ T cells in 30% of 
volunteers following the prime dose of vaccine, which increased to 92 % after boosting 
(Sandström et al., 2008). Also, SIV proteins, such as Gag, Pol and Env, expressed by the 
modified vaccinia virus Ankara (MVA) were injected intramuscularly into rhesus macaques 
and then challenged intravenously using pathogenic SIVsm-E660, thus resulting in a reduction 
of viremia in the vaccinated macaques (Ourmanov et al., 2000). 
1.4.2.2.3. Canarypox virus vectors 
Canarypox is a strain of the avian pox virus strain from the Orthopoxvirus family. It is isolated 
from the foci of the pox infection in canaries and attenuated by multiple passaging (200 serial 
passages) in chicken embryo fibroblasts to produce recombinant virus vectored vaccines 
(ALVAC) that express specific genes of pathogenic viruses, such as HIV, influenza, and 
African horse sickness (Bruyn et al., 2004; Bublot et al., 2006; Guthrie et al., 2009). 
Recombinant canarypox has also been used as a vector to express retroviral proteins, such as 
the feline leukemia virus (FeLV) Gag and Env, and when given intranasally induced Gag and 
Env specific cytotoxic T cell immune responses (Poulet  et al., 2003; Tartaglia et al., 1993). 
1.4.2.2.4. Rabies virus vectors 
The rabies virus is a non-segmented RNA virus of the Rhabdoviridae family. It is used as a 
safe and immunogenic vectored vaccine inoculated in animals as a result of complete 
inactivation of the virus (Faber, Dietzschold and Li, 2009). The recombinant rabies virus vector 
(RV) has the ability to express a large viral genes, sequence of up to 4 Kb, such as the HIV-1 
Gag-Pol precursor (Pr160) or 2.2 Kb of the Env protein which is necessary to elicit a broad 
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host immune response in mice and monkeys (Gomme et al., 2010; McGettigan et al., 2003; 
Addo et al., 2001). For example, the recombinant rabies virus expressed HIV-1 Gag (SPBN-
ΔG-Gag) was given intramuscularly in female BALB/c mice as a priming dose and then 
intraperintoneally administered with the vaccinia virus expressed HIV-1 Gag (VV-Gag). This 
induced a significant increase of Gag-specific CD8+ T cell responses (Gomme et al., 2010). 
Recombinant rabies expressing the HIV-1 Gag-Pol precursor protein was given 
intramuscularly in BALB/c mice, and after 6 weeks they were challenged using an 
intraperitoneal dose of the vaccinia virus expressing the whole HIV-1 Gag. This induced about 
12-14% of CD8+ T cells specific for a Gag p24 epitope detected after 5 days of challenge 
(McGettigan et al., 2003). Recombinant rabies viruses expressing the HIV-1 Env (gp 160) 
protein were able to induce a robust humoral and T cell immune responsetargeting Env in 
BALB/c mice vaccinated with a intramuscular-intraperitoneal prime boost regime (Schnell, 
2000). Furthermore, BALB/c mice primed intramuscularly with the recombinant rabies virus 
expressing the HIV-1 Gag protein induced a significant increase of cell response targeting the 
HIV-1 Gag. This is in addition to 26.8% of Gag+IFN-γ+ producing CD8+ T cells in the 
vaccinated mice after an intraperitoneal challenge with a recombinant vaccinia virus expressing 
a HIV-1 Gag (McGettigan et al., 2001). Also, six adult male macaques (Macaca mulatta) were 
injected intramuscularly using the rabies virus vector expressed SHIV-89.6P Env and 
SIVmac239 Gag proteins as a priming dose, which induced seroconversion in vaccinated 
macaques following their initial vaccination. After 45 weeks, they were given an intranasal or 
intramuscular boost dose of the same vaccine but there was no immune response induced 
following the boosting dose. This was as a result of preexisting antibodies for the G protein of 
the rabies virus. Therefore, when this boosting vaccine was replaced by the G protein of the 
vesicular stomatitis virus (VSV) expressing SHIV-89.6P Env protein and SIVmac239 Gag 
protein, strong humoral immune responses and low T cell responses were induced. After four 
months of the boost dose, all vaccinated macaques were intravenously challenged using the 
pathogenic SHIV-89.6Pvirus. Induced robust neutralizing antibodies and T cell responses 
resulted in a reduction of the viral load and maintained a level of CD4+ T cells in vaccinated 
macaques compared to high viremia and rapid loss of CD4+ T cells in the non-vaccinated group 
(McKenna et al., 2007). 
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1.5. Clinical trials of HIV vaccines 
1.5.1. Phase 1 and phase 2 clinical trials 
Many HIV-1 candidate vaccines have been tested in Phase I and II clinical trials and found to 
be safe and immunogenic. Some key examples include:  
1) The ALVAC vaccine trial: This was the first clinical trial of HIV-1 vaccines involving 150 
high and low behavioral  risk HIV-1 uninfected volunteers (18-60 years old), using 
recombinant canarypox vaccine candidates expressing whole Gag and Pol proteins (ALVAC-
HIV vCP205) alone or combined with the recombinant subunit Env protein boosting dose 
(Envgp120). All volunteers were divided into 8 treated groups and then vaccinated 
intramuscularly using various schedules of multiple doses of vaccines in addition to four 
control groups followed for a period of 2 years. At the end of the vaccination period, a 
significant cytotoxic T cell response (64-89%) was detected in all vaccinated groups depending 
on the number of doses compared to control groups. A significant response of neutralizing 
antibodies was also detected in all vaccinated groups compared to controls with no serious 
diverse reactions which confirmed the vaccine was safe and immunogenic (Gupta et al., 2002). 
A similar trial was also followed in phase II that involved 330 healthy HIV seronegative 
volunteers using intramuscular administrating canarypox vaccine candidates (vCP1452) 
expressing Gag and Pol proteins alone or combined with a Env gp 120 subunit vaccine boosting 
dose. This result was strong neutralizing antibody response in the range of 57-95%, while 
cytotoxic CD8+ T cell response was only 13-16% in all vaccinated groups (Russel et al., 2007). 
2) The HIV Envgp120/Nef-Tat/AS02A vaccine trial: This was a randomized phase 1 trial of 
the subunit protein vaccine conducted in 20 HIV-1 chronically infected volunteers who were 
well controlled by highly active antiretroviral therapy (HAART). This vaccine included a 
plasmid DNA encoding HIV-1 proteins, Nef, Tat and Env gp120 (clade B), and was conjugated 
with AS02 adjuvant. It also included strong and highly significant HIV Env specific CD4+ cells 
that produced IL-2 cytokine, with proliferation of both CD4+ and CD8+ T cells following 
multiple doses of intramuscular immunization compared to controls (Lichterfeld et al., 2012; 
de Rosa and McElrath, 2008).  
3) The EUROVAC 02 trial: This was a randomized phase 1 trial using recombinant attenuated 
poxvirus (vaccinia virus: NYVAC) expressing genes isolated from the HIV-1 clade C. These 
genes included gag, env, pol and nef. This clinical trial involved 50 healthy participants (low 
behavioral risk of HIV infection) who were injected intramuscularly by the recombinant 
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NYVAC vaccine alone or primed first by intramuscular administration of the recombinant 
DNA expressing the same HIV-1 proteins. The prime boost vaccine induced a higher T cell 
response, with 90% of participants compared to only 33% following the NYVAC vaccine only. 
Also, this vaccine induced polyfunctional CD4+ and CD8+ T cells as IL-2+IFN-γ+TNF-α+ 
secreting cells. Furthermore, the highest and most frequent T cell responses targeted Env gp120 
(91% of vaccinees) compared to only 48% for Gag-Pol-Nef. However, this vaccine has induced 
lower antibody response, and was only IgG specific for the Env protein, which was detected in 
75% of participants who received the DNA/NYVAC prime boost vaccine compared to only 
25% induced for the NYVAC vaccine alone (Harari et al., 2008; Midgley et al., 2008). 
4) The RV 172 trial: This was a randomized phase I/II clinical trial that included a mixture of 
three plasmid DNA expressing HIV Env glycoprotein (isolated from HIV-1 clades A, B, and 
C) and three plasmids encoding Gag, Pol, and Nef proteins (clade B), in addition to a boosting 
dose of replication-defective recombinant adenovirus 5(rAd5) expressing the HIV-1 Gag/Pol 
polyprotein (clade B) and Env glycoprotein (clades A, B, and C). This vaccine was conducted 
in 324 of HIV-1 non-ninfected African participants from Kenya, Tanzania, and Uganda who 
were injected intramuscularly with a single dose of rAd5 or intramuscular prime boost vaccine 
(DNA/rAd5) of multiple dosesover 24 weeks. Induced HIV-specific T cells responses were 
represented by IFN-γ+ ELISPOT in 63% of the total participants, with no significant difference 
between T cell responses specific for Env, Gag and Pol  induced in groups vaccinated by rAd5 
alone (63%) or prime boost DNA/rAd5 (62%). Also, there was a low level of HIV specific 
antibody responses in all groups and no effect of preexisting Ad5 neutralizing antibodies on T 
cell responses in prime-boost vaccinated individuals (Kibuuka et al., 2010). 
5) The trial (HVTN 041): This was a randomized phase 1 trial conducted in 84 HIV-1 
uninfected volunteers who were injected intramuscularly with multiple doses of HIV-1 
recombinant proteins included Env gp120, Nef and Tat (HIV-W61D). These were expressed 
by recombinant Pichia pastoris yeast cells, and formulated with AS02A adjuvant. This vaccine 
induced robust neutralizing antibodies in all vaccine recipients following the second week with 
third dose of the vaccination. There was also a strong titer of binding antibody responses 
induced specifically for Env gp120, which was detected by antibody-dependent cellular 
cytotoxicity assay (ADCC), also with a significant increase of HIV-specific CD4+ T cells. 
However, no CD8+ T cell response was detected in vaccinated individuals (Goepfert et al., 
2007). 
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1.5.2. Phase 3 clinical trials 
1) The VAX004 trial: This was a double-blind and randomized trial held in Canada and the 
Netherlands in 1998-1999. This included two recombinant HIV-1 Env gp120 proteins, MN-
rgp120/HIV-1 and GNE8-rgp120/HIV-1 clade B administered intramuscularly within multiple 
doses in 5403 healthy volunteers, such as men who had sex with men and women at risk of 
heterosexual transmission of HIV-1. This vaccine was used as a subunit vaccine with multiple 
doses to induce specific Env gp120 neutralizing antibodies. This clinical trial of HIV vaccine 
resulted in low specific binding neutralizing antibodies (nAbs) that led to a low level of 
immuno-efficacy (6%) but with no significant overall protection in vaccinated individuals 
(Flynn et al., 2005). A similar trial called the VAX003 trial was also conducted in 2546 healthy 
volunteers among heavy intravenous drug users at high behavioral risk of HIV-1 infection. 
This trial also used also two recombinant Env glycoproteins, MN-rgp120/HIV-1 and A244- 
rgp120/HIV-1 (clade B and E). Volunteers were injected intramuscularly within multiple doses 
held in Thailand in 1999-2000. However, this trial only resulted only 0.1% efficacy in all 
vaccinated participants without a significant difference between vaccinated and control 
individuals following 36 months of vaccination (Pitisuttithu et al., 2006). 
2) The STEP trial: This trial started in 2004 and concluded in 2007 with approximately 1500 
healthy participants who were at high risk of HIV infection, including homosexual men and 
female sex workers. This trial included the development of recombinant adenovirus serotype 5 
(rAd5) by Merk, which was used as a vector for expressing the HIV-1 whole proteins, Gag, 
Pol and Nef (MRKAd5-gag/pol/nef). To begin with results were promising as this vaccine 
induced a CD8+ T cell response in intramuscular vaccinated volunteers without a serious 
adverse reaction. However, the stimulated immune response could not prevent the transmission 
and progression of a HIV-1 infection and the trial was terminated because of an increased risk 
of HIV-1 infection represented by a high titer of the virus at the last stage of the trial. 40,000 
copies/ml were detected in the vaccinated group and 37,000 copies/ml in the control group. 
This was as a result of the high prevalence of preexisting Ad5-specific neutralizing antibodies 
that led to no suitable efficacy after vaccination (O’Brien et al., 2009; Takahashi, Rolling and 
Owen, 2010; Zak et al., 2012).  
3) The RV144 phase 3 trial: This trial used a combination of the recombinant Canarypox live 
virus vector (ALVAC-HIV,vCP1521) that was genetically modified to express the HIV-1 Gag 
and Pro protein obtained from the HIV-1 subtype B combined with Env gp120 protein (subtype 
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E) boost with (AIDSVAX B/E HIV-subtypes) the vaccine containing bivalent Env 
glycoproteins. This was undertaking during two trials. The first was conducted in Thailand in 
1999-2000 with a high risk group including 2546 intravenous drug users using the AIDSVAX 
B/E HIV (VaxGen) vaccine for 36 months. No protection was induced against HIV-1 infection 
in vaccinated subjects (Pitisuttithum et al., 2006). The second was also held in Thailand, 
involved 16395 subjects divided into three groups: female sex workers, drug users and 
homosexual men, and the results of this trial were concluded in 2009 (Rerks-Ngarm et al., 
2009; Vaccari, Poonam and Franchini, 2010). As a result of a HIV-specific response (90.1%) 
and (49.3%), a T cell proliferation induced in the vaccinated participants targeting both Env 
and Gag proteinsalong with the T cells that produced an interferon-γ, were also detected in 
19.7% of vaccine recipients by ELISPOT, and 11.1% and 7.6% of IFN-γ+CD8+ T cells were 
detected for Env and Gag by ICS. Also, binding antibody responses induced for Env (98.6%) 
and Gag (52.1%) were detected by antibody-dependent cellular cytotoxicity assay (ADCC) 
(Rerks-Ngarm et al., 2009). Overall results demonstrated partial protection (31.2 %) with 
modest reduction in the rate of HIV-1 infection (Pitisuttithum et al., 2010; Rerks-Ngarm et al., 
2009). This provides hope for future work to control HIV/AIDS infection rates (Pantaleo et al., 
2010; Vaccari, Poonam and Franchini, 2010). 
1.6.  Influenza virus 
Influenza virus is a single stranded, negative sense segmented RNA virus infecting a wide 
range of mammals and bird species. It belongs to the Orthomyxoviridae family and causes 
respiratory illness, ranging from mild respiratory symptoms to severe pneumonia causing 
death, particularly in infants, elderly and immuno-compromised individuals (Barnard, 2009; 
Bouvier and Lowen, 2010). Five influenza virus genera have been identified: A, B, C, 
Thogotovirus and Isavirus (Kawaoka et al., 2005). Influenza virus type A and B are comprised 
of a genome with eight RNA segments compared to type C viruses, which have seven segments 
(Lamb and Krug, 1996; Lewis, 2006). The three types differ in their pathogenicity and ability 
to infect humans (Mateo  et al., 2007). The most pathogenic influenza viruses are the type A 
viruses which are characterized by high virulence causing the most severe disease in humans. 
For instance, the H1N1 influenza virus infected humans and led to a high mortality rate with 
the Spanish flu in 1918 (Johnson and Mueller, 2002), the Asian flu of 1957 (the result of a re-
assorted H2N2 virus), the Hong Kong flu of 1968 (caused by a re-assorted H3N2 virus), and 
the swine flu in 2009 (caused by re-assorted H1N1) (Garten et al., 2009; Klenk, 2005). In 
addition, the avian re-assorted H5N1 influenza virus is considered one of the highest 
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pathogenic influenza viruses in humans as it has the ability to infect humans leading to severe 
complications, such as multiple-organ and respiratory failure and ending with death (de Jong 
et al., 2006; Uyeki et al., 2009; Tran et al, 2004; Beigel et al., 2005).  
 
Influenza A viruses have a spherical or filamentous virion with a diameter of 80-120 nm. These 
viruses have two surface glycoproteins, hemaglutinin (HA) and neuraminidase (NA), 
embedded in a lipid envelope surrounding the virus in addition to other viral glycoproteins, 
such as matrix proteins (M1 and M2), nucleoprotein (NP), polymerase complex proteins PB1, 
PB2 and PA, and non-structural proteins NS1, NS2 (Palese and Shaw, 2007; Jagger et al., 
2012). HA plays a direct role in regulating the infectivity of the influenza virus through 
attachment to the host cell membrane by binding to sialic acid on specific receptors located at 
the cell surface. NA is responsible for the assembly and release of new progeny viruses from 
infected cells. There are 17 subtypes of HA and 9 subtypes of NA amongst influenza A viruses 
(Kaverin et al., 2000; Pushko et al., 2005; Taubenberger, 2006; Tong et al., 2012). Therefore, 
antigenic drift caused by gradual accumulated mutations in highly variable regions of HA 
resulting seasonal influenza epidemic outbreaks, with antigenic shift introducing new subtypes 
of influenza A viruses in the human population, thus leading to pandemic outbreaks of an 
influenza virus infection (Smith et al., 2004; Herfst et al., 2012). Both mutation mechanisms 
enable influenza viruses to evade an immune response through escape recognition by virus 
specific antibodies because of an absence of neutralizing antibodies to these viruses in the total 
population (Fouchier et al., 2005; de Jong et al., 2000). 
1.6.1. Pathogenesis of the influenza virus 
Influenza viruses have a high affinity for replicating at the mucosal surfaces of the upper and 
lower respiratory tract. The first step of influenza infection is the attachment of the virus to 
molecules on the surface of the target cells by the haemagglutinin glycoprotein (HA) binding 
to the epithelial surface receptor (sialic acid) followed by the cleavage of HA into two linked 
subunits, HA1 and HA2, by membrane-associated proteolytic enzymes. This enables the virus 
to enter the cytoplasm of the target cells and then replicate in these infected target cells 
(Taubenberger, 2006; Zhirnov, Ikizler and Wright, 2002). Following the first few hours of 
initial infection, newly forming viruses are released to infect other cells facilitated by the 
neuraminidase glycoprotein (NA) (Lamb and Krug, 1996; Murphy and Webster, 1996). The 
infectivity of the influenza virus depends on the level of HA cleavage. For example, highly 
pathogenic influenza viruses, such as H1, H5, and H7 subtypes, are characterized by high levels 
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of HA cleavage compared to low pathogenic or non-pathogenic influenza viruses (Senne et al., 
1996; Shortridge et al., 1998). After its replication in respiratory epithelial cells, the influenza 
virus subsequently infects macrophages and monocytes located in the alveoli, leading to the 
destruction of these cells and the formation of necrotic areas as a result of damaged and dying 
cells accumulating in these locations and ending with pneumonia (Fesq et al., 1994; 
Taubenberger and Morens, 2008). 
  
There are different models of laboratory animals that are characterized with high sensitivity to 
infectin by influenza viruses and can be used in preclinical experiments to evaluate vaccines 
produced for influenza viruses. These animal models include animals naturally susceptible to 
be infected by human influenza viruses like ferrets and guinea pigs, and other animals which 
need adaptation to be infected by influenza viruses like mice (Bouvier and Lowen, 2010). The 
susceptibility of mice to be infected by the influenza viruses depends on the strain of mice and 
the laboratory adapted influenza viruses. For example, BALB/c and C57BL/6 mice are 
considered the main commonly laboratory strains used in research. These mice are the highest 
sensitive strain of mice infected intranasally with adapted influenza viruses, such as A/Puerto 
Rico/8/1934 (H1N1; PR8), A/WSN/1933 (H1N1; WSN) or A/Aichi/2/68 (H3N2; X31). These 
viruses replicate in the respiratory tract and lead to weight loss or death depending on the 
pathogenic strain and lethal doses of the influenza viruses used in the two lab strains of mice, 
with wild mice mainly resistant to these influenza viruses (Staeheli et al., 1988; Haller, 1981).  
Indeed, the ability of these mice adapt to the influenza viruses that induce the pathogenic effects 
following primary intranasal infection depends on the dose of infective viruses. For example, 
BALB/c mice start losing weight on day 2 of intranasal infection of a highly lethal dose (10x 
the 50% lethal dose, LD50) of the PR8 (H1N1: A/PR/8/34) influenza virus strain (2 × 103 pfu), 
and died between days 6 to 8 of infection as a result of rapid replication of the virus in the 
lungs. The X31 (H3N2: A/Aichi/2/68) influenza virus strain resulted in less pathogenic effects 
detected in BALB/c mice who were infected intranasally using (10× LD50) 3.5 × 106 pfu of 
X31, with gradual weight loss beginning with day 2 of infection and then death on day 10 
(Quan et al., 2008; Yetter et al., 1980; Tamura et al., 1992). This is compared to a sub-lethal 
dose of the X31 influenza virus of 1× 104 pfu which showed a peak of viremia within days 3 to 
5 of primary intranasal infection accompanied with gradual weight loss in BALB/c mice. This 
declined within days 6 to 7 to a complete recovery and clearance of the virus on day 10 of 
infection (Cukalac et al., 2009). 
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A similar course of infection was also detected after the intranasal influenza infection in 
BALB/c mice using a sub-lethal dose of 50 pfu of the PR8 influenza virus but with higher 
weight loss (Edenborough, Gilbertson and Brown, 2012; Tamura and Karuta, 2004; Tamura et 
al., 1998). Similar results were also detected in BALB/c mice infected by a sub-lethal dose of 
the PR8 influenza virus, 10 TCID50. The infected mice showed a short period of mild weight 
loss and then began to recover on day 7 post-infection, with complete recovery on day 9 post-
infection. This was compared to a moderate pathogenic effect of a higher dose (100 TCID50) 
of the PR8 (A/PR8/34) influenza virus represented by higher weight loss that started on day 3 
of infection, and reached 25% weight loss. These infected mice began to recover on day 10 and 
then reached their starting weight within 10-14 days post-infection. While rapid viremia and 
severe weight loss were detected in mice after intranasal infection using a higher lethal dose, 
1000 TCID50 of the PR8(A/PR8/34) influenza virus saw mice reaching 30% weight loss on day 
8 and then dying on day 15 post- infection (Verhoeven, Teijaro and Farber, 2009). 
1.6.2. Influenza immunity 
Mucosal surfaces represent not only the main portal of entry for influenza, but also the first 
line of non-specific defense. This involves the epithelium, mucin layer, non-specific cytokine 
responses and secretory IgA released by the epithelial cells. Following the infection of 
epithelial cells, the innate and adaptive immune system play the major role in defense (Lamb 
and Krug, 1996; Murphy and Webster, 1996; Tamura and Kurata, 2004). 
1.6.2.1. Innate immune response 
Innate immune response is the first line of defense mechanisms against an influenza virus 
infection characterized by a fast onset and a short period of effectivity following primary 
influenza infection. Innate immunity includes several components facilitated by recognition of 
influenza antigens that also induce other parts of the immune response to control infection 
(Banchereau and Steinman, 1998; Guermonprez et al., 2002). Dendritic cells (DCs) are 
considered the main professional antigen presenting cells (APCs) during early influenza 
infection by degrading viral proteins into small peptides by proteasomes or phagocytosis. 
Dendritic cells transport these small peptides to the endoplasmic reticulum and then load to 
MHC class I molecules to be recognized by the CD8+ T cells or present them to the MHC class 
II peptide complexes and then recognized by CD4+ T helper cells (Bhardwaj et al., 1994; 
Yewdell et al., 2003). As a result of early recognition of influenza viral antigens, naïve T and 
B lymphocytes are activated to control infection. Dendritic cells also work as a link between 
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an innate and adaptive immune response, induced activation and proliferation of cytotoxic 
CD8+ T cells against influenza viral antigens, and also migrate to various draining lymph nodes, 
such as the mediastinal lymph node (Braciale, Sun and Kim, 2012; Kim and Braciale, 2009). 
 
Influenza viruses are first detected after a few hours of primary infection in an infected human 
or in animals by the innate immunity.Viruses are then destroyed as a result of non-antigen 
specific mechanisms involving macrophages, natural killer cells, and cytokines, such as IFN-
α and β interferons. These are not active for a long time during induction, thus giving influenza 
viruses the opportunity to escape this early mechanism of defense (Murphy and Webster, 1996; 
Ada and Jones, 1986). High amounts of IFN-α and β, secreted by influenza infected cells, are 
rapidly detected following influenza infection in both nasal and pulmonary regions and their 
level is directly related to reducing the replication of influenza viruses in humans and animals 
(Husseini, Sweet, Collie and Smith, 1982; Wyde, Wilson, and Cate, 1982). Natural killer cells 
are cytotoxic lymphocytes activated in an innate immune response that israpidly detected in 
upper respiratory mucosa and the lungs within 24 hours following primary influenza infection. 
These cells produce IFN-γ in addition to their direct role in reducing the spread of the virus by 
the lysis of influenza infected cells enhanced by perforin activity (Hicks et al., 1978; Kopf et 
al., 2002). IFN-γ acts as a linking factor between the innate and adaptive immune response 
against influenza infection as it induces the cytotoxic CD8+ T cell response and regulates 
homeostasis and proliferation of these cells in secondary lymph nodes and their trafficking to 
the site of infection necessary to control the influenza infection (Turner et al., 2007; Bot, Bot, 
and Bona, 1998). The early innate immune response for the influenza virus includes some 
inhibitory factors located in the respiratory tract mucosa, which have an identical structure to 
acetyl-neuraminic acid biding to the HA glycoprotein and highly reduces its infectivity and 
spread of influenza viruses inthe host cells of BALB/c mice infected nasally with mouse 
adapted influenza viruses such as the PR8 influenza virus (A/PR/8/34; H1N1) (Yoshikawa et 
al., 2004; Shugars, 1999). Also, macrophages localized in the alveoli have an important 
inhibitory role against influenza virus infection by direct lysis of infected cells or influenza 
virus particles by phagocytosis. Activated macrophages in alveoli also induce a pro-
inflammatory response, including IL-6 and TNF-α (van Riel et al., 2011; Becker, Quay and 
Soukup, 1991), and they regulate an adaptive immune response as there is a direct correlation 
between the depletion of alveolar macrophages leading to low levels of antibodies and a 
reduction of CD8+ T cells induced following influenza infection (Kim et al., 2008). There is 
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also an indirect immune role of macrophages during early influenza infection by activating 
natural killer cells through their secreting specific cytokines, such as IL-1, IL-6, IL-12 and 
TNF-α, which are also necessary for decreasing virus shedding following primary influenza 
infection (Monteiro, Harvey and Trinchieri, 1998).  
 
However, influenza viruses easily escape the early innate immunity defense mechanism but 
these viruses can be detected and eliminated by the main active components of the adaptive 
immune mechanism, such as influenza specific antibodies and cytotoxic T cells targeted 
influenza virus and the infected cells (Tamura and Kurata, 2004). There was a high level of 
both T and B cells accumulated in the upper respiratory mucosa of BALB/c mice intranasally 
infected with the A/PR/8/34 influenza virus. The infected mice reached their peak on day 7 
post-infection. The first detected antibody response was on day 5 post-infection and reached 
its peak on day 7 of infection, with IgM being the first antibody detected for the primary 
influenza infection, followed by IgA and IgG (Tamura et al., 1998). IgM was first detected in 
a few days of primary influenza infection and then diminished quickly within a few days (Qiu 
et al., 2011). This is in comparison to IgA and IgG immunoglobulins, which are the only 
immunoglobulins that detected following secondary influenza infection (Tamura et al., 1998; 
van de Sandt, Kreijtz and Rimmelzwaan, 2012). 
1.6.2.2. Adaptive immune response 
Adaptive immune response is the second line of the defense mechanism for influenza virus 
infection characterized by slow induction against primary infection but with faster onset and 
stronger effectiveness for the secondary influenza infection (van de Sandt, Kreijtz and 
Rimmelzwaan, 2012). The adaptive immune response includes two parts, humoral immune 
response represented by influenza-specific antibodies produced by B cells, and cellular 
immune response represented by T cell response, which includes both CD4+ and CD8+ T cells 
(Tamura et al., 1998; van de Sandt, Kreijtz and Rimmelzwaan, 2012; Baumgarth et al., 2000). 
1.6.2.2.1. Humoral immune response 
The humoral immune response represents the main defense against primary influenza infection 
in humans (Strugnell and Wijburg, 2010; Lamb and Krug, 1996), especially in young infants 
who are mainly protected against influenza virus infection by maternal antibodies produced 
following vaccination in  humans and mice (Hwang et al., 2010; Zuccotti et al., 2010). The 
early humoral immune response against influenza virus infection is characterized by the 
production of specific IgM, IgA and IgG antibodies, while later stages involve IgA and IgG 
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only (van de Sandt, Kreijtz and Rimmelzwaan, 2012; Qiu et al., 2011). IgM antibodies are 
highly active in neutralizing the influenza virus, but only for a short lived period. They also 
contribute to activating the complement system necessary to inhibit virus replication 
(Fernandez Gonzalez, Jayasekera and Carroll, 2008; Jayasekera, Moseman, and Carroll, 2007). 
IgA works as the predominant immunoglobulin necessary for recovery from recent influenza 
infection in humans (Tamura et al., 1998). On the other hand, IgG antibodies directed for 
influenza antigens are characterized with a long lived protective role against influenza infection 
(Koutsonanos et al., 2011; Onodera et al., 2012). Most immunoglobulins mainly target 
influenza HA, NA, NP and M proteins, although the most predominant antibodies are those 
induced by HA and NA, which are highly involved with protective immunity against influenza 
infection. The Ig-molecules play a major role in preventing replication of the influenza virus 
(Glathe, Bigl and Grosche, 1993; Lamb and Krug, 1996; Murphy and Webster, 1996). For 
instance, antibodies directed to HA bind tothe receptor located on the globular head of HA, and 
prevent the virus from binding to targeted host cells (de Jong et al., 2003; Knossow and Skehel, 
2006), and most HA-specific antibodies are not effective for neutralizing new variants of 
influenza subtypes produced by antigenic drift mutation (Yu et al., 2008; de Jong et al., 2000). 
Antibodies produced targeting the NA glycoprotein act either by inhibiting the sialidase 
activity of NA and preventing the release and spread of newly formed viruses from virus 
infected cells, or antibodies are actively involved in destroying virus-infected cells by 
facilitating the ADCC mechanism important for virus clearance (Palese and Shaw, 2007; 
Hashimoto, Wright and Karzon, 1983; Bosch et al., 2010). Furthermore, antibodies induced 
against influenza NP are potentially involved in protection against hetero-subtypes of influenza 
A viruses as it is highly conserved glycoprotein between these viruses, and their protective role 
may include ADCC mechanism of infected cells and activating T cell responses in human and 
mice (Lamere et al., 2011; Sambhara et al.,  2001; Carragher et al., 2008). 
 
The protective role of influenza specific antibodies was also evident between 1991 and 1992. 
Using one dose of trivalent influenza vaccine containing A/Singapore/6/86 (HIN1), 
A/Beijing/353/89 (H3N2) and B/Yamagata/16/88, five different groups of people were 
vaccinated. The result was an increased level of antibodies directed for HA, with 96-100% 
protection in the vaccinated groups (Glathe, Bigl and Grosche, 1993). Furthermore, the 
therapeutic role of antibodies to control influenza infection was proven in B-cell-deficient 
muMT (-8) mice, who were highly susceptible to the intranasal infection of mouse-adapted 
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influenza type A virus A/PR/8/34 (H1N1). Around 80%-94% of these infected mice survived 
by intravenous transferred spleen cells obtained from normal B6 mice and included a higher 
virus-specific precursor B cell response. This was compared to muMT (-8) mice which did not 
produce antibodies and were highly sensitive to influenza infection, with BCR-transgenic 
spleen cells transferred, these cells contained 10 times lower virus-specific precursor B cells, 
and were not protected from PR8 influenza infection (Mozdzanowska et al., 2005). Also, 
specific-influenza antibodies have an important role in the control of primary influenza 
infection in mice using intranasal PR8 infection. This was detected by a higher increase of the 
virus titer in B cell-deficient (muMT) mice compared to less sensitive IgM-/-and wild-type 
infected mice (Kopf et al., 2002). 
1.6.2.2.2. Cellular immune response 
Cellular immune response for influenza A viruses consist of CD4+ and CD8+ T cells as they 
have a regulatory role for influenza specific immune response and recovery from infection (van 
de Sandt, Kreijtz and Rimmelzwaan, 2012). Indeed, the cellular immune response is more 
efficient than the humoral arm in the protection against influenza virus infection because the 
humoral response is induced specifically for each virus subtype and is less efficient in 
recognizing newly mutant influenza A subtypes resulting from antigenic drift. This includes 
altered HA or NA compared to high cross activity of cytotoxic T cells in recognition of hetero-
subtypes of influenza A viruses, thus giving the cellular immune response a higher efficient 
role in the clearance of influenza virus infection in humans (Biddison, Shaw  and Nelson,  1979; 
Shaw and Biddison, 1979; McMichael  and Askonas, 1978). For instance, CD4+ and CD8+ T 
cells are mainly involved in broad cross-protection for hetero-subtypic influenza viruses. This 
was recognized by impaired hetero-subtypic protection represented by no efficient control of 
virus replication in acute CD4 and CD8 depleted mice infected intranasally using a prime dose 
of H1N1, H2N2 or H3N2. The mice were then challenged intranasaly using H1N1 or N3N2 
influenza viruses, represented by higher virus titer in the lungs and a higher mortality rate 
compared to depleted Ig-/- immunoglobulin infected mice (Benton et al., 2001). This protective 
role was also recognized by intranasal inoculation of the live influenza virus, A/Munich/1/79 
virus (H1N1) into 63 volunteers conducted in the United Kingdom to check their levels of 
Hemagglutination-inhibition titer (HAI). An anti-neuraminidase titer and cytotoxic T cell 
response in infected individuals, with induced cytotoxic T-cell responses higher than 10% with 
no shedding of the virus following three weeks of infection was compared to lower effective 
antibodies in the clearance of the influenza virus (McMichael et al., 1983). 
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As the first component of cellular response in regulating immune responses to influenza 
infection, CD4+ T cells are activated directly after recognition of influenza viral epitopes loaded 
with MHC class II molecules. They are then differentiated into two functional types, T helper 
1 cells (Th1) or Th2 CD4+ T cells based on the cytokine they produce (Zhu and Paul, 2010). 
The T helper 1 lymphocyte secretes IFN-γ, TNF-α and IL-2 is also directly involved in CTL 
responses and induction of memory CD8+ T cells (Mosmann et al., 1986; Deliyannis et al., 
2002). The CD4+ T helper 1 cell also mediates delayed types of hypersensitivity (DTH) 
reactions inhibiting the replication of the influenza virus bysecreting IFN-γ (Cher and 
Mosmann, 1987; Tamura et al., 1996). In addition, robust IgG and IgA antibodies are induced 
following intranasal influenza infection in mice produced by the CD4 T helper 1 lymphocyte 
(Topham et al., 1996; Roman et al., 2002). While the CD4+ T helper 2 lymphocyte plays an 
important role in producing IL-4, IL-5 and IL-13, and in activating B cells to produce 
antibodies, such as IgG1 and IgE in BALB/c mice (Gerhard et al., 1997). In addition, it also 
acts as a bridge between CD4+ and CD8+ T lymphocytes that are required for a protective 
immune response against hetero-subtypic influenza A viruses, which share the same internal 
proteins but differ in HA and NA subtypes (Okoye and Wilson, 2011; Lamb et al., 1982; 
Kamperschroer et al., 2006). Furthermore, the CD4+ T cell has another protective role in the 
cell mediated immune response following intranasal PR8 influenza infection in BALB/c mice. 
These mice were transferred intravenously with the CD4+ effectors harvested from TCR Tg 
BALB/c mice directly with the HA126-138 peptide from influenza A/Puerto Rico/8/34 (PR8) 
CD4+ T cells 18-24 hours previous to an influenza challenge. The function of these CD4+ T 
cells in the transferred mice was represented by enhanced perforin and granzymes to lyse 
influenza-infected cells, inducing high amounts of anti-influenza antibodies, thus leading to 
clearance of the influenza virus and significant survival of the mice compared to controls 
(Brown et al., 2006). Also, memory CD8+ T cells were mainly induced following primary 
influenza infection and then localized in the respiratory airways compartments especially in 
the lungs, to provide faster control of secondary influenza infection (Teijaro et al., 2011; Strutt 
et al., 2010).  
 
The protective role of CD4+ T cells in clearance of the influenza virus infection in mice was 
also evident in CD4- depleted C57BL/6J (B6) (Ig-/- mMT) mice infected intranasally using a 
prime or prime boosting dose of HK-X31 (H3N2) influenza A virus. Results obtained from this 
study indicated a significant delay of influenza virus clearance from lungs harvested from CD4- 
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depleted mice for a period extending from one to three months of infection. A significantly low 
percentage of survival for the CD4- depleted (-CD4mMT) challenged mice was detected and a 
significantly diminished number of recruitment CD8+ T cells directed to Db NP366, which were 
detected in BAL and the spleen compared to the control group of mice (Riberdy et al., 2000). 
Also, there was highly significant reduction of secreted cytokines, such as IL-2, IFN-γ, IL-4 
and IL-5, detected in draining lymph nodes, mediastinal LN and BAL of the CD4-deficient 
mice following intranasal influenza infection compared to the wild type of mice (Tripp, 
Sarawar and Doherty, 1995). This was highlighted the very important role of CD4+ T cell in 
clearing influenza virus by those secreted cytokines at the site of the infection. Furthermore, 
the μMT mice generated from BALB/c back-cross mice, and then maintained as homozygous 
CD4- depleted mice (-CD4 μMT-/-) by treating them with anti-CD4 depleting antibodies, did 
present with a high mortality rate (80%) when they were infected intranasally using a small 
dose of a virulent strain of the PR8 influenza virus. This was in comparison to only 15% in 
normal μMT mice (Mozdzanowska, Maiese and Gerhard, 2000). 
 
The CD8+ T cell is the second major component of cellular immune response induced to control 
primary or secondary influenza virus infection (Benton et al., 2001; Hemann, Kang and Legge, 
2013). After influenza virus antigen has presented by the MHC-I molecule and loaded on 
antigen presenting cells (APCs), a T cell receptor (TCR) of a naïve CD8+ T cell binds to a 
specific influenza peptide for activation (Norton et al., 1992). The activated CD8+ T cells 
undergo high differentiation into cytotoxic CD8+ T cells localised in respiratory lymphoid 
organs, especially in draining lymph nodes. These cells then migrate to the site of the infection 
and destroy infected cells through lytic activity of perforin and granzymes, and inhibit the 
replication and the spread of newly formed viruses by producing pro-inflammatory cytokines, 
such as IFN-γ and TNF-α (Nakanishi et al., 2009; Topham, Tripp and Doherty, 1997). 
Influenza specific CD8+ T cells are characterized by high cross-reactivity against 
herterosubtypes of influenza A viruses in humans when they directed to the highly conserved 
internal viral proteins, such as NP, PA, PB2 and M, among various influenza virus subtypes 
(Assarsson et al., 2008; Kreijtz et al., 2008). 
 
The protective role of CD8+ T cells, response directed for a heterosubtypic immune response 
was also detected in mice following influenza A virus infections (Grebe, Yewdell, and 
Bennink, 2008). For instance, C57BL/6 mice primed intranasally with the influenza virus X-
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31 (H3N2) and then challenged intraperitoneally following 4 weeks with a virulent strain of 
the  A/PR/8/34 (H1N1) virus, presented a higher significant level of specific CD8+ T cells 
detected for the H-2Db restricted NP366–374 epitope, with fast clearance of the A/PR/8/34 virus 
from the lungs and increased survival rates of mice compared to controls which were not 
primed with the X31 virus. Furthermore, it was evident that there were no neutralizing 
antibodies directed to the HA or NA of the PR8 challenge virus, allowed the heterosubtypic 
CD8+ T cell response to be protective against the virulent challenge virus (Kreijtz et al., 2007).  
The hetero-subtypic protective CD8+ T response detected in C57BL/6J mice primed 
intranasally with the human influenza virus, A/Hong Kong/2/68 (H3N2), which was 
characterized by the ability to replicate in mice, actually protected mice from the intranasal 
challenge with the highly pathogenic influenza virus A/Indonesia/5/05 (H5N1). This robust 
hetero-subtypic CD8+ T cell response was mainly directed to the highly conserved influenza 
epitopes, such as NP366–374 and PA224–232, and inhibit replication of the virus in the lungs and 
significantly reduce body weight loss and mortality rates compared to unvaccinated infected 
mice with the highly pathogenic avian influenza virus (HPAI A/Indonesia/5/05) (Kreijtz et al., 
2009).  
 
Indeed, the majority of cross-reactive immune response against influenza A viruses included 
CD8+ cytotoxic T lymphocytes that were directed toward the highly conserved viral proteins, 
such as NP and M1. These CD8+ T cells were detected in the spleen of the CBA/J strain of 
mice after 5 days of intraperitoneal administration of hetero-subtypes of influenza A viruses, 
such as PR8 (A/PR/8/34: H0N1), and AA (A/Ann Arbor/23/57: H2N2) (Effros et al., 1977). 
Therefore, the effective vaccine used for protection against various subtypes of influenza 
viruses needs to induce the heterosubtypic immunity (HIS) included specific CD8+ T cells that 
recognize influenza specific epitopes located in the highly conserved six shared internal viral 
proteins (Grebe, Yewdell, and Bennink, 2008; Hillaire, Osterhaus and Rimmelzwaan, 2011). 
Several studies related to influenza vaccines in humans and mice have shown the most 
commonly detected proportion of the CD8+ T cell response has been that directed toward the 
the relatively conserved NP and M1 protein, which allows cross-protection against various 
subtypes of influenza viruses (Yewdell et al., 1985; Kees and Krammer, 1984; Lee et al., 2008). 
  
The protective role of the CD8+ T cell in controlling influenza virus infection was also 
associated by a significant delay with virus clearance in CD8+ T cell-deficient mice (Thomas 
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et al., 2006). As recognised in transgenic homozygous B2-M mice (-/-), lack of MHC-I 
molecules and being unable to produce mature CD8+ T cells showed a significant delay in the 
clearance of the from the lungs until day 15 after intranasal administration of the mice using 
influenza viruses, such as A/Port Chalmers/1/73 (H3N2) or A/Puerto Rico/8/34 (H1N1). This 
was in comparison to complete clearance of the virus between day 6 and 8 in normal mice or 
heterozygous B2-M (+/-) mice who were able to express MHC-I molecules (Bender et al., 
1992). The CD8+ T cell response induced following both primary and secondary influenza 
virus infection in mice was detected within a highly protective role in humans and mice (Flynn 
et al., 1998; McMichael et al., 1983). The CD8+ T cells were induced firstly in lungs and BAL, 
and later detected in MLN of the C57BL/6J (B6) in significant numbers after seven days 
following the intranasal primary infection using a sub-lethal dose of A/HKX31 (H3N2) which 
was higher than that induced for primary intranasal infection using the B/HK influenza virus. 
The percentage of NP366-374 specific CD8+ T cell responses induced robust influenza specific 
CD8+ T cell responses in the BAL of X31 infected mice with 7.3% compared to less than 0.1% 
for the CD8+ T cell induced for the primary infection the B/HK influenza virus (Flynn et al., 
1998). This was because the virus did not include the NP366-374 peptide (Allan et al., 1993). 
However, influenza specific CD8+ T cells that produced IFN-γ+ were first detected after five 
days of the secondary intranasal challenge using the PR8 influenza virus, and the detected 
response in BAL was 5 fold higher than that detected in the primary response at the peak of 
response on day 10 of infection (Flynn et al., 1998). The CD8+ T cells were also detected 
expressing IFN-γ+ directed to endogenous influenza H2-Kd NP147 in BALB/c mice following 
secondary intranasal infection using a prime boosting dose of recombinant X31-NA-Env311 
plus PR8-NA-Env311. This was higher than the primary response of 9 fold in the spleen and 4 
fold in the BAL (Cukalac et al., 2009). 
 
Moreover, it was also detected that the highly important protective function of CD8+ T cells in 
B cell–deficient mice promoted their recovery from lethal dose influenza virus infection. The 
B cell deficient mice (μKO mice; H-2b) were firstly intranasally inoculated using 10x LD50 
influenza A/Japan/57 (H2N2) virus and 30 minutes later they were intravenously administered 
with 107 clone cells (including CD8+ T cells) obtained from spleen cells. The cells were 
harvested from μKO and C57Bl/6 mice who had received a sub-lethal intranasal dose of A/ 
Japan /57 and stimulated in vitro with influenza A/ Japan /57 virus-infected cells. This induced 
complete protection of CD8+ T cell transferred mice represented by the fast clearance of the 
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virus from the lungs compared to non-transferred mice who were more than 100-fold more 
susceptible to a lethal virus infection than the wild-type C57Bl/6 mice. On the other hand, there 
was only a partial protective role of CD4+ cells adoptively transferred in B cell-deficient or 
antibody-deficient mice (Graham and Braciale, 1997; Epstein et al., 1998). 
1.6.3. Influenza virus as a vaccine vector 
Influenza virus type A has been used as an efficient viral vector for the expression of 
recombinant viral antigens, particularly those targeting various infectious diseases, especially 
mucosally transmitted diseases (Marsh and Tannock, 2005; Satterlee, 2008; Smith, 2007). For 
instance, HIV, tuberculosis and malaria antigens have been inserted into influenza virus vectors 
for use for vaccination (Martínez-Sobrido and García-Sastre, 2007). This is due to the ability 
of this virus to infect through mucosal portals, resulting in broad and long term humoral 
immune responses (Mueller et al., 2010; Yao and Wang, 2008). 
 
It is also relatively easy to manipulate gene segments of the influenza virus by reverse genetics 
to generate novel recombinant viruses for use as vaccine vectors (Steinhauer and Skehel, 2002; 
Steinhauer et al., 2009; Hoffmann et al., 2002). Furthermore, influenza virus vectors are not 
integrated in the host chromosomal sequences, and so will not induce any adverse mutation in 
the host DNA, and there is no ability for influenza viruses to progress into a persistent or 
chronic infection in humans, which avoids neutralizing antibodies affected by immune 
response induced by the virus vector (Martínez-Sobrido and García-Sastre, 2007). Most of the 
recombinant influenza viruses generated by reverse genetics have involved the manipulation 
of HA and NA genes (Hwang et al., 2000; Kobayashi et al., 1992; Poon et al., 1998). The 
strategy of reverse genetics has been used for developing many live vaccine vectors generated 
from different segmented and non-segmented viruses, such as the influenza virus (Neumann, 
Whitt and Kawaoka, 2002). The first attempt to express foreign sequences into the modified 
genome of the influenza virus as a negative-sense RNA virus was in 1989. At this time, it was 
used a recombinant influenza virus bearing recombinant RNA containing the coding sequence 
of the chloramphenicol acetyl-transferase gene that replaced the NS gene for re-assorting the 
influenza helper virus but this attempt failed as the generated virus rapidly lost this gene 
following few passages (Luytjes et al., 1989). However, the first successful recombinant 
influenza virus was generated in 1999 by using the plasmid based technique which resulted in 
12 modified plasmid recombinant influenza viruses, such as A/WSN/33 (H1N1) and 
A/PR/8/34 (H1N1) that have generated from the clone cDNA (Neumann et al., 1999). 
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Subsequently, various foreign epitopes from the infectious agents have been inserted into HA, 
NA and NS gene segments in order to generate a live influenza virus vector using the reverse 
genetics strategy (Li et al., 2005; Nakaya et al., 2004; Takasuka et al., 2002). In this way, 
influenza viruses have been used as vector expressed malaria-specific CD8+ T and B cell 
epitopes which induced robust CD8+ T cell and antibody responses in intraperitonealy- 
vaccinated BALB/c mice. For instance, the SYVPSAEQI  CD8+ T cell epitope sequence of  
Plasmodium yoelii was inserted in the NA protein of the influenza virus A/HIQ8/68 (H3N2; 
HK virus), while the B cell epitope, QGPGAPQGPGAP was inserted in the HA protein of the 
A/WSN/33 virus (WSN virus) (Rodrigues et al., 1994). Another attempt in BALB/c involved 
intraperitoneally or intranasally infected using the recombinant HIV-1/MN-A/WSN/33 
influenza virus (HK-WSN) including a modified HA protein, expressing HIV-Env gp120 
peptide  (IHIGPGRAFYTT), induced neutralizing antibodies and cytotoxic CD8+ T cells in the 
vaccinated mice (Li et al., 1993). A similar study in BALB/c mice primed using recombinant 
influenza virus with HK-WSN expressing the Env protein on the HA segment. A boosting dose 
of the recombinant vaccinia virus expressing the same peptide, which induced robust CD8+ T 
cells (Gonzalo et al., 1999) was then given. Furthermore, a robust CD8+ T cell response was 
induced in macaques following multiple doses of a prime boosting dose of intratracheal and 
intranasal administration of influenza viruses like X31, (H3N2, A/HKx31) and PR8, (H1N1, 
A/Puerto Rico/8/1934). Expressed SIV-CD8+  T cell epitopes, such as SIV Gag146-172, SIV 
Tat87-96 and SIVTat114-123 inserted in the manipulated NA gene segment. (Sexton et al., 2009). 
Also, both X31 and PR8 influenza viruses expressed the CD8+ T cell Env311 (RGPGRAFVTI) 
epitope that was also inserted in the NA segment. These were used in BALB/c mice to induce 
a protective CD8+ T cell response (Cukalac et al., 2009). The methodology is discussed for the 
whole procedure used in generating our influenza virus vectors in Chapter 2, Section (2.2.8), 
and more details about their results are mentioned in Chapter 3, Section (3.1.1). 
1.6.3.1. Influenza virus vectors in HIV vaccine candidates 
Live recombinant influenza viruses have been used as viable HIV vaccine vectors because of 
their ability to stimulate immune responses in the respiratory and urogenital tracts to control 
various mucosal infectious diseases (Holmgren and Czerkinsky, 2005; Johansson et al., 2001). 
Indeed, recombinant influenza viruses manipulated in this way have been used to express HIV 
or SIV-CD8+  T cell epitopes to stimulate cytotoxic T cell responses (Liu  et al.,  2009; Pachler, 
Mayr and Vlasak, 2010; Sexton et al., 2009). For example, a recombinant influenza-HIV 
vaccine (rFlu-p17) involved the PR8 (A/PR/8/34, H1N1) influenza virus expressing the HIV 
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Gag protein (P17) which was inserted into the NA segment to stimulate both the humoral and 
CD8+ T cell responses in prime boost intranasal or intraperitoneal vaccinated BALB/c and 
C57BL/6 mice. Both the specific p17 neutralizing antibody and the CD8+ T cell responses were 
highly induced in the two groups of mice vaccinated with the rFlu-p17 vaccine compared to 
those groups given the rFlu-Rev vaccine as a negative controls (de Goede et al., 2009). 
Furthermore, the HIV-1 matrix Gag p17 protein is considered a good vaccine candidate. It 
regulates most stages of HIV-1 virus replication and reduces HIV-1 pathogenesis by inducing 
specific CD8+ T cell and neutralizing antibody responses directed to the HIV-Gag p17 protein 
(Fiorentini et al., 2010).  
 
Furthermore, both the core/matrix proteins (p24 and p17) and the Env glycoproteins (gp120 
and gp41) which are considered the most frequent HIV proteins targeted by high levels of 
neutralizing antibodies (Robey et al., 1985). These are regarded as the most frequent HIV 
protein recognized by specific cytotoxic T cells in HIV/AIDS patients (Addo et al., 2003). The 
HIV-H-2Dd Env311 epitope has been inserted into the NA stalk of recombinant influenza viruses 
using reverse genetics and also used in prime boost experiments to stimulate immunity 
(Cukalac et al., 2009). In this instance, vaccination involved a primary dose using mouse-
adapted (A/HKx31), X31-NA-Env311 as the intranasal primary infection in BALB/c mice. This 
was compared with secondary infection in another group of BALB/c mice primed with a dose 
of virulent (A/Puerto Rico/8/34, H1N1), PR8-NA-Env311 administered intraperitonealy and 
then challenged with an intranasal dose of X31-NA-Env311. This vaccination regime induced a 
robust polyfunctional Env311+CD8+ T cell with IFN-γ, IL-2 and a TNF-α subset of HIV-Env311 
CD8+ T cells detected in the spleen and BAL following secondary infection compared to a 
lower response detected in primary infected BALB/c mice (Cukalac et al., 2009). Also, 
recombinant influenza viruses expressing CD8+ T cell epitopes (SIV Gag164-172), (SIV Tat87-96), 
and (SIV Tat114-123), inserted separately into the NA stalks of viral vectors were generated for 
using in the vaccination regimen of macaques (Rollman et al., 2008). These two lab strains of 
the influenza viruses were also used to induce SIV-mucosal CD8+ T cell response in macaques. 
The macaque study included an inoculation of naïve and chronic SIVmac251 infected macaques 
with a prime dose of initial intranasal X31-SIV, boosted with PR8-SIV, and then challenged 
intravenously using infective doses of SIVmac251. Data from this study indicated the ability of 
this vaccination regimen to maintain high levels of SIV mucosal CD8+ T cells. However, there 
was no control of viremia in all infected vaccinated macaques (Sexton et al., 2009) because of 
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the ability of the virus to escape the narrow immune response directed to highly variable SIV-
CD8+ T cell epitopes. Recombinant influenza virus vectors (H1N1 and H3N2) expressing 
CD8+ T cell epitopes have also been used previously in mouse model trials as a vector of the 
HIV vaccine because they are mouse adapted strains of influenza viruses and are serologically 
distinct containing the same six internal gene segments, and differ in the expression of HA and 
NA genes. This is important to avoid neutralizing antibodies that inhibit the secondary T cell 
response (Cukalac et al., 2009). 
1.7. Project hypotheses 
The project is based on two hypotheses: 
1- Vaccination with recombinant influenza viruses expressing HIV epitopes will enhance 
the specific and mucosal CD8+ T cell immune response in mice.  
2- Adoptive transfer of induced mucosal CD8+ T cells protected naïve mice against the 
challenge virus (recombinant Vaccinia virus expressing the whole HIV-Gag protein). 
1.8. Project aims 
In order to investigate these hypotheses, the followingspecific aims will be explored: 
1- To generate live influenza vaccine vectors using a reverse genetics strategy expressing 
HIV-CD8+ T cell epitopes. 
2- To compare the ability of different mucosal routes of vaccination inducing CD8+ T cell 
immune responses. 
3- To study both the quality and characteristics of induced mucosal CD8+ T cell responses. 
4- To transfer induced mucosal CD8+ T cells into naïve mice for protection against the 
challenge rVac expressing the whole HIV-Gag protein. 
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2. Chapter 2: Materials and Methods 
2.1. Materials 
A detailed list of materials is provided in Appendix A. 
2.2. Methods 
2.2.1. Cloning strategy to generate X31-NA and PR8-NA with HIV-CD8+ 
T cell epitopes 
The 8 plasmid reverse genetics system was used to generate and rescue recombinant influenza 
viruses, X31 or PR8, expressing a modified NA gene segment inserted with the exogenous 
CD8+ T cell epitopes, H2Kd Gag197-205 or H-2d Tat17-25 as described by Hoffmann et al., (2000). 
Generation and rescue of recombinant viruses involved in all viral RNAs and mRNAs were 
generated through bi-directional transcription and translation from the specific single DNA 
template (Andreansky et al., 2005). In order to generate these recombinant influenza viruses, 
nucleotide sequences of H-2Kd Gag197 (AMQMLKETI: 5’-GCC ATG CAA ATGTTA AAA 
GAG ACC ATC-3’) or of H-2d Tat17 (QPKTACTNC: 5’-CAG CCT AAA ACT GCT TGT 
ACC AAT TGC-3’) were inserted into the sequence corresponding to position 44-45 of the 
NA stalk of X31 (H3N2) or PR8 (H1N1) influenza laboratory strains, using two PCR reactions. 
Standard PCR was performed to generate two overlapping NA fragments inserted with Gag197 
or Tat17 epitopes. The first DNA fragment with a 200 base pair (bp) size and the second DNA 
fragment was with a 1.2 kilobase (Kb) size. In order to form the whole NA fragment inserted 
with the HIV-CD8+ T cell epitopes, recombinant PCR was performed to combine the two NA 
fragments using specific forward primers, such asBm-NA-1 and reverse primers like X31-
NA197-R. All primers used are presented in Table 2.1, and PCR reactions conditions are 
provided in Table 2.2.  
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Table 2.1. Nucleotide sequences of primers used for PCR amplification. Shown are forward 
and reverse primer sequences used in the amplification of modified NA segments expressing 
HIV CD8+ T cell epitopes (Gag197-205 and Tat17-25). 
HIV epitope Primer nucleotide sequences (5’- 3’) Primer name Range of Nucleotides  
Gag 197-205 AMQMLKETI 
(5’-GCC ATG CAA 
ATGTTA AAA GAG 
ACC ATC-3’) into X31-
NA. 
 
Forward (short fragment) 5’TAT TCG TCT CAG 
GGA GCA AAA GCA GGA GT-3’. 
 
Reverse (short fragment) 5’-GAT GGT CTC TTT 
TAA CAT TTG CAT GGC GGA GTC GCA CTC 
ATA TTG CTT AAA ATG CAA TG-3’. 
 
Forward (large fragment) 5’-GCC ATG CAA ATG 
TTA AAA GAG ACC ATC CCC GCG AGC AAC 
CAA GTA ATG CCG TGT GAA-3’. 
 
Reverse (large fragment) 5’ATA TCG TCT CGT 
ATT AGT AGA AAC AAG GAG TTT TTT-3’ 
Bm-NA-1- F 
 
 
X31-NA197- R 
 
 
 
X31-NA197- F 
 
 
 
Bm-NA-1413-R 
924-950 
Tat17-25 QPKTACTNC 
(5’-CAG CCT AAA ACT 
GCT TGT ACC AAT  
TGC-3’) into X31-NA. 
 
Forward (short fragment) 5’TAT TCG TCT CAG 
GGA GCA AAA GCA GGA GT-3’ 
 
Reverse (short fragment) 5’- GCA ATT GGT ACA 
AGC AGT TTT AGG CTG GGA GTC GCA CTC 
ATA TTG CTT AAA ATG CAA TG-3’ 
 
Forward (large fragment)5’-CAG CCT AAA ACT 
GCT TGT ACC AAT TGC CCC GCG AGC AAC 
CAA GTA ATG CCG TGT GAA-3’ 
 
Reverse (large fragment) Reverse (large fragment) 
5’ATA TCG TCT CGT ATT AGT AGA AAC AAG 
GAG TTT TTT-3’ 
Bm-NA-1-F 
 
 
X31-Tat17- R 
 
 
 
X31-Tat17- F 
 
 
 
Bm-NA-1413- R 
5425-5451 
 
Gag197-205 AMQMLKETI 
(5’-GCC ATG CAA ATG 
TTA AAA GAG ACC 
ATC-3’) into PR8-NA. 
 
 
Forward primer (short fragment) 5’-TAT TGG 
TCTCAG CGA GCA AAA GCA GGA GT-3’ 
 
Reverse (short fragment) 5’-GAT GGT CTC TTT 
TAA CAT TTG CAT GGCTTG ACT TCC AGT 
TTG AAT TGA ATG GCT AAT CC-3’ 
 
Forward (large fragment)5’-GCC ATG CAA ATG 
TTA AAA GAG ACC ATCAAC CAT ACT GGA 
ATA TGC AAC CAA AAC ATC-3’ 
 
Reverse Primer (large fragment) 5’-ATA TGG TCT 
CGT ATT AGT AGA AAC AAG GAG TTT TTT-
3’ 
Ba-NA-1- F 
 
 
PR8- NA197- R 
 
 
 
PR8- NA197- F 
 
 
 
Bm-NA-1413- R 
 
 
924-950 
 
 
Tat17-25 QPKTACTNC 
(5’-CAG CCT AAA ACT 
GCT TGT ACC AAT 
TGC-3’)into PR8-NA 
 
 
Forward primer (short fragment) 5’-TAT TGG 
TCTCAG CGA GCA AAA GCA GGA GT-3’ 
 
Reverse primer (large fragment) 5’- GCA ATT GGT 
ACA AGC AGT TTT AGG CTG TTG ACT TCC 
AGT TTG AAT TGA ATG GCT AAT CC-3’ 
 
Forward primer (large fragment) 5’-CAG CCT AAA 
ACT GCT TGT ACC AAT TGCAAC CAT ACT 
GG ATA TGC AAC CAA AA ATC-3’ 
 
Reverse Primer (large fragment) 5’-ATA TGG TCT 
CGT ATT AGT AGA AAC AAG GAG TTT TTT-
3’. 
Ba-NA-1-F 
 
 
 
PR8-NA-Tat 17-R 
 
 
 
 
PR8-NA-Tat 17-F 
 
 
 
Ba-NA-1413-R 
5425-5451 
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Table 2.2. Conditions for PCR reactions. A) Typical PCR conditions used in cloning work, 
B) Conditions for the recombinant PCR reactions to generate the modified NA gene 
segments. 
A) Standard PCR conditions. 
Step of reaction Temp. Time Cycle number 
1 94°C 4 min 1 
2 94°C 20 sec 
30 3 57°C 30 sec 
4 72°C 2 min 
5 95°C 1 min 
1 6 57°C 1 min 
7 72°C 7 min 
8 4°C Hold  
 
B) Recombinant PCR conditions. 
Step of reaction Temp. Time Cycle number 
1 94°C 2 min 
 
2 
2 55°C 30 sec 
3 72°C 2 min 
4 94°C 30 sec 
33 5 59°C 30 sec 
6 72°C 2 min 
7 72°C 7min 1 
8 4°C Hold  
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2.2.2. Gel electrophoresis 
PCR products and restriction digests were examined by gel electrophoresis using 0.8% (w/v) 
Agarose (Analytical grade, Promega) in 1x TAE buffer (Tris-acetate EDTA, Promega) 
containing SYBR safe DNA gel stain (Invitrogen). DNA samples were mixed with a 6x loading 
dye (Bromophenol blue, Xylene cyanol, glycerol and water) (see Appendix A), and loaded 
onto the gel using agarose solution (0.8%) which was electrophoresed at 100 V for 40 min. A 
1 Kb-Plus DNA Ladder (Invitrogen) was used as a size marker for estimation of fragment sizes. 
2.2.3. DNA gel extraction and purification 
Gel slices containing recombinant NA-H-2d Gag197 or NA-Tat17 PCR products were extracted 
using a QIAquick Gel Extraction Kit (manufacturer) using the manufacturer’s instructions and 
quantified using gel electrophoresis with pBR322 standards (New England Biolabs) (NEB). 
2.2.4. Ligation 
Recombinant NA segments containing the H-2d Gag197 or Tat17 epitopes were ligated into 
plasmid pHW2000 using a ligation mixture including 1 μl of T4 DNA ligase, 20 ng of the  
digested and purified plasmid pHW200 treated with CIAP (Alkaline phosphatase, calf 
intestinal; Promega M182A: 1 u/μl), 19 ng of recombinant NA-Gag197, 2 μl of 10x DNA ligase 
buffer. The total volume of this mixture was adjusted to 20 μl by adding DNAase free H2O, 
and then incubated at 16°C O/N in the PCR machine. The ligation products were then examined 
by gel electrophoresis. 
2.2.5. Transformation 
Ligation products were transformed into E. coli, JM109 or DH5α competent cells (Life 
Technologies). Frozen competent cells were removed from storage at -70°C and placed on ice 
for thawing. 30 μl of the competent cells were thenmixed with 10 μl of the DNA ligation 
mixture. The mixture of DNA and competent cells was incubated on ice for 30 minutes prior 
to heat shock for 45 seconds at 42°C without shaking. The cells were immediately returned to 
ice for 2 minutes, and 900 μl of LB broth (RT) was added to each transformation reaction, prior 
to incubation at 37°C for 1 hour with shaking at 225 rpm. The transformation culture was 
centrifuged for 5 minutes at 2000 RPM and the supernatant poured off. The cell pellet was then 
suspended in the residual LB broth medium (˜100μl) and spread onto a LB agar medium 
containing 100 μg/ml Ampicillin, and incubated O/N at 37°C. 
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2.2.6. Plasmid purification 
Single colonies were placed into 2 ml LB broth containing Ampicillin (100 μg/ml) and 
incubated at 37°C with shaking at approximately 250 RPM for 8 hours. Purification of the 
recombinant plasmid DNA from these cells was achieved by using the PureYield™ Plasmid 
Mini Prep-protocol (Promega, USA). For larger cultures, the PureYield™ Plasmid Maxiprep 
protocol (Promega, USA) was used. 
2.2.7. Restriction analysis 
The purified recombinant plasmid DNA was digested with the specific restriction 
endonucleases enzymes, PvuI and PstI, to allow for NA cloning (Hoffmann et al., 2002; Webby 
et al., 2003), using appropriate buffers and temperatures. It was then subjected to 
electrophoresis. 
2.2.8. Sequencing 
Plasmids containing the inserted HIV-1 epitopes in the NA segment, were prepared for whole 
sequencing by mixing each with 1 μl template ds DNA (300 ng), 1 μl of 2.5x Big-Dye 
terminator Premix (v3.1), 3.5 μl of 5x Reaction buffer, 1 μl of Primer 3.2 pmol (5 mM), with 
the total volume brought up to 20 μl by nuclease free water (Table 2.3). Samples were then 
sent to the DSR Sequencing laboratory at CSIRO/AAHL for sequencing using the dideoxy 
chain termination method (Sanger et al., 1980).   
2.2.9. Rescue of recombinant influenza virus by reverse genetics 
2.2.9.1. MDCK and HEK 293 T co-culture 
Plasmids containing modified NA genes were combined with the 7 plasmids encoding each of 
the other 7 influenza virus gene segments (pHW2000 PB1, PB2, PA, NP, M, NS and HA) from 
A/HK/X31 (H3N2) as both influenza laboratory strains (X31 and PR8) contained the same 6 
internal influenza viral genes, with different pHW2000 HA plasmids corresponding to the X31 
or PR8 influenza lab strains. All 8 plasmids were collectively transfected into HEK 293 T cells 
and then amplified in MDCK cells (as described in Chapter 3, Section 3.1.2 and shown in 
Figure 3.11). Two 75 cm2 flasks containing confluent MDCK and HEK cells were maintained 
in a 5% FCS-OPTI-MEM medium. Cells were harvested with 5 ml of (1x) Trypsin-Versene® 
(Trypsin-EDTA) and incubated at 37°C for 5 min. They were then centrifuged at 1600 rpm for 
5 min with 10 ml of DMEM medium for washing added and then re-suspended in 10 ml Easy 
Flu-medium-Invitrogen (OPTI-MEM-1-Reduced-Serum-medium; GIBCO), supplemented 
with hypoxanthine, thymidine, sodium pyruvate, L-glutamine, trace elements, and growth 
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factors (but no fetal calf serum, FCS). The MDCK and HEK 293T cells were then mixed in a 
1:2 ratio (1 ml of MDCK cells + 2 ml of HEK 293 T cells) in a 50 ml tube to seed a co-culture 
of cells. 15 ml of Easy Flu medium was then added to 3 ml of the cell mixture and aliquoted 
into individual wells of a 6-well plate. This was followed by incubation at 37°C, and 10% CO2 
for 18-24 hours to attain confluency. 
2.2.9.2. Transfection 
Transfections involved mixing 1 μg of each plasmid (NP, NS, PB1, PB2, M, PA, HA and NA-
Gag197 or NA-Tat17) into a 1.5 ml tube, with 10 μl of each plasmid taken total volume of 80 μl 
of the mixture of 8 plasmids, followed by incubation at room temperature for 45 min. In a 
second tube, 3 μl of Fugene 6 (Roche Transfection Reagent) for each 1μg of plasmid DNA was 
added (total amount = 24 μl). The total volume of the transfection reagent was brought up to 
200 μl by adding 176 μl of the OPTI-MEM medium (no FCS and no antibiotics) per 
transfection reaction and incubated for 5 min at room temperature. Next, the plasmid solution 
was added to the (Fugene 6 reagent + Opti-MEM) and incubated at room temperature for 45 
min, after which the total volume of the mixture was increased to 1000 μl by adding 720 μl of 
Opti-MEM. Media was removed from each MDCK/HEK 293 T cell co-culture well and 
replaced with 1 ml of transfection mixture for 6 hours at 37°C and 10% CO2. The transfection 
mix was then carefully removed and replaced with 1 ml of Easy flu medium, followed by 
incubation of the 6 well plates for 18-30 hours at 37°C and 10% CO2. To assist replication, 1 
ml of the Easy flu medium containing 1 μg of TPCK-trypsin in PBS (Trypsin stock 1μg/μl) 
was added to the co-culture to give a final volume of 2 ml in each well, with cells incubated 
for a total time of 72 hours at 37°C followed by collection of virus-containing supernatants. 
2.2.9.3. Hemagglutination assay 
The presence of the influenza virus in reverse genetics transfection supernatants was detected 
by hemagglutination activity with the use of chicken red blood cells (RBCs). Firstly, chicken 
red blood cells (RBCs) were washed twice with PBS and then diluted with PBS to 0.5% packed 
cell volume (PCV). Two-fold dilutions of the virus were made and chicken RBCs (0.5%) were 
then added to all wells followed by mixing and incubation for 30 min at room temperature after 
which agglutination was scored as either positive or negative. 
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2.2.9.4. Amplification of modified viruses in 10 day old embryonated chicken 
eggs 
Recombinant influenza viruses were amplified in 10 day old fertilized eggs. The transfection 
supernatants (100 μl) were added directly to 10 day old embryonated chicken eggs and 
incubated for 2 days in a 35°C incubator. Allantoic fluids were then harvested into 50 ml Falcon 
tubes on ice and then at -80°C after being aliquoted into small volumes into cryogenic vials 
(Nunc®CryoTubes®1.8 ml).  
2.2.9.5. RNA extraction of harvested allantoic fluids for sequencing 
RNA was extracted using the RNeasy Mini Kit (Qiagen) as follows. First, 150 μl of harvested 
allantoic fluid was mixed well with 500 μl of 70% (v/v) ethanol and then 500 μl of RLT buffer 
was added. Next, 750 μl aliquots of the mixture were transferred to a purification column, 
followed by centrifugation for 30 seconds at 1500×g. The eluate was discarded and the previous 
step repeated with the remaining mixture. 500 μl of the RW1 buffer was then added to a wash 
column with centrifugation at 1500×g for 30 seconds and the eluate discarded. The column 
was washed twice using a 500 μl RPE buffer in a similar manner. The column was then dried 
by centrifugation for 1 min at 1500×g, followed by elution of RNA with 20 μl of nuclease-free 
water. This eluate was left at room temperature for 1 min to dissolve the extracted RNA and 
followed by centrifugation for 30 seconds at 1500×g to obtain the purified RNA product. 
2.2.9.6. Reverse transcription of RNA to cDNA for NA sequencing 
Purified RNA (1 μg) was added to an RNase-free PCR tube in a 10 μl volume. To this, 2 μl of 
a 10× reverse transcriptase buffer (RT buffer), 2 μl dNTP mix (5 mM each dNTP), 2 μl of 10 
μM oligo-dT primer (or BmNA-1 forward primer), 1μl of Omniscript reverse transcriptase, 
and 3 μl RNA (up to 2μg per 20 μl reaction), were added and mixed well before incubation for 
60 min at 37°C. An aliquot of the resultant cDNA (5 μl) was mixed with 10 μl of 1× phusion 
master mix (PhusionTM Flash High-fidelity PCR master mix, Finnzymes #F-548S), 2 μl of 
forward and reverse neuraminidase primers (BmNA-1 and BmNA-1413), and 1 μl of nuclease 
free water. PCR conditions (Table 2.2 B) were used to amplify DNA.The PCR product was 
electrophoresed on a 0.8% agarose gel, as previously described to check the accurate size of 
the amplified DNA. After that, the sequencing PCR reaction was performed on the amplified 
DNA samples using the reaction mixture included in the 1 μl template ds DNA (300 ng), 1 μl 
of 2.5x Big-Dye terminator Premix (v3.1), 3.5 μl of 5x Reaction buffer, and 1 μl primer 3.2 
pmol (5 mM). The total volume was brought up to 20 μl by nuclease free water. The sequencing 
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reaction mixture followed the reaction cycle conditions (Table 2.3). After this, all samples were 
sent to the DSR Sequencing laboratory in the CSIRO/AAHL for sequencing. 
 
Table 2.3. Conditions of preparation DNA samples for sequencing reaction. This table shows 
typical cycles of sequencing reaction performed on the amplified DNA samples. 
 
Step of reaction Temperature Time Cycle 
1 96 oC 1 min 1 
2 96 oC 10 sec  
30 3 50 oC 5 sec 
4 60 oC 4 min 
5 4  oC Hold  
 
2.2.9.7. Plaque assay 
To measure the titer of newly generated recombinant influenza viruses, a plaque assay was 
performed on Madin-Darby Canine Kidney (MDCK) cell monolayers, using the viral titer of 
pfu/ml for each virus (Tannock, Paul and Barry, 1984; Thomas et al., 2006). A monolayer of 
MDCK cells was grown on 6 well tissue culture plates. The MDCK cell growth media was 
removed and duplicate wells were inoculated with 150 μl of ten-fold serially diluted virus stock 
(10-1 -10-7). The plates were then incubated at 37°C, 5% CO2 for 45 min with shaking every 15 
minutes. A 200 μl aliquot of 0.1% Trypsin Worthington TW (TPCK Trypsin Worthington from 
Scima-R; Cat. No. #LS003740; (stock 1Pg/ml)) was added to 2 × L15 medium (Invitrogen) 
and mixed with 1.8% agarose solution (A-6013 Agarose, Sigma-Aldrich) to generate the 
agarose overlay. 3 ml volume of the agarose overlay was added to the infected cell monolayer, 
followed by incubation at 37°C, with 5% CO2 for 3 days.  Plaques in each well were counted 
and plaque forming units per ml calculated (Cukalac et al., 2009). 
2.2.10. Vaccination of mice 
Six week old BALB/c mice were purchased from the Animal Resources Centre (ARC) and 
inoculated with the recombinant influenza vaccine strains following environmental adaptation 
for 2 weeks. All animal experiments were completed according to protocols approved by the 
CSIRO/AAHL Animal Ethic Committee. 
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2.2.10.1. Procedures for intravaginal and intranasal vaccination of mice 
The vaccination program followed six different vaccine strategies involving primary and 
secondary vaccination to stimulate CD8+ T cell responses. 
2.2.10.1.1. Primary vaccination 
In order to recognize the ability of each of the generated HIV-CD8+ T cell epitopes (H-2Kd 
Gag197 and H-2d Tat17) to induce a specific HIV-CD8+ T cell response, two groups of BALB/c 
mice were used for primary infection using influenza virus vectors expressing Gag197 or Tat17 
epitopes. The first group of BALB/c mice were primed intranasally with 30 μl (1×104 pfu) of 
the recombinant influenza vaccine (X31-NA-Gag197). Also, there is another group of mice were 
vaccinated with a primary intranasal infection of 30 μl (1×104 pfu) recombinant influenza 
vaccine (X31-NA-Tat17). Both groups were rested for 10 days following infection and then 
euthanased to harvest their spleen to detect CD8+ T cell responses. 
2.2.10.1.2. Prime boost vaccination 
There were four different procedures of prime boost vaccination used in BALB/c mice as 
follows: i) Intranasal administration of 30 μl (1 × 104 pfu) of the recombinant influenza vaccine 
(X31-NA-Gag197) as a prime dose, and then after six weeks by intranasal infection with 30μl 
(50 pfu) of PR8-NA-Gag197; ii) Intravaginal administration of 30 μl (1 × 104 pfu) recombinant 
influenza vaccine (X31-NA-Gag197) as a prime dose followed 6 weeks later by intravaginal 
infection with 30μl (50 pfu) of PR8-NA-Gag197; iii) Intranasal administration of 30 μl (1 × 104 
pfu) of the recombinant influenza vaccine (X31-NA-Gag197) as a prime dose followed 6 weeks 
later by intravaginal infection with 30 μl (50 pfu) of PR8-NA-Gag197; and iv) Intravaginal 
administration of 30 μl (50 pfu) of PR8-NA-Gag197 as a prime dose followed 6 weeks later by 
intranasal immunization with 30 μl (1 × 104 pfu) of the recombinant influenza vaccine (X31-
NA-Gag197). To obtain CD8+ T cell population, all gropus of infected mice were euthanased 
after 7 days of the boost dose of the infection for harvesting different organs, such as the spleen, 
brochoalveolar lavage (BAL), mediastinal (MedLN) and inguinal (ILN) lymph nodes. 
2.2.10.1.3. Lymphocyte isolation and preparation 
After 10 days of primary infection or 7 days of prime boost infection, groups of infected mice 
were euthanased by CO2 asphyxiation. After that, spleens, inguinal (ILN) and mediastinal 
(MLN) lymph nodes were harvested from the infected mice. These organs were added to 10 
ml of Hank’s buffered salt solution (HBSS) for the preparation of single cell suspensions of 
lymphocytes. Two frosted slides were used to gently disrupt solid organs (spleen and lymph 
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nodes) before filtration of cell suspensions through 70 μm cell strainer. Enriched T cells were 
obtained from the spleen by the panning of B cells using 15 ml anti-mouse IgM + IgG 
immunoglobulins (5 vials + 200 mL of PBS, H + L; Jackson Immuno-Research Laboratories) 
in a petri dish for 45 min. The non-adherent cell suspension was harvested and then centrifuged 
for 6 min at 1600 RPM and re-suspended in 3 ml of HANKS solution. The supernatant was 
then gently discarded before adding 3 ml of Ammonium Tris-Chloride buffer (see in Appendix 
A) to each tube and incubating for 5 min at room temperature to lyse RBCs. The reaction was 
stopped by adding 7 ml of HBSS to each tube before centrifugation for another 6 min. 
Following removal of the supernatant cells, they were washed twice using10 ml of HBSS and 
re-suspended in 3 ml of complete RPMI for intracellular cytokine staining assay preparation 
and tetramer staining. To obtain T cells from broncho-alveolar lavage (BAL), 3 ml (1x) of 
harvested BAL samples (included PBS as a diluent) were plated in 6 well plates and incubated 
for 1 hour at 37ºC to remove adherent cells (macrophages). The non-adherent cells were 
collected into 10 ml tubes and centrifuged at 1600 rpm for 6 min at 4ºC. The cell pellet was re-
suspended in 2 ml of complete RPMI for intracellular cytokine staining assay preparation and 
tetramer staining. Lymphocytes from all samples were counted using a hemocytometer.  
2.2.10.2. Phenotype and surface marker staining 
T cells were phenotyped using rat-anti-mouse antibodies CD4-FITC (BD-Pharmingen, Clone 
RM-4.4) and CD8-α-PerCP5.5 (BD-Pharmingen, Clone 53-6.7). A 100 μl aliquot of 
lymphocyte suspension was added into a 96 well culture plate (BD Falcon) followed by 50μl 
of an antibody cocktail of rat anti-mouse CD4-FITC (1/400) and CD8-α-PerCP5.5 (1/200) 
antibodies (Appendix A). This was then incubated on ice for 30 min and the cells washed twice 
with FACS buffer (Reagent section, Appendix A). Samples were then analyzed on FACS BD-
FACS LSR II using BD DIVA software. 
2.2.10.3. Intracellular cytokine staining 
For intracellular cytokine staining, 100 μl of enriched CD8+ T cells was added to a 96 well 
round bottom plate (Corning® Costar®), followed by the addition of a 100 μl stimulation 
mixture (Table 2.4). This stimulation mixture of 1 ml included 50 μl of IL-2 (50 U/ml), 2 μl of 
Golgi-plug (Brefeldin) (10 μg/ml) and 20 μl of the H-2Kd Gag197 or H-2Kd NP147 peptides (2 
μg/ml). It was then made up for 1000 μl by adding c-RPMI.  After that, mixture of 100 μl CD8+ 
T cells and 100 μl of stimulation mixture (including Gag197 or NP147 peptide or no-peptide 
stimulation mix) were incubated for 5 hours at 37ºC with 5% CO2.  The plate was then 
centrifuged at 1600 rpm for 4 min at 4ºC. The supernatant was discarded and cells were washed 
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twice with a 150 μl FACS buffer. Cells were then stained in a 50 μl volume of FACS buffer 
that included anti-CD8-α-PerCP5.5 (1/200). 
 
These samples were then incubated on ice for 20 minutes, washed and centrifugation performed 
at 1600 rpm for 4 min at 4qC. Cells were then re-suspended in 100 μl of Golgi-plug solution to 
keep the stimulated intracellular cytokines inside cells and not escaping out of cells (see 
Appendix A). One hundred μl of 0.5% paraformaldehyde was added before incubation for 15 
min at room temperature to fix the treated cells without undergoing any changes. The plate was 
then covered in foil and incubated overnight at 4oC. Following centrifugation, cells were re-
suspended in 150 μl of Perm wash solution (10%) and incubated for 20 min at 4qC prior to the 
addition of a cytokine antibody cocktail (anti-IFNγ-FITC, anti-IL2-PE and anti TNF-α-APC, 
1/100, in a 50 μl volume.The plate was incubated on ice for 30 min and the cells washed twice 
with 150 μl of a 10% Perm Wash buffer. Finally, cells were re-suspended in a final volume of 
200 μl FACS buffer for analysis on the BD-FACS LSR II.  
 
Table 2.4. Stimulation mixture solutions used in intracellular cytokine staining (ICS). The 
three types of stimulation mixture are shown, including the H-2Kd NP147, H-2KdGag197 peptide. 
No peptide stimulation mixture used as a negative control. 
Item used NP147  peptide Gag197  peptide No peptide 
Peptide 
 
20 μl 20 μl - 
rIL-2 
 
50 μl 50 μl 50 μl 
Golgi 
(Brefeldin) 
 
2 μl 2 μl 2 μl 
 
C-RPMI 
 
928 μl 928 μl 948μl 
Total 
volume 
1000 μl 1000 μl 1000 μl 
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2.2.10.4. Tetramer staining 
Tetramers were prepared by complexing MHC-1 molecules with the specific CD8+ T cell 
receptor, conjugated with specific peptides (glycoprotein H-2Kd NP147 or H-2Kd Gag197) and 
then treated with Streptavidin-Phycoerythrin. The Allophycocyanin conjugated H-2Kd NP147 
or H-2Kd Gag197 tetramers were kindly synthesized by the Biomolecular Resource Facility, 
John Curtin School of Medical Research. Aliquots (100 μl) of enriched CD8+ T cells were 
added to a 96 well round bottom plate, followed by centrifugation at 1600 rpm for 4 min at 
4°C. The cell pellet was re-suspended in 50 μl of appropriate tetramer, H-2Kd NP147-APC 
(TYQRTRALV) or H-2Kd Gag197-APC (AMQMLKETI) at 1/100 dilution. The 96 well plate 
was then covered with foil and incubated at room temperature for 1 hr, followed by washing 
(two times) with 150 μl of FACS buffer. An antibody cocktail (anti-CD8-PerCP (1/200), anti-
CD62L-FITC (1/400), anti-CD44-PE (1/400), anti-LPAM-1-PE (1/400), anti-CD103-FITC 
(1/400), anti-CD69-PE (1/1400) and anti-CCR9-FITC (1/400) was added in a 50 μl volume 
using appropriate combinations. The plate of stained cells was incubated for 30 min on ice 
samples washed with 150 μl of FACS buffer and cells re-suspended in a final volume of 200 
μl FACS buffer before FACS analysis (BD-FACS-LSR II). 
2.2.10.5. Cell sorting of HIV Gag+LPAM-1+CD8+ T cell populations 
The total HIV Gag197+CD8+ T cells were harvested from the spleen, mediastinal and broncho-
alveolar lavage from vaccinated BALB/C mice. CD8+ T cells (from the spleen and MLN) were 
enriched as per section (2.2.14.2) and then stained with a H-2Kd Gag197 tetramer for 1 hr at 
room temperature as described above. Two populations of CD8+ T cells were stained with a 
specific purified H-2Kd Gag197 tetramer. Both were HIV-H-2Kd Gag+CD8+ T cells but with 
differentially expressed the mucosal homing integrin, α4β7+ (LPAM-1+) or α4β7- (LPAM-1-). 
The HIV H-2Kd Gag+CD8+ T cells were then stained with anti-mouse LPAM-1(α4β7) (1/400) 
and anti-mouse CD8α PerCP (1/200 dilution) in 2 ml of a sort buffer (0.1% BSA) on ice for 30 
min to sort using the sorter (BDFACS AriaTM II). RNAs were extracted from the HIV-
Gag197+α4β7+CD8+ T cell or HIV-Gag197+α4β7-CD8+ T cell populations using an RNeasy Mini 
Kit (Qiagen), as described in the previous Section (2.2.11). RNA was then reverse transcribed 
to cDNA using a SuperScript kit as previously described (Section 2.2.12). (Superscript III First-
Strand Synthesis Supermix).  
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2.2.10.6. Real time PCR (RT-PCR) for IL-15 and IL-15Rα expression 
Real time PCR (RT-PCR) was performedon the corresponding cDNA synthesized from the 
Gag197+α4β7+ and Gag197+α4β7-CD8+ T cells using the clear optical 96-well plate. This assay 
used ABI-Taq-Mn MGB primer/probes specific for IL-15 or IL-15Rα supplied with ABI 
Taqman gene expression assays (Applied Biosystem), the Taqman gene expression assay mix 
(including probe and primers), (mouse IL-15-FAM (#Mm00434210-ml) (20×) or 
(#Mm04336046-ml). The mouse IL-15Rα was then combined with the ABI Universal PCR 
Master Mixof Taqman gene expression (2×) for standard PCR amplification. The Applied 
Biosystems-StepOneTM/Real-Time PCR protocol of duplicate wells for each cDNA sample 
was used. Firstly, 5 Pl of template cDNA synthesized from RNAs were extracted from 
Gag197+α4β7+ or Gag197+α4β7-CD8+ T cells, and added to each well of a clear optical 96-well 
plate to 20 Pl of the PCR Master-Mix added and mixed gently. After that, a clear film was used 
to cover the plate and then spin down the plate at 1600 rpm for 1 min to be ready for turning 
on the iCycler machine. The cycle conditions used were 2 min at 50ºC and 10 min at 95ºC, 
followed by a denaturation step of 40 cycles, 15 sec at 95ºC and an annealing step with 60 sec 
at 60ºC.  
 
All samples were normalized to the house-keeping gene, GAPDH (#Mm99999915-gl) as an 
internal standard control of genes used in each run to act as a normalizer, and the experiment 
was repeated three times. Data from the IL-15 cytokine or IL-15Rα expression detected by 
real-time PCR used StepOneTM-Software v2.0. The average CT was calculated for both α4β7+ 
or α4β7- samples and GAPDH and then the ΔCT (CT, α4β7+ - CT, GAPDH) and ΔCT (CT, 
α4β7- - CT, GAPDH) were determined. After that, the absolute value of the slope was made 
up to zero and efficiencies of relative quantification for expressed IL-15 cytokine or IL-15Rα 
were detected by calculating the average ΔΔCT (ΔC, α4β7+- ΔCT, α4β7-). 
2.2.10.7. Adoptive transfer and challenge of BALB/c mice 
Gag197+α4β7+ and Gag197+α4β7- CD8+ T cells were sorted (as described in Section 2.2.17.5) 
from intranasal-intranasal prime-boosted BALB/c mice. Gag197+α4β7+or Gag197+α4β7-CD8+ T 
cells, 5 × 104 cells/200 μl were transferred intravenously (tail vein) into two groups of naïve 
BALB/c mice, in addition to a negative group of mice given PBS only (Mock group) and then 
rested for 6 days. These mice were then challenged with a pseudo-virus, a recombinant vaccinia 
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virus expressing the whole HIV Gag protein (rVac-Gag) (see Section 2.2.17.8) to test the 
protective capacity of these populations. 
2.2.10.8. Pseudo-challenge of vaccinated mice with a recombinant Vaccinia 
virus expressing whole Gag protein. 
Six days following the adoptive transfer, BALB/c mice were infected intranasally with 1 × 107 
pfu recombinant vaccinia 633-Gag (rVac-gag) virus expressing the whole HIV-Gag protein. 
Five days after the pseudo-challenge, lungs and ovaries were harvested from individual mice 
and placed on ice before complete homogenization with a clean probe for 1 min. Lung 
homogenates were placed into a 10 ml sealed screw cup tube and centrifuged at 2000 rpm for 
7 minutes, with supernatants tested by a plaque assay to determine the titer of rVac-gag in all 
three groups of infected mice.Both the spleen and mediastinal lymph nodes were harvested 
from the three infected groups of mice at this time point in order to determine HIV-H-2Kd 
Gag197+CD8+ T cell responses using an ICS and tetramer staining assay. 
2.2.10.9. Statistical analysis 
Means and standard deviation (SD) were used to calculate weight change and CD8+ T cell 
immune responses amongst the different groups of mice infected with recombinant influenza-
HIV viruses. ANOVA with Tukey's test were used to make statistical comparisons of immune 
responses induced in different routes of infection. P Values were considered statistically 
significant when levels were P<0.05. In addition, the two sided t-test was used as the statistical 
analysis to compare the two groups of vaccinated animals in some laboratory experiments. 
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3. Chapter 3: Generation of influenza viruses 
expressing HIV-CD8+ T cell epitopes 
3.1. Overview 
This Chapter describes the generation of recombinant influenza viruses that express the H-2Kd 
HIV Gag197 or H-2d Tat17 CD8+ T cell epitopes. Two laboratory strains of mouse-adapted 
influenza viruses, X31 (H3N2) and PR8 (H1N1), were generated using established reverse 
genetics systems.  Reverse genetics systems is the novel molecular strategy discovered in 1978 
to generate newly modified live viruses that belong to various families like Rhabdoviridae, 
Paramyxoviridae, Filoviridae, Bunyaviridae and Orthomyxoviridae through a modification of 
their genome resulting from the cloned cDNA (Neumann, Whitt, and Kawaoka, 2002). Reverse 
genetics systems were first used to modify non-segmented positive stranded RNA viruses by 
transfecting a full length of the RNA genome into appropriate cells that permitted expression 
of viral proteins and generation of attenuated vaccine viruses able to induce an immune 
response to control infectious diseases (Taniguchi, Palmieri and Weissmann, 1978; Racaniello 
and Baltimore, 1981). In 1994, modified rabies virus was the first example of a non-segmented 
negative stranded RNA virus that was successfully generated by a reverse genetics strategy 
(Neumann, Whitt, and Kawaoka, 2002; Schnell, Mebatsion and Conzelmann, 1994). However, 
this was more difficult with segmented negative stranded RNA viruses as there was a big 
challenge to generate the segmented negative-sense RNA viruses because of a complication 
related to treating the segmented RNA genome. In addition, there was also the need to co-
express the viral polymerase complex and vRNAs to initiate transfection of viral RNA 
segments and generate modified viruses (Neumann, Whitt, and Kawaoka, 2002). Fortunately, 
all of these challenges have been overcome using a plasmid based technique. The first 
segmented negative stranded RNA virus, generated in 1996, was a member of the Bunyviridae 
family and included three RNA segments (Bridgen and Elliott, 1996). This was followed by 
the successful generation of an eight segmented negative stranded RNA virus, the influenza A 
virus (Neumann, Whitt, and Kawaoka, 2002; Neumann et al., 1999; Fodor et al., 1999). 
The plasmid-based technique used to generate the genetically modified recombinant influenza 
virus contained a total of 12 plasmids, including eight plasmids transfected into eukaryotic 
cells. The virus also included Vero cells to encode precise copies of eight viral RNA gene 
segments (PB2, PB1, PA, NP, HA, NA, M and NS) (Zobel, Neumann and Hobom, 1993) 
combined to the other four expressing plasmids to encode the four viral polymerase complex 
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proteins, PB1, PB2, PA and NP necessary for the transcription and replication of newly forming 
virus (Hoffmann et al., 2000; Neumann et al., 1999). After two years, a more developed reverse 
genetics technique has been used to generate recombinant genetically engineered influenza 
viruses entirely from cloned cDNA by the eight plasmids reverse genetics system. This system 
uses only eight plasmids encoding the eight viral protein segments transfected into eukaryotic 
cells, such as HEK-293T cells, thus resulting in expression of influenza viral proteins and 
newly formed virus replication that is mainly used as attenuated viral vaccines (Hoffmann et 
al., 2000; Neumann et al., 2005). In this Chapter, live influenza virus vectors were generated 
using a cloned viral genome recombining the eight segments of the virus including modified 
NA segment in which was inserted with HIV-H-2Kd Gag197 or H-2d Tat17 CD8+ T cell epitopes. 
This step included the generation of plasmids containing NA segments from the two influenza 
viruses, X31 (H3N2) and PR8 (H1N1) into HIV-epitopes, H-2Kd Gag197 and H-2d Tat17. HIV-
CD8+ T cell epitopes were amplified by providing all negative sense of the RNA converted 
from the cloned cDNA, and utilizing specific enzymes, such as RNA polymerase 1. The 
recombinant plasmid combined with the additional seven influenza plasmids were transfected 
into HEK-293T cells and further amplification of the virus was carried out via MDCK cells to 
generate the recombinant influenza viruses. Following this, Hemagglutination (HA) assay and 
sequencing were used to confirm the generated viruses. 
3.1.1. Generation of a recombinant X31(H3N2) or PR8 (H1N1) influenza 
viruses expressing HIV-CD8+ T cell epitopes 
HIV-H-2Kd Gag197 (AMQMLKETI) and H-2d Tat17 (QPKTACTNC) CD8+ T cell epitopes  
were cloned into the NA segments of X31 and PR8 viruses after amino acid residue 44 (Figure 
3.1). A recombinant PCR based strategy was used to introduce these epitopes. The first set of 
PCR reactions generated 2 NA fragments (200 bp and 1200 bp) that were then recombined to 
generate a modified NA gene segment expressing the introduced epitopes as depicted in the 
cloning strategy (Figure 3.2). The two amplified fragments totaling 1.4 Kb were then 
recombined using PCR to generate recombinant X31-NA-Gag197-205, X31-NA-Tat17 and PR8-
NA-Tat17 gene segments. These would then be cloned into an established influenza reverse 
genetics backbone plasmid pHW2000 (Figure 3.2) for use in virus rescue experiments to 
generate a modified virus expressing exogenous HIV-CD8+ T cell epitopes (Figure 3.3). 
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Figure 3.1. Amino acid sequences of the X31-NA (A) and PR8-NA (B) genes used for the 
generation of recombinant HIV-influenza vaccine vectors. The position into which the H-2Kd 
Gag197 (AMQMLKETI) or H-2d Tat17 (QPKTACTNC) epitopes were inserted are shown with 
an asterisk (*). 
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Figure 3.2. Generation of a recombinant neuraminidase (NA) gene segment containing HIV-
H-2Kd Gag197 (AMQMLKETI) and H-2d Tat17 (QPKTACTNC) CD8+ T cell epitopes. The 
schematic diagram depicts the stepwise PCR strategy used to generate recombinant reverse 
genetics plasmids. 
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Figure 3.3. Generation of a recombinant influenza virus expressing HIV-CD8+ T cell epitopes. 
This schematic structure shows the full length modified neuraminidase segment of PR8-NA 
and X31-NA, where HIV-CD8+ T cell epitopes, H-2Kd Gag197 and H-2d Tat17 were inserted. 
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PCR reactions were performed to generate the two fragments noted in Figure 3.2 which 
expressed the HIV-H-2Kd Gag197 CD8+ T cell epitope. A DNA fragment of band size 200 bp 
and a second DNA fragment (1.2 Kb) were amplified as predicted with BsmB1 restriction sites 
(Figure 3.4 A). A second recombinant PCR reaction generated a single recombined modified 
NA gene segment (1.4 Kb) with BsmB1 restriction sites at both the 5’ and 3’ends (Figure 3.4 
B). Data shown for the generation of a modified X31-NA-Gag197 gene segment was 
representative of two other manipulated gene NA segments, X31-NA-Tat17 and PR8-NA-Tat17. 
The PR8-NA-Gag197 recombinant virus was generated by the Stambas group at the University 
of Melbourne and was not cloned by the candidate. 
3.1.2. Cloning of modified NA plasmids into the pHW2000 reverse genetic         
plasmid system 
Recombinant influenza NA gene segments (X31-NA-Gag197, X31-NA-Tat17, and PR8-NA-
Tat17) with BsmB1 restriction sites were then cloned into the pHW2000 plasmid for use in 
downstream virus rescue experiments. The ligated products were transformed into competent 
cells to generate new plasmids pHW2000-X31-NA-Gag197, pHW2000-X31-NA-Tat17 and 
pHW2000-PR8-NA-Tat17. These were extracted and purified using the PureYield™ Plasmid 
Miniprep system and run on a 0.8% agarose gel (Figure 3.5). Three products were visualised 
on gel electrophoresis. The largest ligation product (4.4 Kb) contained both the pHW2000 
vector (3 Kb) and the recombinant NA with inserted H-2Kd Gag197 sequence (1.4 Kb). To 
confirm the insertion of the NA segment containing the H-2Kd Gag197 or H-2d Tat17 CD8+ T cell 
epitopes, the recombinant pHW2000 plasmids were digested with PvuI (which cuts within the 
vector), and PstI (which cuts within the insert). Clones that contained the appropriate modified 
NA gene segment generated two products (1.9 Kb and 2.2 Kb), as shown in lane 3, Figure 3.6). 
Lane 2 shows the undigested plasmid (including different forms of DNA) and lane 4 shows the 
pHW2000-X31-NA-Gag197 cut with PvuI alone resulting in a single 4.4 Kb band (Figure 3.6). 
To further confirm insertion of HIV-CD8+ T cell epitopes, sequencing of three plasmids, 
pHW2000-X31-NA-Gag197, pHW2000-X31-NA-Tat17 and pHW2000-PR8-NA-Tat17 was 
carried out in full (Figures 3.7, 3.8 and 3.9). We also confirmed the sequence of pHW2000-
PR8-NA-Gag197 previously generated by the Stambas laboratory (Figure 3.10). 
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Figure 3.4. Gel electrophoresis of PCR products used a 0.8% of agarose gel. Panel A shows 
the predicted PCR products contained the HIV-H-2Kd Gag197 CD8+ T cell epitope. Panel B 
shows the recombined PCR product representing the full length modified NA gene segment 
expressing H-2Kd Gag197. Data shown in this figure is representative of other PCR products 
generated for the rescue of X31 or PR8 influenza viruses expressing HIV-H-2Kd Gag197 or H-
2d Tat17 CD8+ T cell epitopes. 
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Figure 3.5. Gel electrophoresis of ligated PCR products into the pHW2000 reverse genetics 
plasmid used a 0.8% agarose gel. Lane 1 shows the use of 1 Kb plus a DNA ladder ranging 
from 100 bp to 12 Kb. Lane 2 shows the ligation reaction with three products. These bands 
represent the non-ligated plasmid (pHW2000) at 3 Kb and the recombinant modified NA at 1.4 
Kb. The ligation band size at 4.4 Kb represents the recombined pHW2000-NA-Gag197 plasmid. 
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Figure 3.6. Gel electrophoresis of restriction enzyme digestion of the pHW2000-X31-NA-
Gag197 plasmid using endonucleases PvuI and PstI. Lane 1 contains the 1 Kb plus DNA ladder 
with band sizes ranging from 100 bp to 12 Kb. Lane 2 shows undigested plasmid and lane 4 
shows the pHW2000-X31-NA-Gag197 plasmid cut with PvuI alone. The pHW2000-X31-NA-
Gag197 plasmid was digested with both PvuI and PstI in lane 3. Similar results were shown for 
the other generated plasmids, pHW2000-X31-NA-Tat17 and pHW2000-PR8-NA-Tat17. 
 
 
 
 
 
1Kb
3kb
4.4 Kb
2.2 Kb
1.9 Kb
500bp
100bp
1 2 3 4
1.6Kb
2Kb
Chapter 3:                      Generation of influenza viruses expressing HIV-CD8+ T cell epitopes 
80 
 
 
Figure 3.7. Nucleotide sequence of X31-NA-Gag197. The HIV-H-2Kd Gag197 epitope inserted 
into the NA gene segment is highlighted in bold letters (AMQMLKETI-protein and 
GCCATGCAAATGTTAAAAGAGACCATC-DNA sequence). 
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Figure 3.8. Nucleotide sequence of pHW2000-PR8-NA-Tat17. The HIV-H-2d Tat17 epitope 
inserted into the NA gene segment is highlighted in bold letters (QPKTACTNC-protein and 
CAGCCTAAAACTGCTTGTACCAATTGC-DNA sequence). 
 
1/1   
ATG 
M 
 
AAT 
N 
 
CCA 
P 
AAT 
N 
 
CAA 
Q 
 
AAG 
K 
 
ATA 
I 
 
ATA 
I 
 
ACA 
T 
 
ATC 
I 
 
CAG 
G 
 
TGT 
C 
 
CTG 
L 
 
TAA 
S 
 
GTA 
V 
 
GTC 
V 
 
GGA 
G 
 
CTA 
L 
 
ATT 
I 
 
AGC 
S 
 
CTA 
L 
 
ATA 
I 
 
TTG 
L 
 
CAA 
Q 
ATA 
I 
GGG 
G 
AAT 
N 
ATA 
I 
ATC 
I 
AAT 
I 
TCA 
S 
ATA 
I 
TGG 
W 
ATT 
I 
TGG 
W 
AGC 
S 
CAT 
H 
TCA 
S 
ATT 
I 
CAA 
Q 
ACT 
T 
GGA 
G 
AGT 
S 
CAA 
Q 
CAG 
Q 
CCT 
P 
AAA 
K 
ACT 
T 
GCT 
A 
TGT 
C 
ACC 
T 
AAT 
N 
TGC 
C 
AAC 
N 
CAT 
H 
ACT 
T 
GGA 
G 
ATA 
I 
TGC 
C 
AAC 
N 
CAA 
Q 
AAC 
N 
ATC 
I 
ATT 
I 
ACC 
T 
TAT 
Y 
AAA 
K 
AAT 
N 
AGC 
S 
ACC 
T 
TGG 
W 
GTA 
V 
AAG 
K 
GAC 
D 
ACA 
T 
ACT 
T 
TCA 
S 
GTG 
V 
ATA 
I 
TTA 
L 
ACC 
T 
GGC 
G 
AAT 
N 
TCA 
S 
TCT 
S 
CTT 
L 
TGT 
C 
CCC 
P 
ATC 
I 
CGT 
R 
GGG 
G 
TGG 
W 
GCT 
A 
ATA 
I 
TAC 
Y 
AGC 
S 
AAA 
K 
GAC 
D 
AAT 
N 
AGC 
S 
ATA 
I 
AGA 
R 
ATT 
I 
GGT 
G 
TCC 
S 
AAA 
K 
GGA 
G 
GAC 
D 
GTT 
V 
TTT 
F 
GTC 
V 
ATA 
I 
AGA 
R 
GAG 
E 
CCC 
P 
TTT 
F 
ATT 
I 
TCA 
S 
TGT 
C 
TCT 
S 
CAC 
H 
TTG 
L 
GAA 
E 
TGC 
C 
AGG 
R 
ACC 
T 
TTT 
F 
TTT 
F 
CTG 
L 
ACC 
T 
CAA 
Q 
GGT 
G 
GCC 
A 
TTA 
L 
CTG 
L 
AAT 
N 
GAC 
D 
AGG 
R 
CAT 
H 
TCA 
S 
AAT 
N 
GGG 
G 
ACT 
T 
GTA 
V 
GAG 
K 
GAC 
D 
AGA 
R 
AGC 
S 
CCT 
P 
TAT 
Y 
AGG 
R 
GCC 
A 
TTA 
L 
ATG 
M 
AGC 
S 
TGC 
C 
CCT 
P 
GTC 
V 
GGT 
G 
GAA 
E 
GCT 
A 
CCG 
P 
TCC 
S 
CCG 
P 
TAC 
Y 
AAT 
N 
TCA 
S 
AGA 
R 
TTT 
F 
GAA 
E 
TCG 
S 
GTT 
V 
GCT 
A 
TGG 
W 
TCA 
S 
GCA 
A 
AGT 
S 
GCA 
A 
TGT 
C 
CAT 
H 
GAT 
D 
GGC 
G 
ATG 
M 
GGC 
G 
TGG 
W 
CTA 
L 
ACA 
T 
ATC 
I 
GGA 
G 
ATT 
I 
TCA 
S 
GGT 
G 
CCA 
P 
GAT 
D 
AAT 
N 
GGA 
G 
GCA 
A 
GTG 
V 
GCT 
A 
GTA 
V 
TTA 
L 
AAA 
K 
TAC 
Y 
AAC 
N 
GGC 
G 
ATA 
I 
ATA 
I 
ACT 
T 
GAA 
E 
ACC 
T 
ATA 
I 
AAA 
K 
AGT 
S 
TGG 
W 
AGG 
R 
AAG 
K 
AAA 
K 
ATA 
I 
TTG 
L 
AGG 
R 
ACA 
T 
CAA 
Q 
GAG 
E 
TCT 
S 
GAA 
E 
TGT 
C 
GCC 
A 
TGT 
C 
GTA 
V 
AAT 
N 
GGT 
G 
TCA 
S 
TGT 
C 
TTT 
F 
ACT 
T 
ATA 
I 
ATG 
M 
ACT 
T 
GAT 
D 
GGC 
G 
CCG 
P 
AGT 
S 
GAT 
D 
GGG 
G 
CTG 
L 
GCC 
A 
TCG 
S 
TAC 
Y 
AAA 
K 
ATT 
I 
TTC 
F 
AAG 
K 
ATC 
I 
GAA 
E 
AAG 
K 
GGG 
G 
AAG 
K 
GTT 
V 
ACT 
T 
AAA 
K 
TCA 
S 
GAG 
E 
TTG 
L 
AAT 
N 
GCA 
A 
CCT 
P 
AAT 
N 
TCT 
S 
CAC 
H 
TAT 
Y 
GAG 
E 
GAA 
E 
TGT 
C 
TCC 
S 
TGT 
C 
TAC 
Y 
CCT 
P 
GAT 
D 
ACC 
T 
GGC 
G 
AAA 
K 
GTG 
V 
ATG 
M 
TGT 
C 
GTG 
V 
TGC 
C 
AGA 
R 
GAC 
D 
AAT 
N 
TGG 
W 
CAT 
H 
GGT 
G 
TCG 
S 
AAC 
N 
CGG 
R 
CCA 
P 
TGG 
W 
GTG 
V 
TCT 
S 
TTC 
F 
GAT 
D 
CAA 
Q 
AAC 
N 
CTG 
L 
GAT 
D 
TAT 
Y 
CAA 
Q 
ATA 
I 
GGA 
G 
TAC 
Y 
ATC 
I 
TGC 
C 
AGT 
S 
GGG 
G 
GTT 
V 
TTC 
F 
GGT 
G 
GAC 
D 
AAC 
N 
CGT 
R 
CCC 
P 
AAA 
K 
GAT 
D 
GGA 
G 
ACA 
T 
GGC 
G 
AGC 
S 
TGC 
C 
GGT 
G 
CCA 
P 
GTG 
V 
TAT 
Y 
GTT 
V 
GAT 
D 
GGA 
G 
GCA 
A 
AAC 
N 
GGA 
G 
GTA 
V 
AAG 
K 
GGA 
G 
TTT 
F 
TCA 
S 
TAT 
Y 
AGG 
R 
TAT 
Y 
GGT 
G 
AAT 
N 
GGT 
G 
GTT 
V 
TGG 
W 
ATA 
I 
GGA 
G 
AGG 
R 
ACC 
T 
AAA 
K 
AGT 
S 
CAC 
H 
AGT 
S 
TCC 
S 
AGA 
R 
CAT 
H 
GGG 
G 
TTT 
F 
GAG 
E 
ATG 
M 
ATT 
I 
TGG 
W 
GAT 
D 
CCT 
P 
AAT 
N 
GGA 
G 
TGG 
W 
ACA 
T 
GAG 
E 
ACT 
T 
GAT 
D 
AGT 
S 
GAG 
E 
TTC 
F 
TCT 
S 
GTG 
V 
AGG 
R 
CAA 
Q 
GAT 
D 
GTT 
V 
GTG 
V 
GCA 
A 
ATG 
M 
ACT 
T 
GAT 
D 
TGG 
W 
TCA 
S 
GGG 
G 
TAT 
Y 
AGC 
S 
GGA 
G 
AGT 
S 
TTC 
F 
GTT 
V 
CAA 
Q 
CAT 
H 
CCT 
P 
GAG 
E 
CTA 
L 
ACA 
T 
GGG 
G 
CTA 
L 
GAC 
D 
TGT 
C 
ATA 
I 
AGG 
R 
CCG 
P 
TGC 
C 
TTC 
F 
TGG 
W 
GTT 
V 
GAA 
E 
TTA 
L 
ATC 
I 
AGG 
R 
GGA 
G 
CGA 
R 
CCT 
P 
AAA 
K 
GAA 
E 
AAA 
K 
ACA 
T 
TGG 
W 
ACC 
T 
AGT 
S 
GCG 
A 
AGC 
S 
GCG 
A 
AGC 
S 
AGC 
S 
ATT 
I 
TCT 
S 
TTT 
F 
TGT 
C 
GGC 
G 
GTG 
V 
AAT 
N 
AGT 
S 
GAT 
D 
ACT 
T 
GTA 
V 
GAT 
D 
TGG 
W 
TCT 
S 
TGG 
W 
CCA 
P 
GAC 
D 
GGT 
G 
GCT 
A 
GAG 
E 
TTG 
L 
CCA 
P 
TTG 
L 
CCA 
P 
TTC 
F 
ACC 
T 
ATT 
I 
GAC 
D 
AAG 
K 
      
Chapter 3:                      Generation of influenza viruses expressing HIV-CD8+ T cell epitopes 
82 
 
 
Figure 3.9. Nucleotide sequence of pHW2000-X31-NA-Tat17. The HIV-H-2d Tat17 epitope 
inserted into the NA gene segment is highlighted in bold letters (QPKTACTNC-protein and 
CAGCCTAAAACTGCTTGTACCAATTGC-DNA sequence). 
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Figure 3.10. Nucleotide sequence of pHW2000-PR8-NA-Gag197. The HIV H-2Kd Gag197 in 
the NA gene segment is highlighted in bold letters (AMQMLKETI-protein and nucleotides 
GCCATGCAAATGTTAAAAGAGACCATC-DNA sequence). 
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3.1.3. Rescue of recombinant influenza viruses using influenza reverse 
genetics 
Once the sequence of the recombinant plasmids was confirmed, the recombinant influenza 
viruses containing the modified NA genes were generated using reverse genetics. This 
technique is summarized in Figure 3.11 and involved the transfection of the eight pHW2000 
plasmids (pHW2000-NP, pHW2000-PA, pHW2000-PB1, pHW2000-PB2, pHW2000-M, 
pHW2000-NS, pHW2000-HA and the pHW2000-NA-Gag197 or pHW2000-NA-Tat17), each 
containing one of the influenza gene segments into a co-culture of HEK-293T and MDCK 
cells. Supernatant containing the recombinant virus was then further amplified in 10 day old 
embryonated chicken eggs (Figure 3.11).  
3.1.4. Amplification of generated recombinant influenza viruses 
Following reverse genetics, three rescued influenza viruses were further amplified by 
inoculation of the 10 day old embryonated eggs (Methods, Section 2.2.12) and the supernatant 
collected. The allantoic fluids containing the amplified viruses were then harvested and kept at 
-80ºC. All allantoic fluid samples were subjected to a semi-quantitative HA assay to confirm 
the rescued viruses. HA titers were then determined for each virus. X31-NA-Gag197 was 1/256, 
PR8-NA-Tat17 was 1/256, and X31-NA-Tat17 was 1/128 (Figure 3.12). Following confirmation 
of the viral titers, the rescued viruses were determined by plaque assay (see Methods Section 
2.2.14). The virus titer for X31-NA-Gag197 was 6.0 × 107 pfu/ml, X31-NA-Tat17 was 6.7 × 107 
pfu/ml and PR8-NA-Tat17 was 8.2 × 107 pfu/ml. The titer of the fourth virus already generated 
in the Stambas laboratory for PR8-NA-Gag197 was 4.5 × 108 pfu/ml (Table 3.1).  
3.1.5. Sequencing of recombinant viruses amplified in allantoic fluid 
RNA was extracted from the allantoic fluid and PCR was amplified using NA primers, forward 
primer, Bm-NA-1-F (5’TAT TCG TCT CAG GGA GCA AAA GCA GGA GT-3’) and 
reverse primer, Bm-NA-1413-R (5’ATA TCG TCT CGT ATT AGT AGA AAC AAG GAG 
TTT TTT-3’). This PCR product was run on an agarose gel electrophoresis, excised, purified 
and sequenced. It was at the expected 1.4 Kb site as previously described in Figure 3.4 B. 
Sequencing confirmed the NA gene contained our inserted HIV-CD8+ T cell epitopes as 
described previously in Figure 3.7. The confirmed construct was appropriately labelled X31-
NA-Gag197. In addition, the sequencing results confirmed the NA gene segment with inserted 
H-2d epitopes, Gag197 and Tat17, had been faithfully maintained in the amplification process of 
all rescued viruses as shown previously when plasmids were sequenced in Figures 3.8, 3.9 and 
3.10. 
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Figure 3.11. Reverse genetics strategy for the rescue of recombinant influenza viruses 
expressing HIV-CD8+ T cell epitopes. This schematic diagram shows the procedure used to 
rescue recombinant influenza viruses. The manipulated pHW2000-X31-NA-Gag197 or PR8-
NA-Tat17 or X31-NA-Tat17 plasmid was co-transfected with 7 other pHW2000 encoding 
influenza gene segments (pHW2000-PB1, PB2, PA, HA, NP, M and NS) in a co-culture of 
HEK-293T and MDCK cells (Hoffmann et al., 2000). 
 
 
 
 
 
HA NS
NPPAPB1PB2
M
NA
7 master strain 
plasmids of  PR8 or 
X31 viruses
Rescued reverse genetics 
viruses were plaqued to 
determine titre of viruses
pHW2000–PR8 or X31-NA-Gag197-205
Transfection and amplification
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Figure 3.12. Hemagglutination assay of three rescued recombinant influenza viruses. 
Supernatants were harvested from the reverse genetic cultures of three viruses, PR8-NA-Tat17, 
X31-NA-Gag197 and X31-NA-Tat17. They were diluted two fold in a Hemagglutination assay 
(HA) in combination with 0.5% chicken RBCs. This figure shows the positive results of 
hemagglutination applied on a round bottom plate using two serial dilution presented for three 
rescued viruses (A) anda graph that presents the HA titers of these rescued viruses (B). 
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Table 3.1. Titration of rescued recombinant influenza viruses by plaque assay. Allantoic fluids 
harvested following 10 day old embryonated chicken eggs were used in a plaque assay on 
MDCK cell monolayers to determine viral titers. 
Recombinant virus Titer by plaque forming unit (pfu)/ml 
X31-NA-Gag
197
 6.0 × 107 pfu/ml 
X31-NA-Tat17 6.7 × 107 pfu/ml 
PR8-NA-Tat17 8.2 × 107 pfu/ml 
PR8-NA-Gag197 4.5 × 108 pfu/ml (Stambas group) 
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3.2. Discussion 
As a result of the failure of most traditional vaccines to induce appropriate immune responses 
for protection against viral diseases, such as HIV/AIDS, new strategies including live 
virus/bacterial vectors are currently being investigated to use for expressing specific antigens 
or peptides of infectious viruses or bacteria as an effective vaccine control infection (Dudek, 
2006; Fitzgerald et al., 2003; Izumi et al., 2003). These vectors can be generated by a number 
of methodologies, one of which is reverse genetics. Reverse genetics is a powerful strategy 
used in a range of different applications such as gene therapy and vaccine development. This 
involves the manipulation of plasmid DNA in order to create novel modified features in viral 
or bacterial agents when rescued as whole organisms (Jalilian et al., 2010; Stoff-Khalili, Dall, 
and Curiel 2006; Tung et al., 2007). In order to generate these vectors, it is necessary to place 
antigens, polypeptides or epitopes into genes for further manipulation. Given the availability 
of a mouse model for live vaccination (influenza based strategy), well defined HIV-CD8+ T 
cell epitopes derived in the H-2d BALB/c mouse model and influenza reverse genetics plasmids 
can be used to generate recombinant vectors for use in vaccination studies. Influenza virus type 
A has been considered a strong candidate for live viral vector delivery, given its ability to infect 
via mucosal surfaces such as the respiratory tract (Marsh and Tannock, 2005; Satterlee, 2008; 
Smith, 2007). Negative stranded RNA viruses, such as influenza are characterized by their 
ability to infect humans and laboratory animals through mucosal portals of entry resulting in 
broad and long term humoral and cellular immunity (Fodor et al., 1999; Mueller et al., 2010; 
Neumann and Kawaoka, 2001; Yao and Wang, 2008). In addition, influenza viruses are 
especially amenable for use as recombinant vaccine vectors due to the presence of a segmented 
genome and the availability of plasmids that allow manipulation and rescue of novel 
recombinant viruses (Fodor et al., 1999; Palese et al., 1996). As such, influenza viruses have 
been used as vectors to express antigens from HIV, SIV, tuberculosis, malaria and lympho-
cytic-chorio-meningitis virus as a part of the HA or NA gene segments to generate novel 
vaccines (Jalilian et al., 2010; Rodrigues et al., 1994; Sexton et al., 2009). Influenza A viruses 
have also been recombinant vaccine vectors that express HIV antigens or CD8+ T cell epitopes 
that have been inserted into the NA stalk PR8 (H1N1) and X31 (H3N2) (Pleschka et al., 1996). 
Early work in particular focused on the expression of HIV envelope antigens or epitopes  
(Kramer, 2007; Letvin, 2009; Zolla-Pazner, 2004). 
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Various recombinant influenza viruses expressing HIV-CD8+ T cell epitopes have been 
successfully generated to use as HIV or SIV vaccines. For instance, A/PR/8/34 (HIN1) and 
A/Aichi/2/1968 (H3N2) were manipulated by a reverse genetics strategy in order to use in a 
preclinical trial of vaccination in mice or macaques. The result was stimulation of a mucosal 
CD8+ T cell response. These stimulated mucosal CD8+ T cells were critical to decrease viral 
copies and control of HIV or the SIV infection depending on the breadth of stimulated CD8+ 
T cell responses (Casimiro et al., 2005; Hoffmann et al., 2002; Liu et al., 2009; Pachler, Mayr 
and Vlasak, 2010; Rimmelzwaan et al., 2007). Some preclinical and clinical trials of HIV-1 
vaccine candidates have used HIV-1 Env proteins or HIV-Env CD8+ T cell epitopes which 
stimulated strong humoral and cellular immune responses (Sattentau, 2013; Cukalac et al., 
2009; Rerks-Ngarm et al., 2009).  
 
Historically, most HIV-1 candidate vaccines using Env protein/epitopes have been unable to 
elicit protective responses (Cho et al., 2001; McBurney and Ross, 2008; Plotkin, 2009). This 
is because of high variability in envelope glycoprotein amino acid sequences amongst different 
HIV-1 clades (Sreepian et al., 2009; Stamatatos et al., 2009; Zolla-Pazner and Cardozo, 2010). 
This study has focused on the generation of strong mucosal cytotoxic CD8+ T cell responses, 
and thus have revolved around the use of HIV-Gag+CD8+ T cell epitopes. Gag is a structural 
protein necessary for the assembly of newly generated virions during the life cycle of HIV-1 
in infected individuals and is highly conserved making it an ideal candidate for CTL based 
vaccines (Bryant and Ratner, 1990; Currier et al., 2006). Tat epitopes were also incorporated 
into our vaccine constructs. Tat is also a frequently targeted by cytotoxic CD8+ T cells as a 
highly conserved regulatory protein with defined CD8+ T cell epitopes (Addo et al., 2001; 
Gavioli et al., 2008; Gavioli et al., 2004; Scriba et al., 2005).  
 
In this project, three recombinant live influenza viruses expressing HIV-CD8+ T cell epitopes, 
H-2Kd Gag197 or H-2d Tat17 epitopes have been successfully generated. These two candidate 
HIV-1 epitopes were inserted individually into the NA stalk of A/Puerto Rico/8/34 (H1N1) or 
A/Aichi/2/1968 (H3N2) influenza viruses and then rescued using reverse genetics. These virus 
strains were used as they were adapted in mice. Three rescued influenza viruses, X31-NA-
Gag197, X31-NA-Tat17 and PR8-NA-Tat17 were obtained with similar titers tested by HA and 
plaque assay. However, they were different from the titer of PR8-NA-Gag197 generated 
previously by the Stambas group. This was probably because the ability of three newly 
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generated viruses to modify and replicate in allantoic fluids was similar as they were 
transfected and modified into a similar batch of co-culture. The viruses were also inoculated as 
supernatant into the same batch of embryonated chicken eggs, which was completely different 
from the co-culture inoculated with the PR8-NA-Gag197. This may also be the result of the 
different batches of embryonated eggs inoculated with supernatants of these generated viruses 
compared to the fourth previously generated virus which might be adapted to grow on different 
types of chicken eggs. There was also a highly significant increase in the affinity of egg-adapted 
variants of influenza A and B viruses to replicate compared to the non-adapted. This occurred 
by increased binding of the plasma membranes of the chorio-allantoic cells of the chicken eggs 
and also by increasing their multiplication (Gambaryan, Robertson and Matrosovich, 1999). It 
was anticipated that targeting two different epitopes would broaden the overall CD8+ T cell 
response and decrease opportunities for the generation of CTL escape in the future if the virus 
was further studied in pre-clinical trials in humans or macaques. Given the success of initial 
studies with X31 and PR8-NA-Gag197 recombinant viruses, analysis of X31 and PR8-NA-Tat17 
viruses was not taken further but could be explored at a later point in time. 
 
However, there are several limitations that can affect highly efficient influenza reverse genetics 
systems in HIV vaccine production. For instance, a limited number of mammalian cells are 
likely to be infected to amplify the eight plasmids to generate influenza viruses (Palache et al., 
1999; Halperin et al., 2002; Brühl et al., 2000). Although MDCK and Vero cells are mainly 
used to produce the recombinant influenza virus, there is no high efficiency to produce a large 
amount of the virus (Fodor et al., 1999; Nicolson et al., 2005). Also, some modified influenza 
viruses are unable to grow with high titer which leads to delay in virus production (Neumann 
et al., 1999; Hoffmann et al., 2002). Another limitation of using HA or NA in the influenza 
reverse genetics system is due to their small size. For instance, there is space for approximately 
10 amino acids in a foreign amino acid sequence to be inserted into the HA molecule (Garcia-
Sastre and Palese, 1995; Palese et al., 1997; Staczek et al., 1998). Although the NA stalk 
tolerates a longer foreign peptide sequence to be introduced into the stalk region, the maximum 
inserted length would be less than 82 amino acids with high opportunity for poor presentation 
of these peptides to the immune system. Another study using mice recognized that the 
neuraminidase (NA) stalk can tolerate as many as 41 amino acid peptide insertions expressed 
on the rescued influenza virus A/WSN/33 (HlNl), which was well replicated in intranasal 
infected BALB/c mice (Castrucci and Kawaoka, 1993; Luo, Chung and Palese, 1993). 
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Furthermore, it was clearly detected that the maximum length of a foreign peptide is 58 amino 
acids can be introduced into the neuraminidase stalk without the loss of viral function. The 
peptide was introduced with the H-2d LCMV nucleoprotein that expressed on the A/WSN/33 
(HIN1) influenza virus and was used intranasally and intraperitonealy in BALB/c mice. This 
induced CD8+ T cell protected vaccinated mice for the intracerebral challenge CA 1371 strain 
of LCMV (Castrucci et al., 1994). In addition, a limited size of the NA gene segment inserted 
with efficient amount of the HIV-1 protein was noted with loss of its functionality. This was 
detected by the insertion of the HIV-1 p17 Gag protein (rFlu-p17) gene that included 1-132 
amino acids inserted into the NA segment of the PR8 (A/PR/8/34) influenza virus. Insertion of 
the amino acids was not possible until complete removal of the start codon of NA and most of 
the NA coding sequence was excised by MluI and SpeI endonucleases and replaced by the 
HIV-1 p17 Gag protein, or HIV-1 Rev protein for use as a HIV vaccine in C57BL/6 and 
BALB/c mice (de Goede et al., 2009; van Baalen et al., 2005). Furthermore, recombinant 
influenza viruses generated from this transgenic process were replication deficient viruses 
because they lacked functional NA, despite the inducementof a detectable immunity response 
as they were depended on the exogenous source of NA (Sigma-Aldrich) added to enhance the 
replication (De Wit et al., 2004; Rimmelzwaan et al., 2007). As a result, the strategy for this 
project was to use only a limited number of amino acids as specific epitopes inserted into the 
NA stalk, which requires knowledge of the MHC haplotype of specific peptides or epitopes to 
generate a vaccine.  An alternative strategy to rescue recombinant influenza viruses expressing 
full HIV polypeptide sequences is possible. For example, the residue of 137 amino acids from 
the HIV-1 Nef protein that contains nucleotides 210-618 inserted into the NS1 segment of PR8 
(A/PR/8/34: H1N1), or the A/Aichi/1/168 (H3N2) influenza virus that uses an intranasal 
vaccine in BALB/c mice to induce robust antibodies and CD8+ T cell responses in the systemic 
and mucosal compartments, especially in the urogenital tract (Ferko et al., 2001). This problem 
can be avoided by using the NS gene segment with an inserted whole green fluorescent protein 
(GFP) containing 125 amino acids in the NS1 only (consisted of 230 amino acids), that 
maintains the fully functional non-structural proteins of the recombinant influenza viruses 
(Kittel et al., 2004). This provides an opportunity to introduce large sequences of HIV-1 
proteins into the NS segment (Takasuka et al., 2002; Kittel et al., 2005). Therefore, it is highly 
recommended any future work involve expressing full length HIV proteins using the NS as this 
would overcome the need to know the MHC haplotypes. 
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Live influenza vaccines are currently in use and licensed by MedImmune in the USA. Using 
seasonal vaccines as a backbone or uncommon HA and NA combination will avoid issues with 
neutralizing antibodies. 
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4. Chapter 4: Induction of CD8+ T cell responses 
using recombinant influenza viruses.  
4.1. Overview 
Chapter 3 described the generation of recombinant influenza viruses expressing the HIV-H-2d 
CD8+ T cell epitopes, Gag197 or Tat17. This chapter tests these recombinant vaccines in vivo in 
a mousee study using different mucosal routes of vaccination in order to elucidate the optimal 
approach for inducing HIV-specific CD8+ T cell immune responses in various lymphoid organs 
and regional lymph nodes distributed in different parts of the body, especially in the urogenital 
region which would provide a good opportunity to control HIV-1 infection (Garulli, Kawaoka 
and Castrucci, 2004). For this reason, different mucosal routes were used, specifically 
intranasal and intravaginal routes. This is because influenza virus naturally infects various 
mucosa, especially pulmonary mucosa. The intranasal route of vaccination is commonly used 
to deliver recombinant influenza A viruses in order to generate antigen specific mucosal 
responses in the spleen and respiratory tract mucosa that are represented by CD8+ T cells and 
neutralizing antibody responses targeting endogenous influenza antigens and exogenous HIV-
1 peptides (Byron et al., 2011; Takasuka et al., 2002). A study using a modified A/WSN/33 
expressing HIV-Env protein (HIV-1 IIIB gp160) in BALB/c mice resulted in a 4 fold increase 
of CD8+ T cell responses in the spleen and less frequent but detectable response in the genital 
lymph nodes (Gherardi et al., 2003). 
 
In contrast the intravaginal route of vaccination is rarely used in women (Johansson et al., 
2001). It is not common for the intravaginal route to be used to induce a mucosal immune 
response following influenza infection in mice given the lack of trypsin like enzymes to assist 
replication. There are a couple of examples however to note. Intravaginal using the 
recombinant influenza A virus vector expressing the HIV-Env protein produced strong durable 
mucosal CD8+ T cells specific for the influenza H-2Kd NP147 (TYQRTRALV) and HIV- H-2 
Dd Env (RGPGRAFVTI) peptide in regional vaginal draining lymph nodes, the inguinal lymph 
nodes and the spleen when compared to intranasally vaccinated mice that produced robust 
CD8+ T cell responses in the distant urogenital lymph nodes and the respiratory lymphoid 
tissues (Garulli, Kawaoka and Castrucci, 2004). In addition recombinant adenovirus (AdC6) 
expressing HIV-H-2Kd Gag197 (AMQMLKETI) viruses have been used in BALB/c mice via 
intranasal and intravaginal, vaccination to induce large numbers of CD8+ T cells in the spleen, 
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iliac lymph nodes and e vaginal tract (IELs). Higher vaginal Gag197+CD8+ T cell responses 
were mainly induced in the intravaginaly primed mice (de Souza et al., 2007). The responses 
induced through intravaginal vaccination have also been shown to be protective following 
pseudo-challenge (Li et al., 2008). 
  
The work in this chapter extends previous studies through an analysis of HIV-H-2d CD8+ T 
cell epitopes, Gag197 or Tat17. A direct comparison between intranasal and intravaginal 
vaccination, and a combination of intranasal and intravaginal routes in eliciting CD8+ T cell 
responses will be undertaken. To characterize induction of HIV-specific and mucosal immune 
responses in a mouse model, two laboratory strains of the influenza virus, (X31, H3N2 and 
PR8, H1N1) were used as vectors expressing CD8+ T cell epitopes (as described in Chapter 3). 
CD8+ T cell responses from different effector sites including the broncho-alveolar lavage 
(BAL), the spleen, mediastinal lymph nodes (MedLN) and inguinal lymph nodes (ILN) were 
characterized using intracellular cytokine and tetramer staining in combination with staining 
for specific mucosal phenotypic markers. Finally, CD8+ T cells expressing mucosal surface 
markers were sorted using flow cytometry and RNA extracted to detect expression of cytokine 
IL-15 and its surface receptor IL-15Rα, all of which are known to be involved in the migration 
of CD8+ T cells into effector mucosal sites. 
4.1.1. Characterization of CD8+ T cell responses following primary 
infection with recombinant X31-NA-Gag197  influenza virus 
To evaluate the immunogenicity of the recombinant viruses and their ability to induce immune 
responses against the exogenous HIV-H-2Kd Gag197 epitope and the endogenous influenza 
virus H2-Kd NP147 epitope, various mucosal routes (i.n and i.v) of vaccination were tested in 
mice to determine which route provided robust HIV specific and mucosal immune responses, 
and whether these recombinant influenza viruses were safe to use in mice. Six to eight week 
old BALB/c mice purchased from the Animal Resources Centre (ARC) were housed in a 
conventional animal house for 7 days for environmental adaptation before inoculation with the 
recombinant influenza virus. All animal experiments were conducted according to protocols 
approved by the CSIRO AAHL and Deakin University’s Animal Ethics Committees.  
 
BALB/c mice were primed intranasally or intravaginally with 1 × 104 pfu X31-NA-Gag197 
influenza viruses and their body weight monitored daily for ten days following infection. 
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Following the first two days of intranasal infection, mice maintained normal weight but started 
to lose weight gradually on the third day. The weight loss continued into the fourth fifth and 
sixth days, dropping approximatey (7.8 ± 1.0 %) from their original starting weight. This 
weight loss was significant and consistent with results in the literature (Cukalac et al., 
2009).Mice gradually began regaining weight on day 7 with complete recovery of original 
weight occurring by day 10, thus indicating clearance of the influenza virus (Figure 4.1A). 
However, mice in the intravaginal infected group showed no signs of weight loss throughout 
the monitoring period following primary infection with the recombinant influenza virus, X31-
NA-Gag197 (Figure 4.1B). Weight loss for intranasally infected mice was expected as influenza 
viruses replicate in the respiratory tract due to the presence of tryptase Clara an enzyme 
necessary for cleavage of hemagglutinin (HA) (Garulli, Kawaoka and Castrucci, 2004).  
 
In contrast, the absence of protease enzyme activity in the vaginal mucosa results in abortive 
replication (Garulli, Kawaoka and Castrucci, 2004; Böttcher-Friebertshäuser et al., 2010; 
Zhirnov, Ovcharenko and Bukrinskaya, 1984). This expected lack of replication in the genital 
tract mucosa translated to a lack of weight loss. However, there was an immune response 
induced in the inguinal lymph nodes following intravaginal influenza infection due to this 
abortive infection. This is because influenza antigens were presented by the regional antigen 
presenting cells to the immune system in these nodes. Further studies such as a quantitative 
PCR or immuno-histochemistry could be used to determine antigen levels at these sites. 
Importantly, these observations serve as evidence that there was no cross contamination 
between the vagina and respiratory tract during experimental infection as there was no 
influenza specific CD8+ T cell response detected in the pulmonary mucosal compartments, 
such as BAL or Mediastinal lymph nodes following intravaginal vaccination.  
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Figure 4.1. Weight loss measured in BALB/c mice following primary infection with 
recombinant X31-NA-Gag197 influenza virus. BALB/c mice (each group n = 5) were infected 
intranasally (A) or intravaginally (B) with 1 × 104 pfu of X31-NA-Gag197 influenza virus and 
were monitored for changes in body weight over a ten day period following infection. Also, 
change in the actual weight of individual BALB/c mice infected intranasally (C) or 
intravaginally (D). All data represents the mean ± SD of three experiments, using the Student 
t-test **p<0.01 and ***p<0.001 compares drop in weight of the infected mice with the second 
day following infection. 
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Next, the HIV-Gag197 and influenza NP147 specific CD8+ T cell responses were analyzed to 
determine the efficacy of the newly generated recombinant viruses. As mentioned above two 
groups of six to eight week old BALB/c mice were infected intranasally or intravaginally with 
1 × 104 pfu/30 μl recombinant influenza viruses X31-NA-Gag197. After 10 days of infection, 
the spleens of infected mice were harvested to determine responses at the known peak of 
adaptive immunity (Figure 4.2). A single dose of X31-NA-Gag197 given intranasally to BALB/c 
mice induced a detectable IFN-γ+CD8+ T cell response against HIV-Gag197  peptide using ICS 
of the harvested spleen. We also saw a co-dominat influenza NP147-specific response (2.56 × 
105 ± 2.29 ×104) IFN-γ+CD8+ T cells for influenza NP147 compared to (2.32 × 105  ± 8.77 × 103) 
IFN-γ +CD8+ T cells for Gag197 (Figure 4.3). 
  
This is unusual for exogenous CD8+ T cell responses induced using a live vaccine vector, where 
responses are often directed towards the vector. An example of this is the Step/Phambili HIV 
trial vaccine that used a recombinant adenovirus (rAd5) to express multiple HIV-1 proteins, 
Gag/Pol/Nef or Env. These epitopes induced both CD8+ and CD4+ T cell responses in 
vaccinated groups of homosexual men who were at risk of HIV infection but the majority of 
the immune responses weredirected against the Ad5 vector (Koup and Douek, 2011; Koup et 
al., 2010). In addition our results are similar to those observed by Cukalac and colleagues who 
found co-dominance of Kd NP147 and exogenous HIV-Dd Env311 in the spleen and BAL of 
BALB/c mice following a single intranasal dose of the X31-NA-Env311 influenza virus 
(Cukalac et al., 2009). We were unable to detect IFN-γ+CD8+ T cell responses against HIV-H-
2d Tat17 following primary intranasal infection of mice using the X31-NA-Tat17 virus (data not 
shown) and so all subsequent experiments have focused on the HIV Gag197 CD8+ T cell epitope. 
We believe this may have been a processing issue but given time constraints we were unable 
to analyse this further.  
 
 
We further analysed the quality of the CD8+ T cell responses by analysing the proportion of 
TNF-α+IFN-γ+CD8+ and IL-2+IFN-γ+CD8+ T cells for the endogenous H-2Kd NP147 and the 
exogenous H-2Kd Gag197 epitopes as described previously (La Gruta, Turner and Doherty, 
2004). No significant difference in TNF-α+IFN-γ+CD8+ T cells specific for H-2Kd NP147+ (74.8 
± 3.0331%) and H-2Kd Gag197+ (72 ± 3.4641%), (p<0.210) responses were observed. This was 
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also the case for IL-2+TNF-α+IFN-γ+CD8+T cells were the H-2Kd NP147 epitope (33.2 ± 
3.4205%) and H-2Kd Gag197 epitope (30.8 ± 3.9623%) were equivalent (Figure 4.4). 
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Figure 4.2. Cytokine staining profiles for CD8+ T cells during a primary response following 
intranasal influenza virus infection in BALB/c mice. After panning of B cells, FACS dot plots 
depicting intracellular cytokine staining for CD8+ T cell responses were gated to firstly identify 
T lymphocytes (A), CD8+ T cells (B) and then IFN-γ+CD8+ T cells specific for HIV-H-2Kd 
Gag197 (C), influenza H-2Kd NP147 (D) and No peptide negative control (E). Lymphocytes were 
obtained from the spleens of BALB/c mice (n = 5 mice) at 10 days following primary intranasal 
influenza infection.  
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Figure 4.3. Intracellular Cytokine staining assay used for comparison of functional IFN-γ+ 
CD8+ T cells responses targeting the influenza Kd NP147 and HIV-Kd Gag197 epitopes. Naïve 
BALB/c mice (number of mice used for each group (n = 5)) were intranasally infected with the 
HK-X31-NA-Gag197 influenza virus and lymphocytes obtained from spleens and stimulated 
with the H-2Kd Gag197 or NP147 peptide. The data shown was statistically analyzed to compare 
the responses between the Gag197 and NP147+IFN-γ+CD8+T cell response using the Student t-
test. All data represents the mean ± SD representative of three experiments, p > 0.05 is non-
significant (ns).  
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Figure 4.4. Quality of antigen-specific CD8+ T cell subsets detected by cytokine staining assay 
(ICS). Naïve BALB/c mice (number of mice used for each group (n = 5)) were intranasally 
infected with the HK-X31-NA-Gag197 influenza virus and lymphocytes obtained from spleens 
and stimulated with the H-2Kd Gag197 or NP147 peptide. The proportion of TNF-α+IFN-γ+CD8+ 
(A) and IL-2+TNF-α+IFN-γ+CD8+ T cells (B) are depicted. All data represents the mean ± SD 
of three experiments, using the Student t-test *p<0.05 and **p<0.01. 
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4.1.2. Comparison of CD8+ T cell responses following various prime-boost 
vaccination regimes detected by ICS. 
In order to compare different mucosal routes for prime-boost infection in BALB/c mice, 
lymphocytes harvested from spleen, bronchoalveolar lavage, respiratory draining lymph nodes 
(mediastinal) and genital draining lymph nodes (inguinal) lymph nodes of various mucosal 
routes of immunized BALB/c mice were assayed for production of cytokines, such as IFN-γ, 
TNF-α and IL-2 specific for HIV-Gag197-205 and influenza-NP147-155 peptides.  
 
Four groups of BALB/c mice were administered different prime-boost vaccination 
combinations. Mice were primed intranasally using 1 × 104 pfu/mouse of X31-NA-Gag197. This 
was followed six weeks later with an intranasal boost using 50 pfu of PR8-NA-Gag197. PR8-
NA-Gag197 and X31-NA-Gag197 are serologically distinct and so neutralizing antibodies are 
avoided allowing boosting of CD8+ T cell responses. The second vaccination group followed 
the same regimen but viruses were administered via an intravaginal-intravaginal route. The 
intent here was to prime immunity in the regional draining node at a site of known viral entry. 
The third vaccination group used a intranasal-intravaginal route and the fourth vaccination 
group a intravaginal-intranasal route. Seven days after boosting, lymphocytes were harvested 
from the spleen, broncho-alveolar lavage, respiratory draining lymph nodes (mediastinal, 
MedLN) and genital draining lymph nodes (inguinal, ILN). These were analyzed for CD8+ T 
cell ex vivo responses, particularly for the production of cytokines, such as IFN-γ, TNF-α and 
IL-2 in response to the HIV-Gag197 and influenza-NP147 peptides. These polyfunctional cells 
are present in non-progressive HIV-infected individuals compared to those people 
characterized with progressive HIV infection (Betts, et al., 2006; de Keersmaecker et al., 2012).  
 
Our results demonstrated the ability of various mucosal routes of vaccination to induce CD8+ 
IFN-γ+ T cells in different lymphoid tissues that are directed against the exogenous HIV-H-2Kd 
Gag197 and endogenous influenza H-2Kd NP147 peptides in BALB/c mice (Figure 4.5). In 
addition, it was clearly demonstrated that an intranasal-intranasal prime boost vaccination 
strategy with recombinant influenza viruses expressing HIVGag197 induced a significantly 
higher proportion of IFN-γ+CD8+ T cells in the spleen, BAL and MedLN (p< 0.001) compared 
to other vaccination strategies like intravaginal-intravaginal, intranasal-intravaginal or 
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intravaginal-intranasal). In contrast, in ILN the highest proportion of IFN-γ+CD8+ T cell 
responses were detected in the intravaginal-intravaginal prime boost vaccinated group of mice 
(Figure 4.5). 
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Figure 4.5. Representative dot plots depicting cytokine production for CD8+ T cells specific 
for HIV-H-2KdGag197 following prime-boost vaccination by various mucosal routes in 
BALB/c mice. ICS was used to detect cytokine production in the spleen (A), MedLN (B), BAL 
(C) and ILN (D). 
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Overall our data shows a significant increase in HIV-Gag197+IFN-γ+CD8+ T cells following 
intranasal-intranasal prime boost vaccination in the spleen, BAL and MedLN (Figure 4.6). In 
total, (9.51 × 105 ± 1.12 × 105) cells were detected following i.n/i.n prime boost infection in the 
spleen, compared to (1.49 × 105  ± 1.31× 104) for i.v/i.v, (4.58 × 105  ± 4.41 × 104) for i.v/i.n 
and (1.16 × 105 ± 3.87 × 104) cells for i.n/i.v (Figure 4.6A). Similar trends were observed in 
the BAL (Figure 4.6B) and MedLN (Figure 4.6C). This can be explained by the fact that 
influenza viruses replicate in the lung and respiratory system due to the presence of a protease 
required for the cleavage of haemagglutinin. The higher levels viral antigen are likely to drive 
increased CD8+ T cell responses (Garulli, Kawaoka and Castrucci, 2004; Lu et al., 2012, Lu et 
al., 2013). However, results were different in the ILN as the intravaginal-intravaginal prime 
boost strategy induced the largest increase in HIVGag197 specific IFN-γ+CD8+ T cells given it 
is the draining lymph node of the genital tract  (Figure 4.6 D). Moreover, the intravaginal-
intravaginal route induced responses in the spleen and ILN while there were no obvious antigen 
specific CD8+ T cells detected in either the BAL or MedLN of the respiratory compartments.  
 
The secondary NP147+IFN-γ+CD8+ T cell immune response following intranasal-intranasal 
prime boost vaccination elicited a higher response in the spleen, BAL and MedLN compared 
to the other routes of mucosal vaccination. In the spleen (9.31 × 105 ± 1.86 × 105) IFN-γ+CD8+ 
T cells were detected following i.n/i.n prime boost infection, compared to the (1.44 × 105 ± 
2.21 × 104 ) cells for i.v/i.v, (4.17 × 105 ± 6.64 × 104) cells for i.v/i.n and (1.27 × 105 ± 4.99 × 
104) cells for i.n/i.v (Figure 4.7A). Similar trends were observed for the BAL and MedLN. 
Intravaginal-intravaginal prime boost vaccination again led to the greatest increase in NP147+ 
CD8+ T cells in the ILN, the draining lymph node of the urogenital tract (Figure 7D). Moreover 
H-2Kd Gag197 and NP147 CD8+ T cell responses were co-dominant following i.n/i.n, i.v/i.v, 
iv/i.n and i.n/i.v prime boost vaccination in spleen, BAL and MedLN (Figure 4.6 and Figure 
4.7). 
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Figure 4.6. Number of HIV-H-2Kd Gag197 IFN-γ+CD8+ T cells in different organs following 
different routes of vaccination in BALB/c mice. Four groups of BALB/c mice were infected 
i.n/i.n, i.n/i.v, i.v/i.v and i.v/i.n with X31-NA-Gag197 and PR8-NA-Gag197 influenza viruses 
and ICS use to determine the number of HIV-Gag197+CD8+ T cells in the spleen (A), BAL (B) 
MedLN (C) and ILN (D). Lymphocyte populations were harvested and stimulated for five 
hours with 1μM HIV-H-2Kd Gag197 peptide before staining with anti-mouse CD8α and anti-
IFN-γ antibodies. Data were normalized using a no-peptidecontrol. Data  represent mean ± SD 
from three repeated experiments, and statistical differences were determined using a one way 
of variance (ANOVA) and Tukey's multiple comparison test, ***p<0.001. 
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Figure 4.7. Number of H-2KdNP147+IFN-γ+CD8+ T cells in different organs following different 
routes of vaccination in BALB/c mice. Four groups of BALB/c mice were infected i.n/i.n, 
i.n/i.v, i.v/i.v and i.v/i.n prime boost infection with X31-NA-Gag197 and PR8-NA-Gag197 
influenza viruses and ICS use to determine the number of NP147+CD8+ T cells responses in the 
spleen (A), BAL (B) MedLN (C) and ILN (D). Lymphocyte populations were harvested and 
treated for five hours with 1μM influenza H-2Kd NP147 peptide before staining with anti-mouse 
CD8α and anti-IFN-γ+ antibodies. Data represents the mean ± SD from three repeated 
experiments, and statistical differences determined using a one way of variance (ANOVA) and 
Tukey's multiple comparison test, **p<0.01 and ***p<0.001. 
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Further analyses focused on poly-functional subsets of the antigen specific CD8+ T cells 
(Figure 4.8). There was no significant difference in the proportion of TNF-α+IFN-γ+CD8+ T 
cells for NP147+ (64 ± 3.8%) and Gag197+ (62 ± 2.8%) (p<0.373) populations induced following 
intranasal-intranasal vaccination. The i.n-i.n prime boost vaccination induced the highest 
proporation of  TNF-α+IFN-γ+CD8+ T cell compared to other routes of vaccination (p<0.001) 
(Figure 4.9). Similar results and trends were observed for the IL-2+TNF-α+IFN-γ+CD8+ T cell 
subsets following intranasal-intranasal prime boost vaccination for NP147 (15.8 ± 1.9%) and 
Gag197 (13.2 ±  2.7%) antigen specific CD8+ T cells in the spleen (Figure 4.10). 
 
 
 
Figure 4.8. Cytokine profiles of poly-functional CD8+ T cells. Schematic figure shows three 
subsets of CD8+ T cells including IFN-γ+CD8+ T cells (A), IFN-γ+ and TNF-α+ CD8+ T cells 
(B), and CD8+ T cells producing IL-2, TNF-α and IFN-γ (C). 
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Figure 4.9. Proportion of TNF-α+IFN-γ+CD8+ T cells in the spleen detected by ICS following 
different routes of vaccination in BALB/c mice. This figure compares HIV-H-2Kd Gag197 (A) 
and influenza H-2Kd NP147 (B) CD8+ T cell responses. Data represents the mean ± SD from 
three individual experiments, and statistical significance was determined using the one way of 
variance (ANOVA) and Tukey's multiple comparison test, ***p<0.001. 
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Figure 4.10. Proportion of IL-2+TNF-α+IFN-γ+CD8+ T cells in the spleen detected by ICS 
following different routes of vaccination in BALB/c mice. This figure compares HIV-H-2Kd 
Gag197 (A) and influenza H-2Kd NP147 (B) CD8+ T cell responses.  Data represents the mean ± 
SD from three individual experiments, and the statistical significance was determined using 
the one way of variance (ANOVA) and Tukey's multiple comparison test, ***p<0.001. 
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4.1.3. Induction of HIV-specific CD8+ T cells detected by tetramer staining 
assay 
Previous mice studies have demonstrated that the number of antigen specific CD8+ T cells 
producing IFN-γ in an ICS assay are comparable to the number of antigen specific 
tetramer+CD8+ cells detected following primary and secondary influenza A virus infection 
(Flynn et al., 1998). To confirm this, the number of tetramer+CD8+ T cells induced against the 
HIV-H2-Kd Gag197 epitope (Figure 4.11) and H-2Kd NP147 epitope (Figure 4.12) were analysed. 
Harvested CD8+ T cells from the spleen, BAL, MedLN and ILN of prime-boost vaccinated 
BALB/c mice were stained with H-2Kd Gag197 and NP147 labelled tetramers. No significant 
difference was detected between the total number of IFN-γ+and tetramer+ CD8+ T cells in the 
spleen following i.n/i.n, i.v/i.v, iv/i.n and i.n/i.v prime boost vaccinationfor both antigen-
specific cell populations in all tissues tested. 
 
The highest numbers of tetramer+CD8+ T cells were induced following i.n/i.n prime boost 
vaccination for HIV Gag197 (Figure 4.11), and influenza NP147 (Figure 12) in the spleen, BAL 
and MedLN as per results obtained using intracellular cytokine staining. In the ILN the higheest 
tetramer response was detected following intravaginal-intravaginal prime boost vaccination 
(Figure 4.11D and Figure 4.12D).  HIV-H-2Kd Gag197+ and NP147+CD8+ T cell responses were 
detected in the urogenital draining lymph nodes following intranasal infection. Previous studies 
have shown that CD8+ T cell responses can be induced in the vaginal regional lymph nodes of 
mice infected intranasally with recombinant influenza A virus vectors expressing the HIV-
Env311 peptide (Garulli, Kawaoka and Castrucci 2004; Lu et al., 2012). Moreover, an increase 
of HIV-H-2Kd Nef (EWRFDSRLAFHHVAREL) and H-2Kd NP147 (TYQRTRALV) specific 
CD8+ T cell responses have been detected in the urogenital draining lymph nodes, in addition 
to the spleen and respiratory regional lymph nodes, of mice infected intranasally with live 
recombinant influenza A viruses expressing the Nef protein (Ferko et al., 2001).  
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Figure 4.11. Number of H-2Kd Gag197 tetramer+CD8+ T cells in different tissues following 
different routes of vaccination in BALB/C mice. Four groups of BALB/c mice (each group 
n=5) were infected with 1 × 104   pfu X31-NA-Gag197 influenza virus and then challenged after 
six weeks with 50 pfu PR8-NA-Gag197 influenza virus. Seven days following the final boost, 
the spleen (A), BAL (B), MedLN (C) and ILN (D) lymphocyte populations were sampled for 
analysis of tetramer+CD8+ T cells. Data shows a representative example of 3 expepriments and 
indicates the mean ± SD. Statistical significance was ascertained using the one way of variance 
(ANOVA), Tukey's multiple comparison test, ***p<0.001.  
 
 
Chapter 4:                  Induction of CD8+ T cell responses using recombinant influenza viruses 
113 
 
 
 
 
Figure 4.12. Number of H-2Kd NP147 tetramer+CD8+ T cells in different tissues following 
different routes of vaccination in BALB/c mice. Four groups of BALB/c mice (each group n=5) 
were infected with 1 × 104  pfu X31-NA-Gag197 influenza virus and then challenged after six 
weeks with 50 pfu PR8-NA-Gag197 influenza virus. Seven days following the final boost, the 
spleen (A), BAL (B), MedLN (C) and ILN (D) lymphocyte populations were sampled for 
analysis of tetramer+CD8+ T cells using i.n-i.n,i.v-i.v, i.v-i.n, i.n-i.v and other vaccination 
strategies. Data shows a representative example of 3 experiments and indicates the mean ± SD. 
Statistical significance was ascertained using the one way of variance (ANOVA), Tukey's 
multiple comparison test, ***p<0.001.  
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4.1.4. Detection of mucosal surface markers (LPAM-1; α4β7 and CD103; 
αEβ7) and other markers, CD44, CD62L, CCR9 and CD69 on 
antigen specific CD8+ T cells using flow cytometry 
In order to further characterize antigen-specific CD8+ T cells in vaccinated mice, cells were 
examined for the expression of homing CD8+ T cell integrins, LPAM-1(α4β7) and CD103 
(αEβ7) which are considered important for the trafficking of mucosal lymphocytes into 
lymphoid tissues. These mucosal markers were detected using species-specific anti-mouse 
mucosal integrin antibodies, and the gating used is shown in Figure 4.13. Cells were first gated 
on total lymphocytes, then on the CD8+ T cell subset before identification of the  the HIV-
Gag197+CD8+T cell population using tetramer staining. Cells were then analyzed for expression 
of the mucosal markers LPAM-1 and CD103 in addition to other markers, such as CD44, 
CD62L, CCR9 and CD69 in samples derived from the spleen, MedLN, ILN and BAL. The 
intranasal-intranasal prime boost vaccination strategy produced the highest proportion of 
α4β7+HIVGag+CD8+T cells following various routes of vaccination in the spleen, BAL and 
MedLN (Figure 4.14A, 4.14B and 4.14C). The intravaginal-intravaginal prime boost strategy 
induced the highest proportion of α4β7+HIVGag+CD8+ T cells in the ILN (Figure 4.14D). The 
levels of CD103+HIVGag+CD8+ T cells were similar to those observed for α4β7+ in the spleen, 
BAL and to a lesser extent the MedLN (Figure 4.16A, 4.16B and 4.16C). However, there was 
little correlation between the two integrins for the ILN (Figure 4.16D). Moreover similar 
patterns LPAM-1+ and CD103+ expression on CD8+ T cells were observed for influenza-
specific NP147 CD8+ T cells (Figure 4.15 and 4.17). 
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Figure 4.13. Gating strategy used to analyze mucosal α4β7+Gag+tetramer+CD8+ T cells. 
Isolated cells were first gated for total lymphocytes (A) followed by CD8+ T cells using an 
anti-mouse CD8α-PercP antibody (B). HIV-specific CD8+ T cells were gated on the basis of 
binding to a specific H-2Kd Gag197-APC tetramer (C). Cells were then interrogated for their 
expression of the mucosal marker α4β7+ using anti-mouse LPAM-1 (α4β7)-PE antibody (D). 
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Figure 4.14. Proportion of HIV-Gag197+α4β7+CD8+ T cells detected in tissues following 
different routes of mucosal vaccination in BALB/c mice. T lymphocytes were obtained from 
different lymphoid organs and then stained with H-2Kd Gag197-APC tetramer, anti-mouse 
CD8α PerCP and anti-α4β7 (LPAM-1)-PE antibodies. α4β7+Gag197+CD8+ T cell numbers were 
determined (as described in Figure 4.13) with data representative of three repeated 
experiments. Data is shown as mean ± SD and significance determined using a one way of 
variance (ANOVA) and Tukey's multiple comparison test, ***p<0.001. 
 
 
 
 
Chapter 4:                  Induction of CD8+ T cell responses using recombinant influenza viruses 
117 
 
 
 
 
 
 
Figure 4.15. Proportion of influenza NP147+α4β7+CD8+ T cells detected in tissues following 
different routes of mucosal vaccination in BALB/c mice. T lymphocytes were obtained from 
different lymphoid organs and then stained with H-2KdNP147-APC tetramer, anti-mouse CD8α 
PerCP and anti-α4β7 (LPAM-1)-PE antibodies. α4β7+NP147+CD8+ T cell numbers were 
determined (as described in Figure 4.13) with data representative of three repeated 
experiments. Data is shown as mean ± SD and significance determined using a one way of 
variance (ANOVA) and Tukey's multiple comparison test, *p<0.05 and ***p<0.001. 
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Figure 4.16. Proportion of CD103+HIV-H-2KdGag197+CD8+ T cells detected in tissues 
following different routes of mucosal vaccination in BALB/c mice. T lymphocytes were 
obtained from different lymphoid organs and then stained with H-2Kd Gag197-APC tetramer, 
anti-mouse CD8α PerCP and anti-CD103-FITC antibodies. CD103+CD8+ T cell numbers were 
determined (as described in Figure 4.13) with data representative of three repeated 
experiments. Data is shown as mean ± SD and significance determined using a one way of 
variance (ANOVA) and Tukey's multiple comparison test; ***p<0.001. 
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Figure 4.17.  Proportion of CD103+NP147+CD8+ T cells detected in tissues following different 
routes of mucosal vaccination in BALB/c mice. T lymphocytes were obtained from different 
lymphoid organs and then stained with H-2Kd NP147-APC tetramer, anti-mouse CD8α PerCP 
and anti-CD103 FITC antibodies. CD103+NP147+CD8+ T cell numbers were determined (as 
described in Figure 4.13) with data representative of three repeated experiments. Data is shown 
as mean ± SD and significance determined using a one way of variance (ANOVA) and Tukey's 
multiple comparison test, ***p<0.001. 
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Following the analysis of mucosal markers, we checked the level of expression of as the marker 
of antigen experience, CD44, and the marker for effector function/memory CD62L, in the 
spleen, BAL, MedLN and ILN harvested from all groups of vaccinated mice. In general, CD44 
and CD62L were differentially expressed on the CD8+ T cell population in naïve, acute effector 
or memory cells as has been previously described by Kedzierska and colleagues (2007) and 
also by Kaufman and colleagues, (2008). CD44-CD62L+CD8+ T cells were isolated from 
different lymphoid tissues, such as Peyer’s patches, inguinal, mesenteric, peripheral lymph 
nodes and the spleen in naïve mice, while effector CD44+CD62L-CD8+ T cells were obtained 
following vaccination of mice with recombinant adenovirus expressing the SIV-Gag+CD8+ T 
cell epitope (Kaufman et al., 2008). Furthermore, in response to a novel vaccine containing 
recombinant Bacillus subtilis or Listeria monocytogenes as a vector expressing HIV-Gag in 
mice, vaginal CD62L+CD44+ CD8+ memory CD8+ T cells were identified five weeks after 
vaccination (Li  et al., 2008).  
 
Following our vaccination regimen, we identified the highest proportion of HIV-
Gag197+CD44+CD8+ T cells and influenza NP147+CD44+CD8+ T cells following intranasal-
intranasal prime boost vaccination in the spleen, MedLN and BAL. In the ILN the highest 
proportion of antigen experienced cells was found after intravaginal-intravaginal vaccination 
(Figures 4.18 and 4.19). As expected  after acute infection only a small proportion of antigen 
specific CD8+ T cells cells were CD62L+(Figures 4.20 and 4.21).  
 
Two final cell surface markers where characterized following vaccination. These included the 
T cell activation marker CD69 and the T cell migration marker CCR9 (Norment et al., 2000; 
Kathuria et al., 2012). Previous studies have shown that expression of CCR9 and α4β7 on CD8+ 
T cells was a characteristic of homing/mucosal T cells (Mavigner et al., 2012). Intranasal-
intranasal vaccination induced the highest proportion of CD69+ antigen specific CD8+ T cells 
(Figures 4.22 and 4.23) whilst differences in CCR9 expression on antigen specific cells were 
only detected in the spleen Figures 4.24 and 4.25). 
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Figure 4.18. Percentage of CD44+Gag197+CD8+ T cells detected in different organs following 
mucosal vaccination in BALB/c mice. T cells obtained from different lymphoid organs were 
stained with the H-2Kd Gag197-APC tetramer, in addition to anti-mouse CD8α PerCP and 
CD44-PE antibodies. Data shows a representative example of three experiments. Results are 
expressed as mean ± SD and statistical significance assessed using the one way of variance 
(ANOVA) and Tukey's multiple comparison  test; *p<0.05 and ***p<0.001. 
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Figure 4.19. Percentage of CD44+NP147+CD8+ T cells detected in different organs following 
mucosal vaccination in BALB/c mice. T cells obtained from different lymphoid organs were 
stained with the H-2Kd NP147-APC tetramer, in addition to anti-mouse CD8α PerCP and CD44-
PE antibodies. Data shows a representative example of three experiments. Results are 
expressed as mean ± SD and statistical significance assessed using the one way of variance 
(ANOVA) andTukey's multiple comparison  test; *p<0.05 and ***p<0.001. 
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Figure 4.20. Percentage of CD62L+Gag197+CD8+ T cells detected following mucosal 
vaccination in BALB/c mice. T cells obtained from different lymphoid organs were stained 
with the H-2Kd Gag197-APC tetramer, in addition to anti-mouse CD8α PerCP and CD62L-FITC 
antibodies. Data shows a representative example of three experiments. Results are expressed 
as mean ± SD and statistical significance assessed using the one way of variance (ANOVA) 
and Tukey's multiple comparison test; **p<0.01 and ***p<0.001. 
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Figure 4.21. Percentage of CD62L+NP147+CD8+ T cells detected following mucosal 
vaccination in BALB/c mice. T cells obtained from different lymphoid organs were stained 
with H-2Kd NP147-APC tetramer, in addition to anti-mouse CD8α-PerCP and CD62L-FITC 
antibodies. Data shows a representative example of three experiments. Results are expressed 
as mean ± SD and statistical significance assessed using the one way of variance (ANOVA) 
and Tukey's multiple comparison test; ***p<0.001. 
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Figure 4.22. Percentage of CD69+Gag197+CD8+ T cells detected following mucosal vaccination 
in BALB/c mice. T cells obtained from different lymphoid organs were stained with the H-2Kd 
Gag197-APC tetramer, in addition to anti-mouse CD8α PerCP and CD69-PE antibodies. Data 
shows a representative example of three experiments. Results are expressed as mean ± SD and 
statistical significance assessed using the one way of variance (ANOVA) and Tukey's multiple 
comparison test; **p<0.01 and ***p<0.001. 
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Figure 4.23. Percentage of CD69+NP147+CD8+ T cells detected following mucosal vaccination 
in BALB/c mice. T cells obtained from different lymphoid organs were stained with the H-2Kd 
NP147-APC tetramer, in addition to anti-mouse CD8α-PerCP and CD69-PE antibodies. Data 
shows a representative example of three experiments. Results are expressed as mean ± SD and 
statistical significance assessed using the one way of variance (ANOVA) and Tukey's multiple 
comparison test; *p<0.05, **p<0.01 and ***p<0.001. 
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Figure 4.24. Percentage of CCR9+Gag197+CD8+ T cells detected following mucosal 
vaccination in BALB/c mice. T cells obtained from different lymphoid organs were stained 
with the H-2Kd Gag197-APC tetramer, in addition to anti-mouse CD8α PerCP and CCR9-FITC 
antibodies. Data shows a representative example of three experiments. Results are expressed 
as mean ± SD and statistical significance assessed using the one way of variance (ANOVA) 
and  Tukey's multiple comparison test; *p<0.05 and ***p<0.001. 
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Figure 4.25. Percentage of CCR9+NP147+CD8+ T cells detected following mucosal vaccination 
in BALB/c mice. T cells obtained from different lymphoid organs were stained with the H-2Kd 
NP147-APC tetramer, in addition to anti-mouse CD8α-PerCP and CCR9-FITC antibodies. Data 
shows a representative example of three experiments. Results are expressed as mean ± SD and 
statistical significance assessed using the one way of variance (ANOVA) Tukey's multiple 
comparison test; *p<0.05, **p<0.01 and ***p<0.001. 
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4.1.5. Detection of IL-15 and IL-15Rα expression on mucosal HIV-
Gag+CD8+ T cells by RT-PCR 
Interleukin 15 (IL-15) is a T cell-stimulating cytokine and has an important role in regulating 
survival, proliferation and development of CD8+ T cells (Zhang et al., 1998).  The IL-15Rα 
receptor binds to IL-15 cytokine on T cells with high affinity (Anderson et al., 1995; Lodolce 
et al., 1998). Both IL-15 and IL-15Rα have an important role in generating and maintaining 
antigen-specific CD8+ T cell responses and are necessary for primary expansion of CD8+ T 
cells following viral infections (Schluns et al., 2002). IL-15Rα is expressed on dendritic, 
natural killer and lymphocytic cells (Anderson et al., 1995). IL-15 also regulates the 
maintenance of lymphoid homeostasis by supporting lymphocyte homing and proliferation 
(Lodolce et al., 1998). IL-15 has been shown to regulate the migration of effector CD8+ T cells 
to pulmonary airways and as such has been used as an adjuvant to induce influenza-specific 
CD8+ T cells to facilitate clearance of virus (Verbist et al., 2011). Its role in migration of 
antigen-specific CD8+ T cells has been demonstrated using trans-well chemotaxis chambers 
through experiments that show 10 fold increases in movement of influenz-specifc NP+CD8+ T 
cell when compared to media alone controls (Verbist et al., 2011). 
 
We set out to determine if IL-15 and/or the IL-15R could be detected in vaccinated mice. We 
chose to focus our attention on HIV Gag197+CD8 T cells that that had shown higher expression 
levels of the α4β7+ mucosal marker. We prepared two HIV Gag197+CD8 T cell populations in 
the spleen, BAL and MedLN (α4β7+ and α4β7-). These populations were sorted following 
intranasal-intranasal prime-boost infection of BALB/c mice with the X31-NA-Gag197 and PR8-
NA-Gag197 recombinant influenza viruses using the gating strategy shown in Figure 4.26. High 
purity populations (98.5%) of Gag197+α4β7+ and Gag197+α4β7-CD8+ T cells were obtained. 
RNA was then extracted from HIV-Gag197+α4β7+and HIV-Gag197+α4β7-CD8+ T cells to 
determine the mRNA levels of IL-15-Rα and IL-15 by RT-PCR. The HIV-Gag197+α4β7+CD8+T 
cell population expressed higher levels of IL-15-Rα when compared to α4β7-CD8+ T cells in 
spleen cells (23 fold), MedLN (18 fold) and BAL (11 fold) (Figure 4.27). There was also 
increased expression of the IL-15 cytokine on the mucosal α4β7+CD8+ T cell population in the 
spleen (10.5 fold), MedLN (9.6 fold) and in BAL (4.8 fold) compared to Gag197+α4β7-CD8+T 
cells (Figure 4.28).  
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Figure 4.26. Gating strategy used to sort and analyze HIV-Gag+α4β7+ and HIV-Gag+α4β7-
CD8+ T cell populations. Total T lymphocytes were gated (A), followed by CD8+ T cells (B), 
H-2Kd Gag197-APC tetramer+CD8+ T cells (C), and finally α4β7+CD8+ T cells (D) to identify 
the Gag+α4β7+ and Gag+α4β7-CD8+ T cell populations. 
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Figure 4.27. IL-15Rα gene expression in α4β7+Gag197+CD8+ T cells following intranasal-
intranasal prime boost vaccination in the spleen, MedLN and BAL by quantitative real time 
PCR (RT-PCR). Data is presented as the fold change expression compared to α4β7-
Gag197+CD8+ T cells, and normalized to 1 using the Δ cycle threshold method. All values are 
representative of three repeated experiments with a mean ± SD, with different significance by 
one way of variance (ANOVA) and Tukey's multiple comparison test; *p<0.05, **p<0.01 and 
***p<0.001. 
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Figure 4.28. IL-15 cytokine expression in α4β7+Gag197+CD8+ T cells following intranasal-
intranasal prime boost vaccination in the spleen, MedLN and BAL by quantitative real time 
PCR (RT-PCR). Data is presented as the fold change expression compared to the α4β7-
Gag197+CD8+ T cells, and normalized to 1 using the Δ cycle threshold method. All values are 
represented as a mean ± SD of three repeated experiments, with different significance by one 
way of variance (ANOVA) and Tukey's multiple comparison test; *p<0.05, **p<0.01 and 
***p<0.001. 
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4.2. Discussion 
Similar to other infectious diseases, the need for an effective vaccine to control HIV infection 
is of prime importance in the efforts of global HIV programs. A number of CD8+ T cell 
properties are thought to be important in a vaccine-induced response. Mucosal immune 
responses stimulated by HIV/AIDS vaccines are considered highly desirable for blocking the 
main portal of HIV-1 entry which is through mucosal surfaces (Shattock et al., 2008), 
particularly gastrointestinal, vaginal, or oral surfaces (Haynes and Shattock, 2008; 
Challacombe and Sweet, 2002; Clerici et al., 2001; Demberg and Robert-Guroff, 2009; Jespers 
et al.,  2010). 
 
As the main portal of entry for most infectious agents is through the mucosal surfaces, the best 
way to control their transmission is by strengthening the mucosal immune responses to ensure 
that infections do not pass local draining lymph nodes and disseminate throughout the body. 
Previous studies that looked at mucosal immune responses in HIV infected or high risk 
individuals have noted high interferon-gamma (IFNγ) and interleukin-2 (IL-2) expression in 
CD8+ T cells and IgA production in the cervix and blood of resistant HIV female sex workers 
in Nairobi. There was also a direct correlation between the level of induced mucosal HIV-CD8+ 
T cells and control of the HIV infection (Orga, Faden and Welliver 2001; Stevceva et al., 2002). 
This chapter describes the use of different routes of vaccination to determine which strategy 
generates not only the highest immune response but also has the ability to stimulate a high 
proporation of antigen specific cells that express mucosal markers.   
 
Many routes of vaccination are thought to induce mucosal immune responses. Vaccines 
administered intrarectally, intranasally or orally in BALB/c mice using the synthetic HIV 
peptide PCLUS3–18IIIB and combined with a cholera toxin were effective in stimulating long 
lived HIV-specific CD8+ T cells in regional and distant lymph nodes in addition to the spleen 
when compared to subcutaneous vaccinated mice (Belyakov et al., 1998). The intranasal and 
intravaginal route of vaccination is also thought to facilitate the induction of strong mucosal 
CD8+ T cell immuity as a strong link has been established between tthe mucosa of the upper 
respiratory tract and the urogenital tract following administration of antigen on these surfaces 
(Holmgren and Czerkinsky 2005). Influenza viruses have been used as mucosal vectors to 
induce mucosal CD8+ T cell immunity following both intransal and intravaginal vaccination. 
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Intravaginal infection of BALB/c mice with recombinant influenza viruses expressing the H-2 
Dd HIV-Env+CD8+ T cell epitope (P18IIIB) stimulated CD8+ T cell responses in both the 
inguinal lymph node and the spleen (Garulli, Kawaoka and Castrucci, 2004). Recombinant 
influenza viruses expressing the HIV-1 Env311 epitope have been shown to stimulate IFN-γ+ 
and tetramer specific CD8+ T cell responses  a in the spleen following a prime boost vaccination 
(Cukalac et al., 2009).  
 
Previous studies using HIV vaccines in animal models have involved the use of numerous 
vaccine vectors to deliver specific HIV/SIV epitopes or proteins, i.e., adenovirus, vaccinia virus 
and fowl pox virus. All of these viral vectors were capable of inducing strong immune 
responses (Gonzalo et al., 1999; Sexton et al., 2009; Ranasinghe et al., 2011). Use of these 
recombinant HIV vaccines has induced mucosal CD8+ T cell immune responses that have led 
to decreased RNA copies of SIV virus and controlled the viremia in non-human primate models 
(Casimiro et al., 2005; Hoffmann et al.,  2002; Liu et al., 2009; Pachler, Mayr and Vlasak, 
2010; Rimmelzwaan et al., 2007; Sexton et al., 2009; Wit et al., 2004). Moreover recombinant 
influenzaA viruses (H3N2, A/HKx31 and PR8 H1N1, A/Puerto Rico/8/1934) have been used 
as candidate SIV vaccine vectors to express SIV-CD8+ T cell epitopes, SIV-Gag164-172, SIV- 
Tat87-96, and SIV-Tat114-123.  Importantly intranasal or intramuscular vaccination of macaques 
with the HIV-1SF162 envelope protein facilitated the development of mucosal immune 
response in the vaginal mucosa of macaques, and protected them against virulent SHIV 
(SHIVSF162P4) challenge (Barnett et al., 2008). This result indicates the intranasal route of 
vaccination can induce e mucosal immune responses at distant urogenital lymph nodes to 
enable vaccinated macaques to resist SIV challenge.  
 
Our main aim was to stimulate mucosal Gag197+CD8+ T cells  however we did also assess the 
magnitude and quality of the endogenous influenza NP147+specific CD8+ T cell response. 
Similar levels of endogenous influenza NP147+specific CD8+ T cells were induced in our 
experiment following primary intranasal vaccination to those results achieved from the study 
performed by Cukalac and colleagues (Cukalac et al., 2009). The two main integrin molecules 
α4 and β7, presented in as α4β7, α4β1 and αEβ7, are components regulating the migration of 
lymphocytes into mucosal areas (Kang et al., 2011). Expression of β7 integrin has previously 
been associated with the use of recombinant influenza viruses. SIV-specific CD8+ T cell 
responses following vaccination and challenge with SIVmac251 (Sexton, et al., 2009). Use of 
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other live vaccine vectors has also been associated with an increases in α4β7 mucosal marker 
expression on CD8+ T cells following oral vaccination in macaques. Recombinant Salmonella 
expressing the SIV-Gag protein and vaccinia virus expressing the SIV-Gag protein were both 
used in these experiments to stimulate SIV-Gag181-189 specific CD8+ T cells (Evans et al., 2003). 
The importance of the α4β7 mucosal homing integrin in virus control has also been observed 
in other model systems. Rotavirus specific α4β7+CD44+CD8+ T cells has been very effective 
in the clearance of rotavirus infection. Adoptive transfer of 2 × 104 α4β7+CD44+ CD8+ T cells 
showed that mice were protected from rotavirus (Rosé et al.,  1998). Moreover, the transfer of 
increased numbers of α4β7+CD44+ CD8+ T cells improved protective efficacy. Finally blocking 
of both CD62L and α4β7 has been shown to impair the migration of CD8+ T cells to mesenteric 
lymph nodes (Ciabattini et al., 2011). 
 
We noted high levels of mRNA expression of interleukin IL-15Rα and IL-15 in HIV-H-2Kd 
Gag197+α4β7+CD8+ T cells compared to the HIV-H-2Kd Gag197+α4β7-CD8+ T cells following 
intranasal-intransal vaccination in multiple tissues (spleen, BAL and mediastinal lymph nodes) 
as seen in Figures 4.19 and 4.20. Removal of dendritic cells that produce IL-15 or blocking of 
IL-15R has been previously shown to inhibit the migration of influenza specific CD8+ T cells 
to the site of infection (Verbist et al., 2011; Brincks and Woodland, 2010; McGill, Van Rooijen 
and Legge, 2010; McInnes et. al., 1996).  This may be a direct result of th use of live influenza 
virus as similar results (high IL-15 Rα mRNA expression) were detected in the BAL, 
mediastinal lymph nodes (MedLNs) and spleens harvested of intranasally infected (X31 
(A/Hong Kong x31)) C57BL/6 mice. These mRNA levels were detected for the first time on 
day 3 and continued increasing until day 7 with a 4 fold change compared to naïve mice 
(Verbist et al., 2011). Therefore, increased expression of IL-15 Rα in mucosal CD8+ T cells 
might provide evidence for the important role of this cytokine in regulating survival of HIV-
H-2KdGag197+CD8+ T cells at mucosal sites. This is further supported by the fact that 
expression of IL-15 Rα correlated with a high level of IFN-γ+ expression in CD8+ T cells 
obtained from HIV positive chimpanzees (Rodriguez et al., 2007). An increase of IL-15 Rα 
was also expressed in response to intranasal influenza infection in mice which was highly 
effective in facilitating the trafficking of CD8+ and natural killer cells into mucosal sites of 
infection and assist in the control of virus replication (Verbist et al., 2012). 
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4.3. Conclusion 
According to the results of our mice studies, we conclude that intranasal prime boost 
vaccination in BALB/c mice has an important role in stimulating antigen specific CD8+ T cells 
that express known mucosal markers such as α4β7 and CD103. In addition, these mucosal HIV-
Gag197+α4β7+CD8+ T cells stimulated following intranasal prime boost vaccination expressed 
high levels of IL-15R and also produced small but detectable amounts of expressed IL-15 
compared to HIVGag197+α4β7- CD8+ T cells. 
 
The next chapter will test the ability of these cells to protect against a pseudo challenge 
infection, recombinant vaccinia virus expressing the whole HIV-Gag protein. 
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5. Chapter 5 Pseudo-Challenge study 
5.1. Overview 
Human immunodeficiency virus (HIV) naturally uses mucosal surfaces, such as those of the 
intestinal and urogenital regions as the preferential sites for rapid replication. Therefore, these 
mucosal compartments are considered the most important in which to stimulate immune 
protection in order to control HIV infection and transmission. Previous studies have used 
various HIV-1 proteins to induce mucosal immunity. For example, HIV-1 Gag protein 
delivered orally using a recombinant Listeria monocytogenes vector given as prime-boost 
vaccine induced HIV-Gag-specific cytotoxic CD8+ T cell immunity in a mouse model. HIV 
Gag-specific CD8+ T cells producing both interferon gamma (IFN-γ+) and tumour necrosis 
factor (TNF-α+) were induced in the spleen and mucosal-associated lymphoid tissue (MALT) 
of vaccinated BALB/c mice. These CD8+ T cell responses completely protected mice against 
a intravaginal or intranasal pseudo-challenge using recombinant vaccinia virus expressing the 
whole Gag protein (rVac-HIVGag) (Zhao et al., 2006). An additional pseudo-challenge study 
in mice also indicated a protective role of HIV-1 Env-PCLUS3–18 IIIB 
(RIQRGPGRAFVTIGK) specific CD8+ T cells in BALB/c mice. These mice were initially 
primed intrarectally, intranasally, intragastrically or subcutaneous with HIV-1 Env-PCLUS3–
18 IIIB. CD8 T cells were then intravenously transferred into naïve mice 5-6 days prior to 
intrarectal pseudo-challenge with 2.5 × 107 pfu rVac virus expressing HIV-1 Env gp160 protein 
(Belyakov et. al., 1998). Recombinant Listeria monocytogenes expressing HIV-1 Gag protein 
has also been used in pseudo challenge experiments following vaccination. HIV Gag specific 
CD8+ T cells protected BALB/c mice against an intraperitoneal pseudo-challenge using 2.5 × 
107 pfu recombinant vaccinia virus expressing whole HIV-1 Gag protein (vVK1) (Rayevskaya 
and Frankel, 2001). 
 
Our results from Chapter 4 indicate the presence of a large number of HIV-Gag197+α4β7+CD8+ 
T cells following i.n-i.n prime boost vaccination. These cells expressed higher levels of IFN-
γ+ and IL-15R when compared to HIV Gag197+α4β7-CD8+ T cells. This chapter will assess the 
protective efficacy of this population using adoptive transfer experiments using a pseudo-
challenge mouse model. 
 
 
Chapter 5:                                                                                              Pseudo-Challenge study  
138 
 
5.2. Results 
5.2.1. Adoptive transfer of mucosal CD8+ T cells into naive mice 
To assess the effectiveness of our recombinant influenza HIV vaccine, a pseudo-challenge 
experiment was performed in BALB/c mice using the recombinant vaccinia virus expressing 
the whole Gag protein (Rosé et al., 1998; Kaufman et al., 2008). This involved the adoptive 
transfer of mucosal HIV-1 Gag197+ CD8+ T cells induced in response to the vaccination of 
BALB/c mice as described in Chapter 4. Seven days after the booster vaccination, spleens and 
mediastinal lymph nodes were harvested from mice and used for the isolation of mucosal 
HIVGag197+α4β7+CD8+ T cells. These HIV-Gag197+α4β7+CD8+T cells along with 
HIVGag+α4β7-CD8+T cell controls were sorted (as previously described in Chapter 4, Section 
4.1.5 and Methods, Section 2.2.15.6) and enumerated. A total of 5 × 104 cells/ 200μl PBS of 
HIV-Gag+α4β7+CD8+T cells, HIV-Gag+α4β7-CD8+ T cells or PBS (Mock control) were 
adoptively transferred via the intravenous route into separate groups of naïve BALBC mice 
and six days later used in  challenge studies as per previous studies (Rose et al., 1998) 
(Kaufman et al., 2008) .  
5.2.2. Pseudo-challenge of BALB/c mice with recombinant vaccinia virus 
expressing HIV Gag (rVac633-gag)  
Three groups of BALB/c mice containing adoptively transferred cells (HIV-Gag+α4β7+CD8+ 
T cells, HIVGag+α4β7-CD8+ T cells and Mock) were challenged intranasally with 1 × 107 
plaque forming units (pfu) of recombinant vaccinia virus-633 expressing the whole Gag protein 
(rVac-gag) to test the protective efficacy of these cells. Five days of challenge, the mice were 
euthanized and the lungs and ovaries harvested and homogenized to ascertain the titer of the 
challenge virus (rVac-Gag) as determined by plaque assay (Belyakov et. al., 1998). Analysis 
of our three vaccinated groups revealed lower number of plaques in the lungs of mice following 
adoptive transfer (Figure 5.1) of Gag+α4β7+CD8+ T cells (7.82×105 pfu/lung) in comparison to 
those in which Gag+α4β7-CD8+ T cells were transferred (1.36×106 pfu/lung) or those Mock 
treated BALB/c mice (1.80 ×106 pfu/lung) infected with the rVac-Gag challenge virus (Figure 
5.3). Moreover, none of the harvested ovaries showed any plaques (Figure 5.2). The data was 
analysed using a one way of variance test (ANOVA), which determined a significant difference 
among the three groups of infected mice. Our results demonstrate an important role for mucosal 
Gag+α4β7+CD8+ T cells in the control and dissemination of the rVac-Gag virus in this BALB/c 
mouse model when compared to both Gag+α4β7-CD8+ T cells and the Mock challenged group 
(Figure 5.3).  
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Figure 5.1. Plaque assay on infected lungs when challenged with the rVac-gag challenge virus. 
Lungs were harvested from three groups of r-Vac-Gag-challenged BALB/c mice, homogenised 
and then diluted to 10-2, 10-3 and 10-4, as indicated. These dilutions were used to infect 143B 
cells and after two days of infection, the supernatant was removed and plaques visualised by 
staining with 0.1% crystal violet. Data shown are representative assay for Gag+α4β7+CD8+ 
transferred T cells (A), Gag+α4β7-CD8+ transferred T cells (B) and Mock (C). 
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Figure 5.2. Plaque assay on ovaries of challenged BALB/c mice. Ovaries were harvested from 
the three groups of rVac-Gag-challenged BALB/c mice, homogenized and then diluted to ten 
fold dilutions, 10-2, 10-3 and 10-4 and used to infect 143B cells as described in Figure 1. Groups 
containing Gag+α4β7+CD8+ transferred T cells (A), Gag+α4β7-CD8+ transferred T cells (B) or 
Mock (C) as displayed. 
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Figure 5.3. Graph of a virus titer in the lungs of r-Vac-Gag-challenged BALB/c mice. All data 
shows the mean ± SD from two repeated experiments with significance determined by a one 
way of variance test (ANOVA) and Tukey's multiple comparison test, *p<0.05 and 
***p<0.001, which compares Gag197+α4β7+CD8+ T cell intravenous recipient mice to both 
Gag197+α4β7-CD8+ T cell transferred mice and Mock controls. It also compares reduction of 
the challenge virus titer between the group of mice that received the Gag197+α4β7-CD8+ T cells 
and mock controls. 
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5.2.3. CD8+ T cell immune responses following the r-Vac-gag challenge 
mice trial 
Our three groups of BALB/c mice were also assayed for CD8+ T cell responses 5 days 
following the intranasal r-Vac-gag challenge. Both spleens and mediastinal lymph nodes were 
harvested for detection of HIVGag197+CD8+ T cell responses using ICS and tetramer staining 
assays. 
5.2.3.1. CD8+ T cell immune response detected by tetramer staining 
Spleen and MedLN samples were assayed by tetramer staining to determine the percentage of 
HIV-H-2Kd Gag197+CD8+ T cells. In summary, there was a significant increase in the 
percentage of tetramer HIV-H-2Kd Gag197+CD8+ T cells in both the spleen and MedLN of the 
group of mice that received adoptively transferred Gag197+α4β7+CD8+ T cells when compared 
to both Gag197+α4β7-CD8+ T cells and Mock as detected by flow cytometry in Figure 5.4.  
 
Analysis of the numbers followed a similar pattern. The total number of tetramer+HIV-Kd 
Gag197+CD8+ splenic T cells was (2.87 × 105 ± 5.03 × 104) in the group of mice that received 
adoptively transferred Gag197+α4β7+CD8+ T cells (p<0.01) compared to (1.38 × 105 ± 2.65 × 
104)  total cells for the group of mice that received adoptively transferred Gag197+α4β7-CD8+ T 
cells and (2.53 × 104 ± 7.30 × 103) HIV-H-2 KdGag197+CD8+ T cells (p< 0.001) in Mock 
controls (Figure 5.5 A). A similar pattern was observed in the MedLN (Figure 5.5 B) 
Significant differences were also found in the Gag+α4β7-CD8+ T cell transfer group when 
compared to Mock controls in both the spleen (p< 0.05) and MedLN (p< 0.01) (Figure 5.5). 
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Figure 5.4. Tetramer staining of spleen cells from following r-Vac-gag-challenge. Flow 
cytometry of single cell spleen supsensions was used to detect the percentage of HIV-Kd 
Gag197+CD8+ T cells in three groups of mice: mice that received adoptively transferred 
Gag197+α4β7+CD8+ T cells (A), mice that received adoptively transferred Gag197+α4β7-CD8+ T 
cells (B) and PBS control only (Mock) (C). A lymphocyte CD8+ T cell and tetramer+ gated 
were used for analysis. 
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Figure 5.5. The number of tetramer+HIV-H-2Kd Gag197+CD8+ T cells following a pseudo-
challenge. Flow cytometry of single cell spleen suspension was used to detect the percentage 
of HIV-H-2Kd Gag197+CD8+ T cells in three groups of mice: mice that received adoptively 
transferred Gag197+α4β7+CD8+ T cells, mice that received adoptively transferred Gag197+α4β7-
CD8+ T cells and PBS only (Mock) in spleen (A) and MedLN (B). Data are represent the mean 
± SD of two repeated experiments. Statistical differences were analysed using one way of 
variance (ANOVA),*p<0.05, **p<0.01 and***p<0.001 comparing Gag197+α4β7+CD8+ T cells 
to Gag197+α4β7-CD8+ T cells. In addition, there was a comparison between results of 
Gag197+α4β7-CD8+ T cells transfer group and Mock controls. 
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5.2.3.2.  Functional analysis of CD8+ T cell immune response detected by ICS 
following the pseudo-challenge 
The spleen and MedLN samples were also assayed for functional cytokine responses using the 
intracellular cytokine assay to measure the number of IFN-γ+HIVGag197+CD8+ T cells. T cells 
harvested from the spleen and individual MedLN were stimulated for five hours with the 
stimulation mixture containing HIV-Kd Gag197 peptide, IL-2 and Golgi-plug (Brefeldin). The 
number and function of specific CD8+ T lymphocytes was then detected by flow cytometry. 
This revealed a statistically higher number of specific IFN-γ+HIVKd Gag197+CD8+ T cells in 
the group of mice that received adoptively transferred Gag197+α4β7+CD8+ T cells, (3.05 × 105 
± 2.64 × 104) cells (p< 0.001) compared to the group of mice that received adoptively 
transferred Gag197+α4β7-CD8+ T cells (1.07 × 105  ± 2.07 × 104) cells, and this was also 
statistically higher in the group of mice that received adoptively transferred Gag197+α4β7+CD8+ 
T cells (p< 0.001) compared to Mock controls (2.42 × 104 ± 8.53 × 103) cells.  
 
It is important to note that the group of mice that received adoptively transferred Gag197+α4β7-
CD8+ T cells had significantly higher numbers of HIVKdGag197+CD8+ T cells than Mock 
controls (p< 0.001). Similar results to tetramer staining of the spleen were observed (Figure 
5.6 A). The MedLN data was consistent with the observations noted via tetramer staining 
(Figure 5.6 B) when compared to mice that received adoptively transferred Gag197+α4β7-CD8+ 
T cells. Statistical significance was also established when compared to mock controls (Figure 
5.6). 
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Figure 5.6. Number of IFN-γ+HIV-Kd Gag197+CD8+ T cells following pseudo-challenge. 
Functional CD8+ T cell populations were analyzed for their ability to express IFN-γ+ in the 
spleen (A) and MedLN (B). Data is representative of the mean ± SD from two repeated 
experiments. Statistical significance was determined using a one way of variance (ANOVA), 
*p<0.05, **p<0.01 and ***p<0.001 when comparing the Gag197+α4β7+CD8+ T cell transfer 
mouse group to both Gag197+α4β7-CD8+ T cells and Mock controls. There was also a 
comparison of results between the Gag197+α4β7-CD8+ T cell transfer mouse group and Mock 
controls. 
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5.2.3.3.  Analysis of α4β7+ and CD103+ surface markers on CD8+ T cells 
following a pseudo-challenge 
Mucosal integrins, such as α4β7+ and CD103+ were assessed on HIV-Kd Gag197+tetramer+ 
CD8+ T cells following pseudochallenge. We detected an increase in the percentage of mucosal 
markers on HIV-Kd Gag197+α4β7+ CD8+ T cells following challenge in both spleen and 
mediastinal lymph nodes in the group of mice that received adoptively transferred 
Gag197+α4β7+CD8+ T cells (12.95 ± 0.78%), compared to the group of mice that received 
adoptively transferred Gag197+α4β7-CD8+ T cells (9.18 ± 0.13%) and Mock controls (5.1 ± 
2.12%) (Figure 5.7). Similar trends were observed in the MedLN (Figure 5.7 B). 
 
CD103 has been used in previous studies as a mucosal marker expressed on specific Gag+CD8+ 
T cells detected in the vaginal and gut mucosa of mice or macaques (Kiravu et al., 2011; Cerf-
Bensussan et al., 1987;Schon et al., 1999; Stevceva et al., 2002). A similar percentage of 
HIVGag197+CD103+CD8+ T cells was detected in the group of mice that received adoptively 
transferred Gag197+α4β7+CD8+ T cells compared to the group of mice that received adoptively 
transferred Gag197+α4β7-CD8+ T cells and Mock controls suggesting there may be co-
expression of these molecules on mucosal cells (Figure 5.8). 
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Figure 5.7. Percentage of HIV-H-2Kd Gag197+4β7+CD8+ T cells following a pseudo-challenge.  
The percentage of HIV-Kd Gag197+α4β7+CD8+ T cells in the spleen (A) and MedLN (B) were 
compared in three groups of mice that received adoptively transferred cells. Data is 
representative of the mean ± SD from two repeated experiments. Statistical significant 
difference was analyzed using a one way of variance test (ANOVA), **p<0.01 and 
***p<0.001. This was then used to compare Gag197+α4β7+CD8+ T cells to Gag197+α4β7-CD8+ 
T cells and Mock controls. There was also a comparison between the Gag197+α4β7-CD8+ T 
cells transfer group and Mock controls. 
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Figure 5.8. Percentage of CD103+HIV-H2Kd Gag197+CD8+ T cells following challenge. The 
percentage of HIV-KdGag197+CD103+CD8+ T cells in spleen (A) and MedLN (B) were 
compared in three groups of mice that received adoptively transferred cells.The data represents 
the mean ± SD from two repeated experiments. Statistically significant differences were 
analyzed using a one way of variance test (ANOVA), **p<0.01 and***p<0.001 to compare 
the Gag197+α4β7+CD8+ T cell transfer mouse group to the Gag197+α4β7-CD8+ T cell transfer 
group and Mock transfer group. A statistical analysis was also performed between the 
Gag197+α4β7-CD8+ T cell transfer group and Mock controls. 
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5.3. Discussion 
The ultimate aim of a HIV-1 vaccine is to successfully control HIV-1 infection by decreasing 
HIV-1 virus progression and dissemination via the mucosal points of entry. Therefore, the aim 
of this chapter was to investigate the protective capabilities of a subset of HIV-specific mucosal 
CD8+ T cells (α4β7+Gag197+CD8+ T cells) induced by an intranasal prime boost strategy using 
a recombinant influenza-HIV vaccine (see results from Chapter 4) to control naïve mice 
challenged with the recombinant vaccinia virus expressing the whole Gag protein. This 
involved the adoptive transfer of α4β7+or α4β7-Gag197+CD8+ T cells that were also shown to 
express high levels of IL-15Rα and IL-15 cytokine as described in chapter 4. 
 
The use of adoptive transfer has been utilized in experimental human trials. HIV-specific CD8+ 
T cells sorted from a non-infected identical twin brother of a HIV infected patient following 
vaccination with recombinant vaccinia virus expressing Env glycoprotein, and then transferred 
into the HIV-infected individual, led to a decrease in the titer of the HIV-1 virus (Bex et al., 
1994). This showed that adoptive transfer of HIV-specific CD8+ T cells could control virus in 
a limited capacity as the cells were able to reduce virus dissemination through mucosal 
compartments (Jespers et al., 2010; Shattock et al., 2008).  
 
Indeed, mucosal CD8+ T cells expressing HIV-interferon-gamma (IFNγ), tumor necrotic factor 
(TNF-α) and interleukin-2 (IL-2) have been detected at high levels in the cervix and blood of 
female sex workers in Nairobi, thus indicating that mucosal CD8+ T cells represent a key 
important line of defence against HIV-1 transmission and progression (Kaul et al., 2000; 
Trivedi et al., 2001; Steers et al., 2009). Moreover, strong induction of a mucosal immune 
responses represented by CD8+ T cells that secrete soluble proteins called alpha or beta 
defensins in the oral cavity may contribute to HIV immunity(Weinberg et al., 2006; Tomescu, 
Abdulhaqq and Montaner, 2011; Furci et al., 2007; Zhang et al., 2002). These protective 
immune responses were also detected in rhesus macaques that were administered enteric coated 
capsules containing an adenovirus vector expressing Gag protein via the oral route. The rhesus 
macaques were then given an intranasal dose of adenovirus expressing Env polypeptide that 
was shown to induce robust mucosal CD8+ and CD4+ T cells in the oral cavity, vaginal mucosa 
and intestine in addition to a Gag and Env-specific antibody response (Mercier et al., 2007). 
The main aim of this chapter was to test the protective efficacy of mucosal Gag197+α4β7+CD8+ 
T cells against a rVac-Gag pseudo-challenge. 
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Our results clearly demonstrate that significant partial protection can be achieved with a sorted 
Gag197+α4β7+CD8+ T cell population. Clearly the responses aren’t fully protective, and 
therefore a combination of other mucosal subsets (CD103+ or CCR9+) Kd Gag197+CD8+ T cells 
or those specific for other HIV antigens may be required to improve efficacy. Previous studies 
in BALB/c mice have examined the protective role of mucosal CD8+ T cells induced against 
the Env 18 IIIB (RIQRGPGRAFVTIGK) peptide. CD8+ T cell repsonses were detected in the 
spleen, peyer’s patches and lamina propria following intrarectal immunisation in mice. Mice 
were then challenged intrarectally with 2.5 × 107 plaque-forming units of recombinant vaccinia 
virus expressing the HIV Env protein (gp160IIIB) (Belyakov et al., 1998 ) and 6 days later a 
4.5 log reduction in challenge virus titer was detected in the ovaries of vaccinated mice 
compared to mock controls. Furthermore studies in both rhesus macaques and C57BL/6 mice 
following recombinant adenovirus (rAd5) SIVmac239 Gag protein vaccination and adoptive 
transfer showed upregulation of mucosal homing integrins, (CD103 and CCR9). The transfered 
mucosal CD8+ T cells facilitated protection in mice and macaques following recombinant 
vaccinia-Gag challenge (Kaufman et al., 2008).  
 
Other studies have used an alternative delivery system, such as Listeria monocytogenes as a 
live recombinant vector vaccine to induce Gag-specific cytotoxic CD8+ T cell immune 
responses in mice following vaccination. These Gag specific cytotoxic CD8+ T cells produced 
interferon gamma (IFN-γ+) and tumour necrosis factor (TNF-α) in various mucosal lymphoid 
tissues, such as the spleen and MALT and protected mice against a recombinant vaccinia virus 
(rVac-Gag) vaginal challenge (Zhao et al., 2006). BALB/c mice primed intramuscularly using 
either a rabies virus expressing HIV Gag protein (RABV) and boosted with either RABV-Gag, 
a vesicular stomatitis virus (VSV-Gag), or a Newcastle disease virus expressing Gag protein 
(NDV-Gag), induced a robust functional HIV Gag+CD8+ T cell responses (Lawrence et al., 
2013). 
 
 Our pseudo-challenge experiments demonstrated a 1/2 log reduction in the titer of challenge 
virus by Gag197+α4β7+ CD8+ T cells. Complete protection was not achieved by Gag197+α4β7+ 
CD8+ T cells. This is in contrast to Belyakov and colleagues, (1998) where a 4.5 log reduction 
in the titer of pseudo-challenge virus (rVac-Env) was observed in the ovaries follwoing 4 doses 
of HIV Env peptide IIIB in combination with cholera toxin (Belyakov et al., 1998). 
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Our experimental results are in line with a recent study in BALB/c mice where less than one 
log reduction was observed following an adenovirus 5 Gag protein (Ad5-Gag) vaccination 
regimen (Kanagavelu et al., 2014). In summary, the reduction in challenge virus titer in our 
experiments is promising and provides opportunities to test the protective efficacy of the other 
mucosal markers that could be used in combination with Gag197+α4β7+ CD8+ T cells. These 
markers include CD103+, CCR9+ or a combination of both (CD103+CCR9+).  
 
Pseudo-challenge studies assessing efficacy of  HIV vaccines in mice have focused on 
intraperitoneal, rectal, vaginal or intranasal administration of recombinant vaccinia virus 
expressing recombinant antigens (Belyakov et al.,  1998; Kaufman et al.,  2008; Zhao et al.,  
2006; Nakaya et al., 2004). These vaccines were able to induce protection against challenge 
virus in ovaries, spleen and regional lymph nodes as rVV is capable of disseminating 
systemically. (Belyakov et al., 1998; Zhao et al., 2006).  
 
Previous studies have shown a critical role for mucosal CD8+ T lymphocytes induced following 
intranasal influenza infection. Mucosal surface markers such as α4β7, have been identified in 
the lymph nodes of infected mice (Schnorrer et al., 2006; Sallusto, 1999; Dieli et al., 2003). 
Furthermore, transfer of mucosal influenza-specific CD8+ T cells expressing homing integrin 
receptors has been shown to be critical for protection against intranasal A/PR/8/34 influenza 
infection in BALB/c mice. This involved intravenous adoptive transfer of 107 CD8+  T cells 
and challenge using 10 times the lethal dose of PR8 (A/PR/8/34: H1N1). Results showed a 
significant reduction of influenza virus titer 4 days following infection compared to control 
mice (Cerwenka et al., 1999). As such we can conclude that the ability of mucosal CD8+ T 
cells to control virus infection can be associated with the expression of α4β7 integrin in our 
study and may also involve CCR9 and CD103 and (Tan et al., 2011; Rudraraju et al., 2012; 
Chattha et al., 2013). The cytotoxic potential of the Gag197+α4β7+ CD8+ T cells generated 
following vaccination was not determined in these studies. A comparison with Gag197+α4β7- 
CD8+ T cells may offer further insights. 
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6. Chapter 6: General Discussion 
6.1. Overall discussion 
HIV/AIDS remains a serious threat to humanity with more than 1.8 million HIV-1 infected 
individuals dying world-wide every year because of the global spread of the HIV epidemic. 
According to World Health Organization reports, the mortality rate associated with HIV/AIDS 
infection will remain at current levels until 2030 (McElrath and Haynes, 2010; Boily et al., 
2009; Brown et al., 2008; Bongaarts et al., 2008). Therefore, international efforts to uncover 
effective solutions to control infection remain vital (Duerr, Wasserheit and Corey, 2006; 
Mathers and Loncar, 2006). For this purpose, development of an effective HIV vaccine is still 
regarded as the most appropriate way to control this epidemic (Johnston and Fauci, 2008). 
 
Since 1983, more than 60 vaccine candidates have been generated to control HIV infection 
(Barouch, 2008; Girard, 2006). A variety of approaches have been trialled, which include DNA 
vaccines, recombinant vector vaccines and subunit vaccines, most of which have been 
administered to non-human primates. A very limited number of candidate vaccines have been 
tested in humans, with most of these unable to elicit significant efficacy. The exception, 
however, was a vaccine tested in Thailand in 2009 (RV144: Phase III). For the first time, this 
vaccine elicited a moderate level of protection against HIV-1 (31%). Antibody responses were 
induced for HIV Env and Gag, as detected by antibody dependent cellular cytotoxicity assay 
(ADCC) and also a cell mediated response represented by CD8+ T cell proliferation directed 
against Gag and Env proteins (Rerks-Ngarm et al., 2009). CD8+ T lymphocytes play a major 
role in controlling HIV infection and may contribute to mucosal immune responses (Gómez, 
Smaill, and Rosenthal, 1994; Levy, 2003; Liu et al., 1998). CD8+ T lymphocytes are normally 
stimulated during primary viral infections in humans to support the host immune response 
(Callan et al., 1998; Reddehase, 1984; Reusser et al., 1999; Rickinson and Moss, 2003). 
Mucosal CD8+ T lymphocytes are thought to be important for providing long-term protection 
against HIV-1 virus which is transmitted by mucosally, through blood transfusion and by 
mother-to-child transmission (Belyakovet al., 1998; Gallichan and Rosenthal, 1996; Suvas et 
al., 2007). HIV-resistant female sex workers in Kenya possessed persistent mucosal HIV-1-
specific CD8+ T cells in the cervix (Kaul et al., 2000). In addition, but not specifically covered 
in this thesis, the humoral immune response also plays an important role through the 
stimulation of HIV-specific mucosal antibodies, such as IgA, which acts to directly block virus 
entry through mucosal surfaces in the urogenital mucosa. This has been shown following 
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vaginal challenge with SHIV virus in macaques treated with passive IgA or in humanized mice 
given anti-HIV-polymeric IgA inhibited HIV mucosal transmission. However, the role IgA 
plays in controlling mucosal transmission of HIV-1 is not completely characterized in human 
at this point in time (Mascola et al., 1996; Mascola et al., 2000; Hur et al., 2012; Wolbank et 
al., 2003). Poly-functional CD8+ T cells are stimulated by specific HIV peptides, such as those 
derived from the Gag protein (Duvall et al., 2008; Holmgren and Czerkinsky, 2005; Gillespie, 
2005). During acute and chronic HIV-1 infection, these polyfunctional CD8+ T cells have been 
shown to be involved in the reduction and control of the viral load. Firstly, they control virus 
replication by producing high levels of multiple cytokines, such as IFNγ, TNF-α and IL-2 
(Kobayashi et al., 2004; Viganò et al., 2008). Secondly, CD8+ T lymphocytes can destroy HIV-
1 infected cells through cytolytic action involving granzymes and perforin (Froelich, Dixit and 
Yang, 1998), with HIV-resistant individuals shown to express high levels of both granzymes 
and perforin. Moreover, there is a negative correlation between HIV-1 RNA copy number and 
the level of granzymes and perforin expressed by CD8+ T cells (Kaul et al., 2000; Hersperger, 
2010). 
 
The studies described in this dissertation explored a reverse genetics strategy for generating a 
vaccine that stimulates mucosal HIV-specific immunity. This strategy involved the use of 
recombinant DNA technology and reverse genetics to generate influenza viruses that expressed 
HIV-1 specific CD8+ T cell epitopes in order to induce mucosal CD8+ T cell immunity. Two 
H-2d HIV-1 epitopes, Gag197 (AMQMLKETI) and Tat17 (QPKTACTNC), were inserted into 
the NA gene segment of influenza virus strains PR8 (HIN1) and X31 (H3N2) using reverse 
genetics and mice were immunized via the mucosal route using a prime-boost strategy. 
Previous HIV vaccine studies in animal models have used a range of vectors (including 
adenovirus, vaccinia virus and fowl pox virus) to deliver HIV epitopes or proteins. All of these 
vectors were able to induce HIV-specific immune responses but many did not focus on 
stimulation of mucosal immunity. The influenza virus was chosen as a live vaccine vector 
candidate as it efficiently expresses viral epitopes in the respiratory and urogenital 
compartments (Marsh and Tannock, 2005; Satterlee, 2008; Smith, 2007) and has the ability to 
generate broad and durable long-term immunity at different mucosal surfaces (Fodor et al., 
1999; Mueller et al., 2010; Neumann and Kawaoka, 2001; Yao and Wang, 2008). Moreover, 
there is a documented strong connection between the mucosa of the upper respiratory tract and 
of the urogenital tract (Holmgren and Czerkinsky, 2005). This was detected using nasal Cholera 
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toxin B subunit immunization in humans to induce both IgA and IgG antibody responses in 
cervicovaginal mucosa in addition to the upper respiratory mucosa and regional secretions 
(saliva, nasal secretions) (Holmgren and Czerkinsky, 2005; Kozlowski et al., 1997; Johansson 
et al., 2004). Another advantage of this approach include the fact that the gene segments of the 
influenza virus could be easily manipulated using reverse genetics technology which allowed 
the generation of recombinant viruses as vaccine vectors (Palese et al., 1996; Steinhauer and 
Skehel, 2002; Steinhauer et al., 2009).  
 
Recombinant influenza viruses manipulated in this way have been used as vaccine vectors 
expressing HIV-CD8+ T cell epitopes to successfully stimulate cytotoxic CD8+ T cell responses 
(Casimiro et al., 2005; Hoffmann et al., 2002; Pachler, Mayr and Vlasak, 2010; Sexton et al., 
2009). Intranasal vaccination of macaques with recombinant HIV vaccines has led to 
stimulation of a strong mucosal immune response in vaginal mucosa when challenged 
intravaginally with a virulent SHIV virus (Barnett et al., 2008). Other mucosal HIV-1 
vaccination trials were highly effective in inducing both systematic and mucosal immune 
responses against HIV-1. Examples of this include intranasal immunisation with a recombinant 
influenza vector expressing HIV-1 Env (gp41) that stimulated strong humoral immune 
responses, as shown by HIV-1 specific antibodies in the lung, spleen and urogenital mucosa of 
mice (Ferko et al., 1998). Importantly, the two strains of laboratory influenza viruses associated 
with our study had previously been used to express the HIV-H-2Dd Env311 CD8+ T cell epitope 
in mice (Cukalac et al.,  2009).  
 
The H-2Kd HIV-Gag197 epitope was used as an antigen for this project for several reasons. 
Firstly, this Gag epitope is highly conserved, and so should offer protection against diverse 
viral strains (Mata et al., 1998; Lorgeoux, Guo and Liang, 2012). Indeed, the nine amino acids 
of Gag from 197 to 205 were the most dominant epitope targeted by a breadth of HIV-CD8+ T 
cell responses when compared to other Gag peptides (Cellini et al., 2008). Moreover, 
polyfunctional HIV-specific CD8+ T cells obtained from HIV-elite controllers have been 
shown to be Gag-specific (Ndhlovu et al., 2012; Berger et al., 2011). Secondly, HIV Gag 
protein can stimulate specific HIV-CD8+ T cell immune responses with the mostly dominant 
HIV-1 restricted Gag H-2Kd CD8+ T cell in mouse models (Faul et al., 2009; Lawrence et al., 
2013; McGettigan et al., 2001; McGettigan et al., 2003; McGettigan et al., 2003a). This 
includes conserved regions of the HIV-Gag197 (AMQMLKETI) epitope detected in the wild 
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type virus genome which induced a robust HIV-1 CD8+ T cell immune response in vaccinated 
mice (Lawrence et al., 2013; Wallace et al., 2013). Also, strong HIV-1 Gag H-2Kd 
(AMQMLKETI) restricted CD8+ T cell responses have previously been identified following 
vaccination of BALB/c mice using a DNA vaccine expressing the HIV-1 Gag protein (Wallace 
et al., 2013). Also, robust HIV-Gag+CD8+ T cell responses were detected in intramuscularly 
vaccinated BALB/c mice using recombinant virus vectors, such as the rabies virus (RABV), 
vesicular stomatitisvirus (VSV) and Newcastle disease virus expressing the Gag protein 
(Lawrence et al., 2013). In addition, Gag-specific CD8+ T lymphocytes have been shown to be 
highly migratory following intramuscular infection with a recombinant adenovirus vector 
expressing the whole Gag protein in mice and macaques (Kaufman et al., 2008). These HIV-
Gag-specific CD8+ T cells dominant in the Gag Db-restricted epitope (AAVKNWMTQTL) 
were found mainly in the spleen and different mucosal sites, Peyer’s patches, the inguinal and 
mesenteric lymph nodes, and vaginal tract mucosa (Kaufman et al.,  2008). It is also important 
to note that the dominant CD8+ T cell specificities induced in macaques following intratracheal 
and intranasal recombinant influenza viruses, X31 (H3N2, A/HKx31) and PR8 (H1N1, 
A/Puerto Rico/8/1934) expressing SIV-CD8+ T cell epitopes and NA stalks were derived from 
the SIV-Tat87–96, SIV-Tat114–123 and SIV- Gag164–172 epitopes that were separately inserted into 
the NA stalk of influenza virus vectors (Sexton et al., 2009). 
 
Our study clearly demonstrate the ability of the influenza virus to replicate in the upper 
respiratory tract of mice when infected intransally. Replication in the genital mucosa is 
normally non-productive due to the lack of trypsin-like enzymes required for the cleavage of 
HA in order to facilitate entry of the viral genome into the cell cytoplasm (Klenk, Rott, Orlich, 
and Blödorn, 1975; Garulli, Kawaoka and Castrucci, 2004; Garulli et al., 2007). As was 
detected in this project, using the recombinant X31-NA-Gag197 influenza virus, intranasally 
infected BALB/c mice experience significant weight loss compared to intravaginally infected 
mice in which no weight loss was detected. This can be explained by the ability of influenza 
viruses to replicate in the respiratory tract mucosa as a result of appropriate protease activity in 
the pulmonary mucosal area, thus increasing the pathogenicity of influenza virus infection 
because this enzyme is lacking in the vaginal mucosa (Garulli, Kawaoka and Castrucci, 2004). 
However, this does not mean that no immune response was induced in the urogenital mucosa 
following influenza infection. Moreover, methods have been developed to improve the 
replication rates of viruses in the urogenital area. For example, subcutaneous administration of 
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progesterone has been shown to improve sensitivity of mice to intravaginal infection with 
viruses such as herpes simplex virus type 2 (Parr,  Bozzola  and Parr, 1998; Parr et al., 1994) 
or influenza virus (Garulli, Kawaoka and Castrucci, 2004). 
Experiments by Garulli and colleagues, (2004) demonstrated that the most highly induced 
CD8+ T cells were specific for HIV-Env epitope (RGPGRAFVTI) of the gp160 envelope 
protein and the immuno-dominant restricted H-2Dd NP147-155 epitope (TYQRTRALV) from the 
HIV-1 IIIB isolate. Most of these CD8+ T cells were detected in the spleen, iliac lymph nodes 
and in the genital mucosa of progesterone treated BALB/c mice that were then infected with a 
high dose of recombinant influenza viruses either A/WSN/33, A/PR/8/34 (PR8) or X-31 
viruses expressing the HIVEnv311 epitope (Flu/P18IIIB; Env gp160). In addition, HIV-specific 
antibody responses were detected in both sera and vaginal secretions of these infected mice.  
However, the group of mice that received a lower dose of the recombinant influenza virus 
vector showed low or undetectable virus titres following intravaginal infection (Garulli, 
Kawaoka and Castrucci, 2004). According to this study, influenza A viruses could induce acute 
infection in the vaginal mucosa of the progesterone-treated BALB/c mice. This means vaginal 
replication could be enhanced by treatments that mimic protease function thus increasing 
pathogenicity of the influenza virus. This was also observed in the female genital organs of 
mice during the estrous cycle on progesterone and resulted in high susceptibility of adult 
BALB/c mice to vaginal infection with herpes simplex virus 2 compared to non-estrous mice 
(Parr, Bozzola and Parr, 1998; Parr et al., 1994). 
Mucosal immune responses are characterized by markers such as α4β7, CD103 and CCR9. An 
important role for LPAM-1 (α4β7) as a mucosal homing CD8+ T cell integrin in protective 
immune responses has been suggested in various virus infections in mice studies. (Holzmann, 
McIntyre and Weissman, 1989; Rudraraju et al., 2012; Tan et al., 2011). When comparing 
different mucosal routes of prime-boost infection in BALB/c mice, the results in this project 
indicate that intranasal vaccination with recombinant influenza virus vaccine vectors induces 
the best polyfunctional HIVGag197+CD8+ T cell response  
The main aim of mucosal vaccines used in this project was to induce HIV specific mucosal 
CD8+ T cells that enable control of a pseudovirus challenge. Therefore, we conducted 
experiments to find out whether the induced mucosal HIV-Gag197+4β7+CD8+ T cells were 
functionally protective. HIV-Gag197+4β7+CD8+ T cells were sorted for adoptive transfer into 
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naïve mice prior to pseudochallenge with the recombinant vaccinia virus expressing HIV-Gag 
(rVac). Importantly this transferred population was partially protective.  
6.2. Research outcomes 
This project has successfully investigated a novel approach to stimulate, detect and characterize 
mucosal CD8+ T cells responses using recombinant influenza viruses as a vaccine vector. The 
key research outcomes of this work were: 
1. The generation of recombinant influenza viruses expressing the H-2Kd restricted HIV-
Gag197 or H-2d HIV-Tat17 CD8+ T cell epitopes using reverse genetics technology.  
2. Demonstration that recombinant influenza viruses expressing the HIV-H-2KdGag197 
epitope stimulated strong CD8+ T cell immunity at multiple anatomical sites as seen 
through the use of tetramer staining and ICS.  
3. Intranasal-intranasal prime-boost vaccination induced the highest proportion and 
numbers of HIV and influenza-specific mucosal CD8+ T cells in the spleen, draining 
lymph nodes and distal mucosal sites.  
4. Adoptive-transfer of Gag197+α4β7+CD8+ T cells into naïve mice enabled partial control 
of whole Gag protein expressing vaccinia virus challenge.  
 
6.3. Future directions 
Due to time limitations, a generic adoptive transfer regime was adopted for protection 
experiments. As such, the most critical experiments to perform are ones that involve fine-tuning 
the adoptive transfer conditions given, since only partial protection was achieved. Experiments 
would therefore involve repeating the intranasal prime-boost vaccination strategy, and 
transferring a higher number of mucosal α4β7+Gag+CD8+ T cells to naïve mice to determine if 
recombinant vaccinia virus challenge could be fully controlled. In addition, these studies could 
be expended by transferring HIVGag197 specific CD8+ T cells that express more than one 
mucosal integrin, such as Gag197+CD103+CD8+ T cells, to improve protection from a pseudo-
challenge virus. This work could also be extended to vaccination that could induce both a 
mucosal and systematic CD8+ T cell immune responses necessary to control challenge virus.  
 
If successful, the transfer experiments could be repeated in macaques. These experiments 
would involve the use of SIV-Gag197+CD8+ T cell epitopes to initially prove the ability of the 
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intranasal prime boost immunisation to induce mucosal CD8+ T cells prior to commencement 
of the adoptive transfer experiments. These experiments are costly and must be carefully 
considered given the ethic issues around the use of non-human primates. Availability and/or 
cross reactivity of mucosal markers in this non-human primate model must also be verified 
prior to commencement. In conclusion, studies that enhance our understanding of mucosal HIV 
immunity are of utmost importance given the portal of entry for most HIV infections in humans 
is the mucosa. Development of vaccines that can stop dissemination of the virus, halt its 
progress at the local draining lymph nodes and therefore avoid latency may prove the most 
effective in bringing this worldwide epidemic under control. 
Finally it would be important to test if influenza-specific α4β7+CD8+ T cells could behave 
similarly in protection experiments against intranasal influenza virus challenge when 
adoptively transferred to mice to establish this mucosal subset as a universal protective marker.
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A.Appendix A 
A.1. Solutions, buffers and reagents 
A.1.1. Agarose solution (0.8%) for gel electrophoresis 
0.8 g agarose (Sigma-Aldrich) 
Add 1x TAE buffer (100 ml) 
Dissolve by microwave 
Add 3 μl SYBR safe DNA gel stain (Invitrogen) 
A.1.2. Agarose solution (1.8%) for plaque assay 
0.9 g Agarose (Analytical grade, Promega) 
Dissolve in Baxter water (50 ml) 
Autoclave for 20 min at 121 oC 
Keep in a 56 oC water bath for 2 hours 
Transfer to a 45 oC water bath to be ready for the assay 
A.1.3. FACS buffer (1%BSA; 0.02% sodium azide) 
500 ml phosphate-buffered solution (PBS)  
50 ml 10% (v/v) bovine serum albumin (BSA)  
500 μl 20% (v/v) sodium azide 
A.1.4. TAE Buffer (40x) (Sambrook et al., 1989) 
1.6 M Tris (Tris: hydroxymethyl methane (Merk) 
40 mM EDTA (Ethylene Diamine Tetra Acetic acid) (Merk) 
Dissolve in 800 ml of deionized water 
pH (8.2-8.4) in a 25oC with 1 M Acetic acid (Merk) 
Bring volume to 1000 ml 
Store at 22-25 oC and use in 1-2 weeks 
A.1.5. Red cell lysis buffer (Ammonium-Tris Chloride buffer) 
0.14 M NH4CL (7.47 g) (BDH, Australia) 
0.017 M Tris hydroxymethyl methane (2.06 g) (BDH, Australia) 
980 ml Baxter water 
Adjust pH to 7.2 with 1 M HCL 
Bring volume to 1 L with Baxter water 
Store at 22-25 oC and use in 1-2 weeks 
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A.1.6. RNeasy Mini Kit for RNA extraction (Qiagen) 
Including the following steps:  
500 μl 70% Ethanol  
500 μl RLT buffer 
500 μl RW1 buffer 
500 μl RPE buffer 
Elution buffer (Nuclease free water) dH2O 
A.1.7. Plasmids 
pHW2000 
pBR322 plasmid cloning vector (New England Biolabs (NEB) 
pUC19 DNA (0.01 μg/ml)  
A.1.8. Competent cells 
A.1.8.1. MAX Efficiency® DH5α™ Competent Cells (Invitrogen)  
DH5α™ Competent Cells  
A.1.8.2. High efficiency JM109 Competent cells (Promega)  
E.coli JM109 competent cells >108 cfu/μg  
A.1.9. Reverse transcription kit for conversion RNA to cDNA 
2μl of 10× Reverse transcriptase buffer (RT buffer) 
2μl dNTP mix buffer 
2μl 10 μM oligo-dT primer 
1 μl Omniscript reverse transcriptase 
A.1.10. Permeabilizing solution 
One part Perm/washTM buffer (Becton Dickinson, UAS) 
Nine part deionized distilled water 
A.1.11. Restriction endonuclease enzymes 
Specific restriction endonuclease enzyme, PstI (Cat# R6325) 
Specific restriction endonuclease enzyme, PvuI (Cat# R611A) 
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A.1.12. QIAquick PCR Purification Kit protocol 
For one volume of the PCR sample: 
Add 5 volumes Buffer PB 
Apply the sample to the QIAquick column 
Centrifugation for 30–60 seconds and Discard flow through 
Add 0.75 ml Buffer PE and centrifuge for 30–60 seconds 
Discard flow-through and Place QIAquick column in 1.5 ml microcentrifuge tube 
Add 30 μl elution buffer and then centrifuge 
A.1.13. QIAquick Gel Extraction Kit protocol 
Add 3 volumes Buffer QG to 1 volume of gel 
Incubate at 50°C for 10 min 
Mix by vortexing the tube every 2–3 min to dissolve the gel 
Add 1 volume of isopropanol 
Apply the sample to the QIAquick column 
Discard flow-through. 
Add 0.5 ml Buffer QG and centrifuge for 1 min 
Add 0.75 ml Buffer PE and centrifuge for 1 min 
Discard the flow-through and Place QIAquick column into microcentrifuge tube 
Add 20 μl Buffer EB (10 mM Tris·Cl, pH 8.5) and centrifuge for 1 min 
A.1.14. PureYield™ Plasmid Miniprep protocol (Promega, USA) 
Add 600 μl transformed bacterial culture to 1.5 ml centrifuge tube 
Add 100 μl cell lysis buffer and mix well 
Add 350 μl cold neutralization solution and mix well 
Centrifugation at 13000 rpm for 3 minutes 
Transfer the supernatant to the PureYield™ Minicolumn into collection tube 
Centrifuge at 13000 rpm for 15 seconds and discard the flow through 
Wash by add 200 μl of Endotoxin removal wash (ERB)  
Centrifugation at 13000 rpm at 15 seconds 
Add 400 μl of column wash solution (CWS) and centrifuge for 30 seconds 
Transfer the Minicolumn to 1.5 ml centrifuge tube 
Elute the plasmid DNA by adding 30 μl of elution buffer and centrifuge for 15 seconds 
A.1.15. Cell lines  
 Madin-Darby Canine Kidney cells (MDCK cells) 
 Human embryonic kidney cells (HEK 293T cells) 
Appendix A 
214 
 
A.1.16. PureYield™ Maxiprep System protocol (Promega, USA) 
Grow up 100–250 ml of transformed E. coli bacterial cell culture for overnight 
Pellet the cells by centrifugation at 5,000 × g for 10 minutes at room temperature 
Discard supernatant and mix the pellet with 12 ml Cell Resuspension Solution  
Add 12 ml Cell Lysis Solution, mix well and incubation for 3 minutes at room temperature 
Add 12 ml Neutralization Solution and mix well 
Centrifuge the lysate at 14,000 × g for 20 minutes at room temperature 
Pour the lysate into the blue PureYield™ Clearing Column 
Apply maximum vacuum for passing the lysate debris through the PureYield™ Clearing 
Column 
Wash the DNA by add 5 ml of Endotoxin Removal Wash and apply the vacuum  
Add 20 ml of Column Wash and apply the vacuum  
Dry the membrane by applying a vacuum for 5 minutes 
Place a 1.5 ml microcentrifuge tube in the base of the Eluator™ Vacuum 
Elute the DNA by 1 ml of Nuclease-Free Water and apply maximum vacuum for 1 minute 
A.1.17. OPTI-MEM 1 medium (Gibco) 
OPTI-MEM® I modification of MEM (Eagle's) 
A.1.18. Easy-flu medium (Invitrogen) 
500 ml OPTI-MEM 1 medium (Gibco) 
5 ml Penicillin (10,000 U/ml) and Streptomycin (10,000 μg/ml) 
A.1.19. Fugene® 6 Transfection Reagent (Roche) 
Lipid blends in 80% ethanol, sterile-filtered, packaged in glass vials 
A.1.20. RPMI-antimedia 
500 ml Gibco RPMI 1640 
300 μl Gentamycin (40 mg/ml) 
5 ml Penicillin 10,000 U/ml (final concentration 100 U/ml) 
Streptomycin 40 mg/ml (final concentration 24 μg/ml) 
A.1.21. 2x L15 (Leibovitz’s) medium 
2 packets of L15 powder media (2x 13.7 g) (Invitrogen) 
Add 900 ml Baxter water 
Stir for 1 hour 
Adjust pH to 6.8 (1 M Hydrochloric acid) 
Add 8 ml of 7% NaHCO3 
Add 800 μl of Hepes buffer (pH 6.8, 1M) 
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Add 20 ml of Pen/Strep (10,000 U/ml) 
Add 1.2 ml Gentamycin (40 mg/ml) 
A.1.22. LB agar culture media 
200 ml LB agar  
Dissolve by microwave for 1-2 min 
Add 0.2 ml ampicillin 100 μg/ml (Sigma-Aldrich)  
Pour 15 ml agar in petri-dish plates 
Wait for 5 min and cover with parafilm 
Keep at 4 oC 
A.1.23. 1% TPCK-trypsin Worthington (1 μg/ μl) 
10 mg of TPCK-trypsin Worthington (ScimaR) 
Dissolve in 10 ml of PBS 
Filtering by 0.45 μm Minisart filter 
Aliquot into 250 μl volume 
Keep at -80 oC 
A.1.24. Trizol kit for RNA extraction 
1 ml Trizol reagent (GibcoBRL) per 5-10x106 cells 
200 μl chloroform (AnalR) 
0.5 ml Propan-2-ol (isopropanol: AnalR) 
1 ml 75% ethanol (AnalR) 
30 μl HPLC water  
Re-dissolve RNA for 10 minutes at 60oC (heat block) 
A.1.25. Plaque assay medium 
500 ml Gibco RPMI 1640 (Invitrogen) 
300 μl Gentamycin (40 mg/ml) 
5 ml Penicillin /Streptomycin (10,000 U/ml) 
5 ml L-glutamine 2 mM (200 mM) 
5 ml Sodium pyruvate (100 mM). 
45 ml Heat inactivated FCS 
A.1.26. Hanks' Balanced Salt Solution (HBSS) 
Gibco Hanks' Balanced Salt Solution (HBSS) (1X) (Invitrogen) 
A.1.27. DNA size ladder 
1 Kb plus DNA ladder (Invitrogen 1μg/μl) 
A.1.28. C-RPMI medium 
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500 ml RPMI media (JRH) 
2 ml Penicillin/Streptomycin (10,000 U/ml) 
40 ml Heat inactivated FCS 
25 ml Hepes buffer 
A.1.29. 4 % Paraformaldehyde 
100 ml Phosphate Buffered Saline (PBS) 
Pour into the conical flask containing 4g of paraformaldehyde (AnalR) 
Stir inside the fume hood 
Aliquot in 1 ml and store at 4oC  
A.1.30. 6x DNA Loading Dye 
0.25% (w/v) Bromophenol blue 
0.25% (w/v) Xylene cyanol FF 
30% (v/v) glycerol in distilled water 
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Table A.1. Fluorochrome conjugated Anti-mouse monoclonal antibodies 
Anti-mouse monoclonal  antibodies Fluorochrome  Clone Supplier 
Anti-mouse CD8-α  PerCP 5.5 53-6.7 BD Pharmingen 
Anti-mouse CD8-α  PE 53-6.7 BD Pharmingen 
Anti-mouse CD8-α  APC 53-6.7 BD Pharmingen 
Anti-mouse CD8-α  FITC 53-6.7 BD Pharmingen 
Anti-mouse CD4  FITC RM4-4 BD Pharmingen 
Anti-mouse CD62L  FITC MEL-14 BD Pharmingen 
Anti-mouse CD62L  APC MEL-14 BD Pharmingen 
Anti-mouse CD44  APC 1M7 BD Pharmingen 
Anti-mouse CD44  PE 1M7 BD Pharmingen 
Anti-mouse CD69  PE H1-2F3 BD Pharmingen 
 Anti-mouse CD69  APC H1-2F3 Biolegend 
Anti-mouse LPAM-1 (α4β7) PE DATK32 BD Pharmingen 
 Anti-mouse LPAM-1 (α4β7) APC DATK32 Biolegend 
Anti-mouse CD103 (αEβ7)  FITC M290 BD Pharmingen 
Anti-mouse CD199 (CCR9)   FITC 9B1 BD Pharmingen 
Anti-mouse CD199 (CCR9)   PE 9B1 Biolegend 
Anti-mouse B1 integrin  FITC HMB1-1 Biolegend 
Anti-mouse B7 integrin (CD) FITC FIB27 Biolegend 
Anti-mouse interferon (IFN-γ)  FITC XMG1.2 BD Pharmingen 
Anti-mouse interferon (IFN-γ)  APC XMG1.2 BD Pharmingen 
Anti-mouse (TNF-α)  APC MP6-XT22 BD Pharmingen 
Anti-mouse interleukine 2 (IL-2)  PE JES6-5H4 BD Pharmingen 
 
